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Abstract 
The cohort of patients with oral malignancy is typically of advanced age with significant co-
morbidity. The causative factors for such malignancies, such as tobacco and alcohol, are also 
those which result in cardiovascular disease. As a result patients undergoing ablative and 
reconstructive surgery, with free tissue transfer, are at considerable risk of peri-operative 
morbidity and mortality from both primary and secondary disease. Free flap failure has a 
significant impact upon patient outcome, with resultant delayed discharge, and increased 
morbidity and mortality. By optimising co-morbidity and peri-operative factors such as fluid 
balance, nutrition, coagulation and blood pressure support, the complications of complex 
surgery are reduced.  
The collective objectives of this thesis were to determine methods, by both routine and novel 
approaches, to enhance patient care following ablative and reconstructive surgery for head and 
neck malignancy.  
As a result of these investigations, fluid optimisation with LiDCO monitoring, which derives 
stroke volume from the blood pressure waveform, is advocated in patients undergoing ablative 
and reconstructive surgery. Peri-operatively when blood pressure cannot be maintained with 
fluids alone and pressor support is required, low dose noradrenaline is considered the optimal 
agent in view of the improvements in flap perfusion and reliable elevation of mean arterial 
pressure. Careful anticoagulation prescribing should be undertaken, with anti-Xa monitoring of 
low molecular weight heparin to ensure adequate response, in combination with 
thromboelastography to identify patients most at risk of thrombotic flap complications.  
This thesis has made original contributions to the literature in the peri-operative management of 
patients undergoing free tissue transfer following ablative surgery for head and neck malignancy 
in terms of pressor support, coagulation, nutrition, fluid management and hospital admission 
route. Collectively these recommendations may improve patient outcome with significant long 
term benefits for both patients and the NHS. 
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1.0 Introduction 
 
The incidence of head and neck cancer, particularly oral cancer continues to rise. Whilst once 
considered a malignancy of advanced age as a result of exposure to alcohol and tobacco, the 
greatest rise in recent years has been amongst a younger cohort, more frequently associated with 
the human papilloma virus (HPV). Whilst the mainstay of treatment for HPV positive 
oropharyngeal carcinomas is primarily radiotherapy, curative management for the majority of 
tumours (HPV negative) includes surgical resection and reconstruction, often in combination 
with chemo/radiotherapy.  
The surgical management of patients following ablative surgery has been revolutionised by 
advances in microsurgical techniques. Such surgery is frequently prolonged and complex, with 
associated morbidity and mortality. Optimised peri-operative management is paramount to 
maximise survival of transplanted tissues and minimise associated morbidity.   
This thesis, via a collection of published work, explores a number of factors in peri-operative 
optimisation in patients undergoing free tissue transfer following ablative surgery for head and 
neck (oral) cancer.  
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1.1 Thesis Structure 
 
This thesis explores the peri-operative management of patients undergoing free tissue transfer 
following ablative surgery for oral malignancy. This work has made original contributions to 
the field with publications in the following key areas: 
1. Pressor support and their effects on transplanted tissues 
2. The management of coagulation  
3. Nutritional support 
4. Fluid management and cardiac events 
The thesis commences with a general overview of oral malignancy, surgical management and 
factors impacting upon patient outcome, with subsequent sections devoted to each of the above 
topics with a focused literature review. A pertinent discussion is included at the end of each 
section, with the main discussion and critical appraisal of the published works on which this 
thesis is based, in the general discussion at the end of the thesis.   
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1.2 Thesis Objectives 
 
The key objectives for this body of work, with respect to patients undergoing ablative surgery 
for oral cancer with free flap reconstruction, were to: 
1. Identify the optimal agent for blood pressure support following free tissue 
transfer 
2. Identify methods for predicting those patients likely to develop thrombotic 
complications to permit early intervention and prevent flap loss 
3. Determine the efficacy of standard anticoagulation prescription and associated 
complications 
4. Identify the complication rate following surgery in terms of myocardial 
infarction  
5. Develop a method to aid in appropriate selection of feeding adjuncts 
Collectively these objectives aim to improve outcome by optimising peri-operative management 
of patients.  
This work was conducted in the departments of Oral & Maxillofacial Surgery and the Intensive 
Care Unit at the John Radcliffe Hospital, Oxford.  
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2.0 Background 
This chapter provides a brief overview of the anatomy, physiology, pathology and surgical 
techniques on which this thesis focuses. As the primary motivation for the thesis was to improve 
peri-operative management in patients with oral malignancy, it is pertinent to commence with 
an overview of relevant anatomy prior to reviewing the pathology and peri-operative 
management.  
2.1 Anatomy of the Oral Cavity 
The oral cavity extends from the vermilion border of the upper and lower lips, extending 
posteriorly to the V-shaped terminal sulcus of the tongue, the junction of the hard and soft 
palates and the anterior border of the anterior faucal arch. The oral cavity is sub-divided into 
seven bilateral sub-sites, demonstrated in Figure 1. The soft palate, the posterior one third of 
the tongue and the fauces are considered to be part of the oropharynx rather than the oral cavity.  
 
Within the floor of the oral cavity, the mucosa overlies the mylohyoid, hyoglossus and 
genioglossus muscles, which provide structural support. The vermilion border of the lips 
provides the commencement of the transition zone between external skin and oral mucosa. 
Continuous with the lips, the cheeks and buccal mucosa provide the lateral limits of the oral 
cavity.  
 
The blood supply to the oral cavity is via the lingual, facial and maxillary branches of the 
external carotid artery, with venous drainage ultimately entering the internal jugular vein (IJV). 
Sensory innervation is via the maxillary and mandibular branches of the trigeminal nerve (CN 
V2 and CN V3). Motor innervation is by the facial nerve (CN VII) and the motor branches of 
the mandibular trigeminal nerve (CN V3). The intrinsic muscles of the tongue, the extrinsic 
muscles except the palatoglossus, and the geniohyoid receive motor innervation from the 
hypoglossal nerve (CN XII). The palatoglossus is supplied by the cranial root of the 
glossopharyngeal nerve (CN IX).  
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The lymphatic drainage of the oral cavity is via the cervical lymph nodes. These basins consist 
of fifty to seventy lymph nodes divided into seven discrete levels by the anatomic structures of 
the neck. The lateral structures of the oral cavity tend to drain to ipsilateral cervical lymph 
nodes. However, midline structures drain bilaterally.  
 
 
 
  
 
Figure 1: Diagram of the oral cavity.   
The oral cavity is sub-divided into seven bilateral subsites; these 
include the alveolus, palate, floor of mouth and retromolar trigones 
[source 
2
]. 
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2.2 Oral Malignancy 
Accounting for approximately 30% of all head and neck malignancies, oral cancer is responsible 
for 2% of all malignant tumours in northern Europe and USA, and 30% in the Indian 
subcontinent.
18,19
 Over 90% of these tumours are squamous cell carcinomas (SCC). Clinical 
presentation is usually with a non-healing ulcer, mass, or tooth mobility. However, in some 
cases initial presentation is with an area of leukoplakia, erythroleukoplakia, erythroplakia, or 
alternatively as a result of metastatic spread. Pain is usually a late feature, although referred 
otalgia is a common manifestation.  
2.2.1 Incidence & Aetiology 
The incidence of head and neck cancer, particularly oral cancer continues to rise and is currently 
the 15
th
 most common form of cancer in the UK.
20
 The tongue is the most frequently affected 
site in the oral cavity, with ethnicity resulting in some variation in incidence at the remaining 
oral cavity sub-sites.
21
 Overall, the floor of mouth is the second most frequently affected sub-
site, with the remainder of sub-sites being almost equally affected.  
Head and neck cancer is more common in advanced age, and is strongly associated with 
alcohol, tobacco use (in any form) and Khat or Betel chewing. 
22-24
 Since many smokers are also 
drinkers, and vice versa, it is difficult to separate these particular aetiological factors. Blot et al
25
 
conducted a large case control study in the USA, identifying that both alcohol and tobacco 
contribute to the occurrence of oropharyngeal carcinoma. They reported a strong dose-response 
relationship with both substances, with the risks of oropharyngeal cancer combining in an 
additive fashion in those who both smoke and drank alcohol. The dehydrating effect of alcohol 
on cell membranes enhances the ability of tobacco-associated carcinogens to permeate mouth 
tissues.
21
 The irritation and chemicals within Khat, Betel, tobacco and alcohol result in 
dysplasia, from which a significant proportion of tumours are thought to arise.  
Leukoplakia presents as a white patch which cannot be scraped off of the tissues, with 
approximately 5-30% of untreated lesions undergoing malignant transformation. Erythoplakia is 
seen as a red patch, with insitu or invasive carcinoma found in approximately 50% of lesions.
19
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In approximately 25% of cases the aetiological factor is demonstrated to be the human 
papilloma virus (HPV), with the most common sub-types being HPV-16 and HPV-18.
26,27
 HPV-
16 is increasingly identified as the aetiological factor in oropharyngeal SCC of younger patient 
cohorts.  
Other predisposing factors include diseases such as syphilis, chronic oral candidiasis, lichen 
planus and lupus.  
2.2.2 Lymphatic Spread 
The lymphatic drainage from the oral cavity is to the cervical lymph nodes in the neck. The 
cervical lymph nodes are classified into six levels (I-VI), which represent the drainage order and 
therefore metastatic involvement (Figure 2). Tumours affecting the maxillary complex (maxilla, 
hard palate and paranasal sinuses), typically present late, resulting in locally advanced disease 
and metastatic nodal involvement.
28,29
 The presence or absence of extracapsular spread of 
tumour in metastatic cervical nodes is the most important single prognostic factor.
18
 
 
 
Figure 2:  The cervical lymph node levels of the neck.  
Tumours involving the head and neck tissues drain to these lymph nodes. 
Surgical clearance of the nodes in levels I-III is typically completed in 
head and neck cancers.    
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2.2.3 Investigation 
The first key step in the investigation of oral carcinoma is a full history with systematic clinical 
examination, which provides an initial clinical stage of the disease (cTNM).  A plain radiograph 
(orthopantogram) provides information on the presence of pathology and can be obtained at the 
time of the first clinic visit. Fine needle aspiration (FNA) of any neck masses and biopsy of the 
region of concern provides histological confirmation of the diagnosis, and may be performed 
with ultrasound guidance. Magnetic Resonance Imaging (MRI) and/or Computed Tomography 
(CT) or Cone Beam CT (CBCT) imaging should be obtained to define the extent of the tumour 
and demonstrate any clinically undetectable lymphatic involvement in the neck. The accurate 
identification of bony invasion is particularly important to determine whether bony resection is 
required, and provide accurate tumour staging.
30
 CT examination should include the chest and 
abdomen to identify any metastatic involvement; where tumours are small, and therefore 
unlikely to have metastasised, or where resources are limited, a chest radiograph may be 
substituted for CT. As synchronous tumours (occurring within 6 months of the first tumour) are 
found in 1-6% of patients, panendoscopy with biopsy is advocated. In cases where patients 
present with metastatic disease and the primary site is not clear, or where there is a question 
regarding the extent of tumour spread, Positron Emission Tomography (PET) in combination 
with CT or MRI may be useful.  
2.2.4 Tumour Staging 
Clinical tumour staging is completed using the TNM system (Tumour Nodes Metastasis) 
(clinical stage, cTNM), first developed in 1977 by the American Joint Committee on Cancer 
(AJCC).
31
 All available information from clinical examination and imaging is utilised to 
determine this initial stage. The final TNM staging of the patient is completed following 
resection of the tumour with histological analysis of the tumour and draining lymph nodes 
(pathological stage, pTNM). The TNM criteria for oral cavity tumours are included in 
Appendix A.  
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2.3 Management of Oral Cancer 
The primary management of oral cavity SCC is with a combination of surgical resection and/or 
chemo- and radiotherapy. For T1 or T2 tumours brachytherapy (implant radiotherapy) provides 
an alternative to surgery with similar control rates, but with potential risk of osteoradionecrosis 
of the bone. Surgical resection requires enbloc excision of the tumour with a margin of 
approximately 1cm of normal surrounding tissue.  
Where there is evidence of bony invasion into the mandible, resection of bone is required in 
addition to the overlying soft tissues. This may be via a rim resection, which involves resection 
of the alveolus with preservation of the body of the mandible, or segmental resection where 
there is significant bony invasion or a history of irradiation. Tumours of the hard palate, 
maxillary alveolus, maxillary sinus or maxilla require enbloc resection of the soft and hard 
tissues.   
Approximately 40% of patients with tongue cancers have nodal involvement at the time of 
presentation, with 20% having bilateral disease. Neck dissection in cases where nodal 
involvement is present is recommended, but prophylactic neck dissection is a contentious 
issue.
19
 The majority of surgeons offer patients with T3 or T4 tumours elective node dissection. 
The dissection of Levels I-IV on the ipsilateral side to the tumour (bilateral in midline tumours) 
is most common. In addition to clearance of the lymph nodes, reducing the risk of lymphatic 
spread, the neck incision provides access to the vessels of the neck for subsequent microsurgical 
reconstruction, as discussed in the following sections. 
HPV positive tumours are typically chemo/radio sensitive, and this forms the basis of treatment 
in these cases. They may however require salvage surgery with or without clearance of the 
lymph nodes in the neck.  
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2.4 Surgical Reconstruction  
Following ablative surgery, the resultant defect requires reconstruction to restore both form and 
function. Reconstructive options are dependent upon the site and size of the defect. The simplest 
methods, limited to small defects, include leaving the site to heal by secondary intention, 
directly closing the incision or applying a skin graft or moving local tissues to fill the void (local 
flap). Direct closure results in scar tissue which may cause difficulty in distinguishing scar from 
tumour recurrence. As a result mucosal grafts are typically preferred for smaller tumours.  
The options for mandibular reconstruction include spanning the defect with a reconstruction 
plate rigidly fixed to either end of the defect, which is the simplest method for patients not 
suited to other methods of reconstruction, have lateral defects with good soft tissue coverage 
and who have not and will not require radiotherapy. Alternatively the bony defect can be 
reconstructed with non-vascularised tissue such as a bone graft, which is used in combination 
with a reconstruction plate. However, the optimal method of reconstruction is with vascularised 
bone.
19
 This is discussed later in this chapter.   
Maxillary defects and their reconstructive options are defined by the Brown classification
1
 
(Figure 3). The simplest method of reconstruction is to utilise an extended denture (obturator). 
The resultant bony defect may necessitate a complete multi-part obturator which requires 
fixations, usually magnetic, to hold it in place and restore the function of chewing. The removal 
and cleaning of such obturators requires a level of manual dexterity from the patient. More 
definitive methods of reconstruction, as demonstrated in the classification by Brown et al
1
 
require composite flaps, but these do not necessarily result in improved function.  
A flap is defined as a unit of tissue of variable composition which, when transferred from a 
donor to a recipient site, brings its own blood supply and intrinsic circulation.
32
 A flap may be 
local or distant. In many cases the defect is too large for reconstruction from the local tissues 
and surgical reconstruction is reliant upon distant flaps in the form of pedicled or free flaps. 
These may contain a combination of skin, muscle, bone, fat or fascia (fasciocutaneous flap). The 
transfer usually leaves a secondary defect which is usually either directly closed, or covered 
with a skin graft.  
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2.4.1 Distant Pedicled Flaps 
A distant flap can be transferred to its destination in several ways. It can be directly applied to 
the primary defect, it can be waltzed, pivoted on its pedicle (blood supply) or it may be attached 
to a carrier (e.g. the wrist) on which it is conveyed to its destination.
33
 The distant flaps most 
frequently utilised in head and neck reconstruction are pedicled (island flaps). In such flaps, the 
pedicle is reduced in size, in some cases down to just the vessels. The flap pivots on the pedicle 
and the distal end, which is frequently muscle with an overlying skin paddle, fills the defect, by 
passing underneath the intermediary tissues which provides protection and prevents drying out 
of pedicle. Reconstructive options following ablative surgery for head and neck malignancy 
include pedicled pectoralis major and latissimus dorsi muscle flaps. Failure of these flaps may 
occur as a result of twisting of the pedicle causing compromise of the blood supply. The main 
limitations of these flaps include the physical distance the flap can provide cover, and the often 
poor cosmetic result. This is because it is more difficult to customise the pedicled flap to the 
defect due to the constraints of the pedicle, and associated tethering and scarring. However, 
these are generally reliable flaps and are therefore valuable in patients who are poor candidates 
for more extensive and lengthier surgery.  
 
Figure 3: Brown Classification of maxillary defects. 
Brown et al
1
 classified maxillary defects into horizontal and vertical components, highlighting 
that whilst obturators can be utilised for even the most complex of defects, composite flaps are 
deemed to be the most optimal method of reconstruction.   
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2.4.2 Free Tissue Transfer 
Free tissue transfer is the process of transferring tissues from one site to another, requiring 
separation of the blood supply at the donor site and surgical anastomosis at the recipient site. 
Microsurgery utilises magnification either using an operating microscope or loupes to enable 
the anastomosis of small vessels or nerves.
34
  
The foundation for microvascular anastomoses began in 1897 when John B Murphy an 
American surgeon successfully united the femoral artery after a gunshot wound. Murphy 
documented that “not a drop of blood escaped at the line of suture” and “pulsation was 
immediately restored.”35 It was a further 60 years until microscopes were utilised in vascular 
surgery permitting anastomoses of vessels 1.4mm in diameter, and the term “microvascular 
surgery” coined by Jules Jacobson.34 However, it is the American plastic surgeon, Harry J 
Bunke who is considered the pioneer of contemporary microsurgery. Bunke replanted a rabbit 
ear, successfully anastomosing vessels of 1mm in diameter, and subsequently developing many 
of the microsurgical instruments in use today. These developments permitted the successful 
replantation of digits, and toe to hand transfers, and in 1972 the first human free flap was 
reported by McLean and Bunke
36
 - an omentum flap for a scalp defect.  
The possibility of composite tissue transfer was subsequently explored and the implementation 
of free groin flaps and iliac bone grafts demonstrated superb results in classically hopeless 
defects.
37
 Subsequent developments in microsurgical tissue transfer evolved at an exponential 
rate, providing the reconstructive surgeon with a toolbox of techniques and flaps for a myriad of 
defects.  
Free flaps are classified according to their composition, which may be cutaneous, fascio-
cutaneous, musculo-cutaneous, osseo-cutaneous, muscle, bone, fascia, tendon or any 
combination.
32
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Musculocutaneous flaps are based on perforators that reach the skin through the muscle. The 
musculocutaneous system predominates on the torso and this is the location of most of these 
flaps.
19
 Mathes and Nahai in 1981 classified muscle flaps into 5 types based upon the 
anatomical relationship between the muscle and its vascular pedicle and the intra-muscular 
anastomoses (Figure 4).
19,32,38,39
 
 Type 1: one vascular pedicle (e.g. gastrocnemius, tensor fasciae latae) 
 Type 2: one dominant vascular pedicle usually entering close to the origin or insertion 
of the muscle with additional smaller vascular pedicles entering the muscle belly (e.g. 
gracilis, trapezius) 
 Type 3: two dominant pedicles from different sources, either of which can support the 
whole muscle (e.g. rectus abdominis, serratus anterior) 
 Type 4: segmental supply each of which only supplies its segment and an immediately 
adjacent segment (e.g. sartorius, sternomastoid) 
 Type 5: one dominant pedicle near the insertion which can supply the whole muscle and 
several minor pedicles near the origin which can also supply the muscle (e.g. latissimus 
dorsi) 
 
 
 
Figure 4: Mathes & Nahai classification of muscle flaps based upon their vascular supply.  
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Fasciocutaneous flaps are based on vessels running either within or near the fascia. Blood 
reaches these flaps from fasciocutaneous vessels (also called septocutaneous vessels) running 
from the deep arteries of the body to the fascia. The fasciocutaneous system predominates on 
the limbs and this is the location for the majority of these flaps.
19
 The main classification system 
was described by Cormack and Lamberty in 1984.
40,41
 This system classifies flaps on the route 
to reach the skin and directness of supply of the vascular pedicle (Figure 5):  
 Type A: (broad based with perforators unseen): multiple perforators at the flap base 
with vessels orientated longitudinally along the flap axis  
 Type B: (perforator, axial): single consistent perforator feeding a fascial vascular plexus 
which may run along flap axis (e.g. groin) 
 Type C (ladder type): longitudinal septal vessel sending multiple perforators to fascia 
and skin as it travels (e.g. radial forearm) 
 Type D (osteo-fasciocutaneous): Type C with bone (e.g. radial forearm with bone). 
 
 
 
 
 
 
 
Numerous variations to these classification systems have been described and these 
modifications are beyond the scope of this thesis. Reconstruction following resection for head 
and neck malignancy is most frequently with the radial forearm, fibula, anterolateral thigh, 
fibula, and/or latissimus dorsi free flaps. These are discussed in further detail below.  
 
Figure 5: Cormack and Lamberty classification of fasciocutaneous flaps based upon 
the vascular pedicle.  
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2.4.2.1 Radial Forearm Free Flap 
The radial forearm free flap was first described in 1978 as a proximally based free flap.
42
 It is a 
Type C flap according to the Cormack and Lamberty classification. The radial forearm flap is 
raised on the flexor aspect of the forearm. The radial vessels supply the plexus of the investing 
layer of deep fascia, from which blood is distributed to the overlying skin.
33
 The flap can be 
limited to skin and fascia, or include a length of the radius bone. For a fascicocutaneous flap the 
plane of elevation lies between the muscles and investing layer of fascia, a subfascial dissection. 
The flap can also be raised suprafascially. The radial artery and its venae comitantes, with or 
without a superficial vein such as the cephalic vein are elevated with the flap. With sacrifice of 
the radial artery, perfusion of the hand becomes dependent upon the ulnar artery. In 12% of 
cases the radial artery is the dominant supply to the hand, with 3% having an incomplete palmar 
arch.
42
 It is therefore necessary to confirm pre-operatively that the ulnar artery can maintain the 
blood supply of the hand by performing an Allen’s test. The donor site can be covered with a 
skin graft without any long term functional deficit. However, the superficial radial nerve may 
need to be sacrificed resulting in some sensory deficit over the extensor aspect of the thumb and 
first webspace. With a long pedicle the radial forearm flap is a very reliable flap in the 
reconstruction of oral defects.  
 
2.4.2.2 Anterolateral Thigh Free Flap 
The anterior lateral thigh (ALT) flap is a fasciocutaneous flap that has become popular in recent 
years. It is classified as a Type B flap if one perforator is included and as a Type C if multiple 
perforators are included.
32
 The flap is located over the middle third of the thigh anterior and 
lateral to the rectus femoris and the vastus lateralis muscles. It is usually used for coverage of 
defects when a relatively thin flap is required. It is based on perforators from the descending 
branch of the lateral circumflex artery, which provides a good length of pedicle. The donor site 
can often be closed directly.  
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2.4.2.3 Fibula Free Flap 
The fibula is elevated on the peroneal vessels, running distally alongside the fibula behind the 
interosseous membrane. Septocutaneous perforators from the peroneal vessels pass laterally 
behind the fibula in the intermuscular septum between the peroneal muscles and soleus, and 
perfuse the overlying skin. These allow the fibula to be transferred as an osteocutanous free 
flap, as well as a vascularised bone graft.
33
 Raised as an osteocutaneous flap, this is classified as 
a Type D flap. Bearing 10-15% of the load the fibula can be removed without functional 
impairment, and the ankle remains stable if the middle third of the fibula is harvested.
32
  
 
2.4.2.4 Latissumus Dorsi Free Flap 
The latissimus dorsi can be transferred as a muscle only, or myocutaneous flap. It is a Type V 
flap according to the Mathes and Nahai classification.
39
 The dominant blood supply is the 
thoracodorsal artery, a continuation of the subscapular artery arising from the third part of the 
axillary artery. It is also supplied segmentally by intercostals and lumbar perforators.
32
 It is a 
reliable free flap, with a long pedicle, good muscle bulk and vessels of a large diameter.  
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2.5 Free Flap Survival  
Since its introduction, free flap viability has improved significantly, with reported success rates 
of over 95%.
43,44
 The flap remains ischaemic after detachment from the blood supply at the 
donor site until completion of the anastomosis (primary ischaemia). Any later hypoperfusion or 
ischaemia (secondary ischaemia) due to impaired inflow or outflow from the flap is even less 
well tolerated and may result in flap failure.
45
  
Anaerobic metabolism in the tissues during ischaemia increases the production of superoxide 
radicals. Following reperfusion, free radical scavengers (e.g. superoxide dismutase) attack the 
radicals, injuring the cells.
32
 This results in endothelial swelling and leakage of fluid into the 
interstitial space further narrowing the vessel lumen. This is followed by intravascular platelet 
aggregation. This process is referred to as ischaemia-induced reperfusion injury.
32
 Clinically, 
the result is referred to as “no-reflow,” where initial flap perfusion gradually decreases resulting 
in irreversible flap ischaemia. 
Flap necrosis, whether partial or total, is an undesirable complication of reconstructive surgery. 
These complications can be avoided to a large extent by meticulous surgical technique with 
careful attention to detail, avoidance of tension, and close post-operative surveillance.
46
 Even if 
the vascular anastomosis is perfect, blood flow may be disturbed by twisting, tension, kinking or 
external compression of the pedicle.
47
  
Peri-operative optimisation is vital to ensure flap survival. This includes measures to maintain 
adequate blood supply to the flap, minimising risk of thrombosis within the feeding vessels and 
minimising external compression of the flap vessels.  
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2.5.1 Flap Flow  
The interrelation of factors influencing flow through a vessel, whilst more complex than a rigid 
tube, can reasonably be described using the Poiseuille-Hagan formula
48
:  
              
 
 
  
 
 
   
  
 
 
Where (PA- PB) = pressure difference between the two ends of the vessel; η = viscosity; r=radius 
of vessel; L=length of vessel. As flow is related to the fourth power of the vessel radius, small 
changes in vessel size results in a large increase in flow.  
The muscular tone of vessels is controlled by four main factors: 
1. Pressure of the blood within the vessels (myogenic theory) – This theory states that 
increased intraluminal pressure results in constriction of the vessels and vice versa. This 
mechanism helps to maintain blood flow at a constant.
19
 
2. Neural innvervation – The arterioles, arteriovenous anastomoses connecting the 
arterioles to the efferent veins, and pre-capillary sphincters are innervated by 
sympathetic fibres.
49
  Increased arteriolar tone results in a decrease in cutaneous blood 
flow, and increased pre-capillary sphincter tone reduces the blood flow into the 
capillary networks.
19
   
3. Humoral factors – These include the effects of adrenaline and noradrenaline which 
result in vasoconstriction, and histamine and bradykinin which result in vasodilatation. 
Low oxygen saturation, high carbon dioxide saturation and acidosis also result in 
vasodilatation.
19
 
4. Temperature – Increased heat produces cutaneous vasodilatation and increased flow 
which predominantly bypasses the capillary beds via the arteriovenous anastomoses.
19
  
As a result, several oscillatory components are observed in the blood flow signal spanning from 
the cardiac frequency (~1 Hz) down to endothelium related frequencies (~0.01Hz).
49,50
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2.6 Maintaining Peri-operative Blood Pressure 
Adequate flap perfusion is dependent upon both adequate flow and systemic blood pressure 
(BP). BP is dependent upon cardiac output and systemic vascular resistance (SVR). SVR is the 
resistance against which the heart pumps, so vasoconstriction results in an increase in SVR 
whilst vasodilatation reduces it.
51
 Cardiac output is the product of heart rate and stroke volume, 
where stroke volume is defined as the volume of blood that is ejected by the ventricle with a 
single contraction, having three major determinants: contractility, preload and afterload. Mean 
arterial pressure (MAP) is the average arterial blood pressure throughout the cardiac cycle, 
recognising that diastole makes up two thirds of the time. It is less liable to error due to 
measuring techniques.  
In low cardiac output states leading to hypoperfusion, the heart rate, preload, afterload and then 
contractility should be addressed, since there is little point in attempting to pharmacologically 
improve the contractility of the heart when it is either too empty or too distended to eject.
51
  
In addition to maintaining blood pressure, accurate fluid balance is required in flap management 
to prevent oedema of the flap tissues which are at increased risk due to the absence of lymphatic 
drainage.
52
 Accurate replacement of fluid depends upon an understanding of the distribution of 
water, sodium, and colloid in the body.
51
 There are two major fluid compartments: the water 
within cells (intracellular fluid), which accounts for about 65% of the body total, and the water 
outside cells (extracellular fluid). Approximately 65% of the extracellular fluid comprises the 
tissue fluid found between cells (interstitial fluid), and the remainder is plasma.
53
  
Pre-operative dehydration, prolonged surgery, intra-operative blood loss and insensible losses 
can make fluid optimisation in patients undergoing resection and free flap reconstruction of oral 
malignancy particularly challenging. Clinical examination including BP, heart rate and urine 
output provide only limited information on fluid balance. As a result the majority of patients 
undergoing such surgery have both central venous catheters and arterial lines placed to provide 
central venous pressure and MAP. It is the response of the CVP to fluid challenges that aids 
volume assessment.  
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A more useful method is transoesophageal Doppler which provides an estimate of stroke 
volume; however the use of such probes is often difficult due to accurate and consistent 
positioning in oral cancer cases. An alternative method is to utilise a system which derives 
stroke volume from the arterial pressure waveform, such as LiDCO™ (Figure 6), which is 
discussed later in the thesis.  
Following optimisation of fluid balance, pharmacological intervention is frequently required to 
maintain MAP.  
Within the circulatory system there are three main types of receptor– alpha, beta, and dopamine 
receptors. Alpha and beta receptors are collectively termed adrenoreceptors (adrenergic 
receptors). These are a class of G protein-coupled receptors that are the targets for 
catecholamines, particularly noradrenaline and adrenaline. Binding of these receptors results in 
stimulation of the sympathetic nervous system.  
 
 
 
 
Figure 6: LiDCO Rapid system 
This system utilises pulse contour analysis from the arterial pressure 
waveform to calculate stroke volume variance.  
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Alpha receptor stimulation results in vasoconstriction of blood vessels, and decreased motility 
of the smooth muscle of the gastrointestinal tract. The alpha receptors are broadly classified into 
two groups – α1 which are located on the post-synaptic membrane and α2 located on both pre-
synaptic neurons and post-synaptic cells. The specific actions of the α1 receptor include vascular 
smooth muscle contraction and constriction of smooth muscle within the genitourinary tract. 
Studies demonstrated that post-junctional responses mediated by α1 adrenergic receptors could 
not be explained adequately on the basis of a single population of receptors.
54
 This concept was 
further advanced by the radioligand binding work of Morrow and Creese who suggested a sub-
division of α1 into α1A and α1B, based upon the finding of different binding profiles for various 
ligands.
54,55
 The classification was further complicated by genetic subtyping, with the 
identification of a third sub-type, α1D. The initial description of the α1C sub-type was later shown 
to be the homologue of the pharmacologically defined α1A and was as such reclassified into this 
group.  
The α2 receptor is located both pre- and post-synaptically and serve to produce inhibitory 
functions including feedback inhibition of neurotransmitter release from pre-synaptic neurons. 
Post-synaptic α2 receptors are located on liver cells, platelets and smooth muscle of blood 
vessels. Four distinct sub-types have been identified, α2A, α2B, α2C, and α2D, with the α2D sub-type 
being identified only in rats to date.
56
 
The alpha receptors have been identified in both the intima and adventitia of blood vessels; α1-
adrenoreceptors appear to be uniformly distributed, whereas α2-adrenoreceptors are located 
nearer the intima.
57,58
 
Using techniques of molecular cloning three distinct beta adrenergic receptor sub-types have 
been identified – β1, β2 and β3.
59
 Beta1 receptors are located mostly within the heart, where their 
stimulation results in an increased rate and force of contraction. Beta2 receptors are located 
within blood vessels and the lungs, and cause vasodilation and bronchodilatation. Beta3 
receptors are involved in the enhancement of lipolysis in adipose tissue and thermogenesis in 
skeletal tissue.  
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The precise roles for each of these multiple sub-types of adrenoceptors in the regulation of 
blood pressure have not been completely defined.  
Sympathomimetic drugs mimic the effects of transmitter substances of the sympathetic nervous 
system. These can be utilised to manage hypotension in the peri-operative period. Direct acting 
drugs include adrenergic receptor agonists which stimulate the α- and β- receptors, and 
dopaminergic agonists which stimulate the D1 receptors. Indirect acting agents act by blocking 
and reversing noradrenaline transporter activity. Sympathomimetics have relatively short 
biological half-lives, achieving a steady state plasma concentration within 5-10 minutes of 
commencing IV infusion.
60
  
Many of the sympathomimetic agents are also considered to be vasoactive agents. Vasoactive 
agents are a group of bioactive chemicals, which change vasomotor tone through their influence 
on various peripheral receptors.
61
 Vasoactive drugs affect heart rate and stroke volume. They 
can broadly be classified into inotropes and vasopressors. An inotrope is an agent that alters 
myocardial contractility.
51,60
 A vasopressor is an agent that causes vasoconstriction. Vasopressor 
agents increase MAP, which increases organ perfusion and preserves distribution of cardiac 
output to the organs. Vasopressor agents also improve cardiac output and oxygen delivery by 
decreasing the compliance of the venous compartment and thus augmenting venous return.
62
  
The sympathomimetics available within the UK are subdivided in the British National 
Formulary (BNF) into inotropic sympathomimetics (dobutamine, dopamine, dopexamine and 
isoprenaline), and vasoconstrictor sympathomimetics (ephedrine, metaraminol, noradrenaline, 
phenylephrine). However many of these drugs have both vasopressor and inotropic effects. A 
more useful method of classification is based on their site of action: 
1. Directly: adrenoceptor agonists e.g. adrenaline, noradrenaline, isoprenaline, 
metaraminol (entirely); and dopamine and phenylephrine (mainly).  
2. Indirectly: by causing a release of preformed noradrenaline from stores in nerve endings 
e.g. ephedrine 
3. By both mechanisms, though usually one predominates.  
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 α β1 β2 Dopaminergic Direct 
Action 
Indirect 
Action 
Adrenaline       
Dobutamine       
Dopexamine       
Metaraminol       
Noradrenaline       
Table 1: Summary of actions of the most frequently used sympathomimetics in the ICU. 
 
The most commonly utilised agents in the intensive care unit to maintain MAP include 
adrenaline, noradrenaline, dobutamine, dopexamine and metaraminol. Their actions are 
summarised in Table 1, and are further considered in the following sections. In the USA 
ephedrine and phenylephrine are also popular.  
 
 
2.6.1 Adrenaline (Epinephrine) 
Adrenaline (Figure 7) is a very potent vasoconstrictor and cardiac 
stimulant, via β1, β2, and α effects.
51,63,64
 It causes BP to rise 
rapidly, to a peak proportional to the dose and with a greater rise 
in diastolic than systolic pressure due to myocardial stimulation 
(inotropic) increasing the strength of contraction, increased heart 
rate (chronotropic), and vasoconstriction. At low doses (0.04-0.1mcg/kg/min) the β1 effects 
predominate, including increased heart rate, CO and stroke volume, and decreased peripheral 
vascular resistance. There is also some effect on β2 receptors in some vessels resulting in 
dilation and potentially a fall in total peripheral resistance. However, BP tends to rise as β1 
effects predominate. At higher doses, alpha stimulation dominates resulting in vasoconstriction 
and a resultant increase in BP. It has a half life of 2 minutes.  
 
 
Figure 7: The chemical 
structure of adrenaline.  
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2.6.2 Noradrenaline (Norepinephrine) 
Noradrenaline (Figure 8) exerts its effects on α and β1 receptors. It 
has minimal effect on β2 receptors. Noradrenaline results in an 
increase in peripheral resistance. It is a potent α agonist and causes 
a rise in BP by increasing SVR. Since it stimulates both α and β 
adrenergic receptors, its haemodynamic effects are variable 
depending on the dosage and clinical setting.
65
 At low doses cardiac output and BP are 
increased, mainly due to predominant β adrenergic stimulation of the heart. However, at higher 
doses cardiac output may fall as a result of an increase in vascular resistance, despite the 
positive inotropic effects. It has a half life of 2 minutes.  
2.6.3 Dobutamine 
Dobutamine (Figure 9) is a synthetic catecholamine with potent 
inotropic and modest vasodilatory properties.
66
 Dobutamine is a 
relatively β1 selective synthetic catecholamine.
63
 β1 effects result 
in elevation of heart rate and increased contractility and therefore 
increased cardiac output. Additionally, dobutamine has mild β2 and α1 effects. The half life is 
approximately two minutes, which provides for rapid onset and prompt dose escalation.
66
 
Despite increases in CO, BP may be reduced or unchanged because of reduction in SVR 
through β2 receptor and baroreceptor-mediated vasodilation.
66
  
2.6.4 Dopexamine 
Dopexamine (Figure 10) is a synthetic catecholamine acting 
mainly through activation of dopaminergic and β2-adrenoceptors. 
Dopexamine is a synthetic analogue of dopamine.
51
 It is 
characterised by a rapid onset and short duration of action.
67
 It 
exerts its effects as a β2 agonist. It causes an increase in heart rate and cardiac output and causes 
peripheral vasodilation and an increase in renal and splanchnic blood flow.  
Figure 8: The chemical 
structure of 
noradrenaline.  
 
Figure 9: The chemical 
structure of dobutamine.  
 
Figure 10: The chemical 
structure of dopexamine.  
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2.6.5 Metaraminol 
Metaraminol (Figure 11) is a sympathomimetic drug with a 
direct effect on vascular-adrenergic receptors and an indirect 
mechanism of action related to the stimulation of noradrenaline 
release.
62,68
 It has both α and β adrenergic activity, with alpha 
action being predominant. Metaraminol is a potent peripheral 
vasoconstrictor. Metaraminol has been utilised to counteract the hypotensive effects of spinal 
and epidural anaesthesia for many years.
69
 It does not tend to cause a change in heart rate.
69
 
Metaraminol has a longer duration of action than adrenaline or noradrenaline. Effects are seen 1 
to 2 minutes after intravenous injection with a duration of action of about 20 minutes.
68
 It has an 
inotropic effect and acts as a peripheral vasoconstrictor, thus increasing cardiac output, 
peripheral resistance, and BP. Coronary blood flow is increased and the heart rate slowed.
68,70
 
2.6.6 Dopamine 
Dopamine (Figure 12) stimulates adrenoreceptors and 
dopaminergic receptors. The effects change with increasing dose.
51
 
Low dose dopamine dopaminergic stimulation predominates 
resulting in increases in renal and mesenteric blood flow. 
Increasing the dose results in a predominance of β1 effects, 
increasing heart rate, cardiac output and myocardial contractility. At high dose, α effects 
predominate causing a rise in SVR and reduction in renal blood flow. Its half life is 2 minutes. 
The main problems associated with dopamine are tachycardia and arrhythmias, myocardial 
ischaemia and excessive peripheral vasoconstriction.  
 
 
 
 
 
 
 
Figure 11: The chemical 
structure of metaraminol.  
 
 
Figure 12: The 
chemical structure of 
dopamine.  
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2.6.7 Isoprenaline 
Isoprenaline (Figure 13) is a non-selective beta-adrenergic agonist, 
thus activating both β1 and β2 receptors. It is structurally similar to 
adrenaline. Isoprenaline relaxes smooth muscle and has negligible 
metabolic or vasoconstrictor effects.
71
 Its main disadvantage is that 
it results in a marked tachycardia. It has a half life of 2 minutes.  
2.6.8 Ephedrine 
Ephedrine (Figure 14) is a plant alkaloid with indirect 
sympathomimetic actions that resemble those of adrenaline 
peripherally and amphetamine centrally.
71
 It has actions on α and 
β adrenergic receptors and displaces noradrenaline from 
adrenergic terminals.
72
 It has a half life of approximately 6 hours. 
Ephredrine has been linked to serious cardiovascular toxicity, including hypertension, 
vasospasm, angina, coronary artery disease, arrhythmia, myocardial infarction, stroke and 
death.
72
 
2.6.9 Phenylephrine 
Phenylephrine (Figure 15) is a selective α1 adrenergic receptor 
agonist. It has the advantage of not being inotropic or chronotropic, 
and so strictly elevates BP without increasing the heart rate or 
contractility. However, a reflect bradycardia may result. The 
elimination half life is approximately 3 hours.   
 
 
 
 
Figure 13: The 
chemical structure of 
isoprenaline.  
 
Figure 14: The 
chemical structure of 
ephedrine.  
 
Figure 15: The 
chemical structure of 
phenylephrine  
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2.7 Vasoactive drugs in free tissue transfer 
Hypotension under general anaesthesia occurs in 40 to 60 percent of hypertensive patients as a 
result of decreased systemic vascular resistance. In addition induced hypotension is a widely 
accepted technique to reduce intraoperative blood loss.
52
 However, systemic hypotension may 
result in flap hypoperfusion, stroke, myocardial infarction, renal failure and death.
73
 
Hypotension is particularly problematic in patients requiring prolonged peri-operative sedation 
for ventilation, particularly in combination with alcohol withdrawal. To counteract the effects of 
hypotension following appropriate fluid administration, anaesthetists and intensivists may 
require the use of vasoactive drugs. Many surgeons are wary of using inotropic agents as a 
method of improving perfusion of the transplanted tissue.
46,74
 However, flap loss has not been 
correlated with vasopressor use in recent retrospective studies.
75
 
Free flap surgery results in the disruption of the autonomic nerves running around the feeder 
vessels of the flap. The microcirculatory effect of sympathectomy causes vasodilatation of 
vessels in muscle and in skin thus potentially improving microcirculation.
76
 However, some 
research suggests that denervation supersensitivity can develop after sympathectomy, leading to 
excessive vasoconstriction in response to catecholamines.
77
 This may be further heightened due 
to the surgical stress response resulting in release of adrenaline and noradrenaline and 
consequent vasoconstriction. Any additional circulating sympathomimetic agents may further 
heighten these effects and result in flap necrosis. Godden et al
78
 in 2000 reported the findings of 
the invitro effect of increasing concentrations of phenylephrine (an α1 agonist) on the rat 
femoral artery after microvascular anastomosis. The vascular tone on the test side confirmed 
supersensitivity to the alpha agonist, which was blocked by the alpha blocker phentolamine (a 
non-selective α-adrenergic blocker). It was concluded that the sympathetic denervation during 
preparation of the vessels for anastomosis resulted in the increased sensitivity of the blood 
vessels to the exogenous stimulation. This work provides evidence for the survival of vascular 
alpha receptors following transplantation, thus providing a potential basis for flap failure due to 
vasoconstriction of the feeding vessels. The effects of pressor agents on free flaps are further 
explored in Chapter 3.  
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2.8 Thrombotic Complications 
Virchow in 1856 postulated that venous thrombosis was related to three factors, commonly 
referred to as Virchow triad: (1) abnormalities in the vessel wall, (2) alterations in blood flow, 
and (3) alterations in the constituents of the blood.
79
 
Coagulation is a complex process which can be divided into intrinsic and extrinsic pathways 
involving numerous clotting factors prior to the final common pathway where fibrinogen is 
converted to fibrin to form a stable clot. This complex interaction is one of the first processes to 
occur after tissue injury. It is reliant upon a number of co-factors, including calcium and vitamin 
K in addition to regulators such as Protein C and anti-thrombin.  
Since the description of thrombophlebitis migrans in association with gastric cancer by 
Trousseau in 1865 hypercoaguability has been well recognised in association with 
malignancy.
79
 Malignancy has a procoagulant effect through interactions with the coagulation 
cascade and the release of fibrinolytic factors and proinflammatory cytokines. As a result 
patients are at increased risk of thrombotic complications, including venous thrombotic events 
(VTE) and flap thrombosis.  
Standard prophylaxis against such complications includes the use of chemical agents, such as 
heparin. Heparin interacts with anti-thrombin III causing its activation which results in the 
inactivation of thrombin and other proteases involved in clotting, most notably factor Xa. 
Alternatives include aspirin which inhibits both prostaglandin synthesis and platelet aggregation 
by irreversibly inhibiting prostaglandin cyclo-oxygenase, and Dextrans which are 
macromolecules composed of glucose subunits. Dextrans have anti-platelet and anti-fibrin 
actions, and also improve microcirculation by decreasing blood viscosity and impeding 
erythrocyte aggregation.   
In flaps that demonstrate venous congestion, Leeches can be used to permit time for 
neovascularisation. Leeches secrete hirudin, a powerful anticoagulant, which inhibits thrombin 
and encourages bleeding for several hours after the leech has finished feeding. Early detection 
of a failing flap due to thrombotic complications increases the chances of successful salvage.   
 Page 50 of 217 
2.9 Flap Monitoring 
Maintenance of blood flow to the flap is of paramount importance and may be adversely 
affected by hypothermia, hypovolaemia, peripheral vasoconstriction, reduced cardiac output, 
hypoxia, and hypocarbia.
80
  
Post operative anastomotic problems requiring immediate re-exploration, occurs in 6-25% of 
cases.
43,81-83
 Successful salvage is dependent upon the time interval between flap compromise 
and anastomotic repair. Regular observation of the flap is paramount in the early post-operative 
period to identify early signs of compromise.  
Clinical assessment includes colour, capillary refill, turgor, and temperature. Pin prick provides 
further information in cases of concern, since a flap with venous congestion will rapidly bleed 
venous blood on pricking, and in cases of arterial obstruction bleeding will be significantly 
delayed or absent. However, clinical observation of intra-oral flaps can be challenging as a 
result of their location, particularly where the flap is buried (e.g. fibula free flap) with no skin 
paddle.
84
   
Adjuncts to enhance detection of the failing flap continue to be actively sought, and 
microsurgeons are increasingly utilising such monitoring devices to complement clinical 
assessment.
85,86
 Such a monitor capable of identifying perfusion compromise prior to the 
development of objective clinical signs would allow earlier intervention and potentially 
improved outcome following flap salvage.
87
 The ideal method for the assessment is non-
invasive, simple in application, inexpensive, rapidly responsive to changes in microcirculation, 
reliable and reproducible.
88
 Currently, one of the most popular devices is laser Doppler.  
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2.9.1 Laser Doppler 
The laser Doppler flow meter measures red cell flux in the skin by illuminating an area of skin 
with monochromatic light, and measuring the amount of light reflected from moving 
erythrocytes and the Doppler shift (change in wavelength) of the reflected light.
89
  
The laser Doppler is not calibrated to measure absolute blood flow in view of variable optical 
properties of different tissues.
77
 It indicates microcirculation in terms of Tissue Perfusion Units 
(TPU) defined by the manufacturer, a number which corresponds to variations in wavelength. 
Erroneously high values can be the result of tissue motion, either extrinsic (room vibration) or 
intrinsic (muscle fasciculation, respiration, or excessive patient movement).
87
 However, the use 
of laser Doppler is non-invasive, allows for continuous recording, and has been shown to be 
reliable.
47,49,90,91
 An alternative to external laser Doppler monitoring is to use an implantable 
Doppler probe attached to the pedicle. A probe implanted around the outflow vein of a flap will 
detect cessation of venous flow almost immediately; interruption of arterial flow will cause a 
near-immediate loss of the Doppler signal.
92
 The main difficulties associated with this system is 
that patients either require a second operation to remove the probe, or in Doppler probes 
designed to detach without surgery, such blind removal carries a potential risk of damage to the 
anastomosis.  
2.9.2 Temperature monitoring  
The monitoring of temperature forms one aspect of routine clinical assessment of flaps; a 
decrease in blood flow results in a decrease in temperature. An alternative to simple palpation 
and thermometers is the utilisation of infrared thermometry (thermography) and thermoelectric 
thermometers. However, these can be unreliable in intraoral flaps where a decrease in surface 
temperature occurs less readily.
84
 As a result an implantable device may offer more reliability. 
A thermocouple is placed adjacent to the inflow artery distal to the anastomosis with a control 
thermocouple adjacent to the recipient artery proximal to the anastomosis.
92
 Reduced blood flow 
due to arterial or venous thrombosis results in a decrease in temperature of the distal compared 
to the proximal probe. The main difficulties associated with this method include accurate 
placement and the avoidance of dislodgement.  
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2.9.3 Microdialysis 
Microdialysis is a sampling technique that monitors the metabolism of the flap. Ischaemia can 
be detected by monitoring the changes in glucose, lactate and pyruvate levels in the interstitial 
fluid of monitored tissue. The technique requires the passage of a microdialysis catheter into the 
flap tissues; the catheter is infused with isotonic Hartmann’s solution at a constant speed thus 
creating a concentration gradient. Diffusion of low-molecular weight substances occur across 
the catheters’ membrane, representing the composition of the interstitial fluid.92,93 Ischaemia is 
characterised by a very low glucose concentration, a rising lactate concentration, and a high 
lactate/pyruvate ratio. The main disadvantages of this system are the high costs, and intermittent 
nature of testing.  
Other potential solutions include the monitoring of tissue pH, glucose, transcutaneous partial 
oxygen pressure and colour Doppler sonography.
94,95
 However, laser Doppler monitoring has 
been most widely accepted by microsurgeons and is one of the most cost effective methods 
currently available. This is further explored in the following section of the thesis.  
 
Chapter Conclusion 
As a result of a combination of extensive surgery and associated co-morbidity, patients 
undergoing surgical management of head and neck cancer are at increased risk of post-operative 
complications with significant morbidity and mortality. At the time of surgery, patients present 
a high incidence of difficult intubations, which may be due to a combination of tumour mass, 
anatomical distortion from previous surgery.
80
 Older patients are also more sensitive to propofol 
and its induction of hypotension in these patients may critically reduce tissue perfusion and 
oxygenation.
69
 Peri-operative optimisation is vital for both free flap and patient survival.  
The following sections further explore the effects of pressor agents, nutrition, anticoagulation 
and fluid balance on morbidity following ablative and reconstructive surgery.  
  
 
 
3. Pressor Support 
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3.0 Pressor Support 
Patients with oral malignancies are frequently of advanced age and have chronically abused 
tobacco and alcohol with resulting co-morbidities.
22,23,25
 Many patients require BP support both 
intra-operatively and during the early post-operative recovery period to counteract the 
hypotensive effects of sedation or anaesthesia compounded by co-morbidities and concurrent 
medication. Whilst the sympathomimetic pressor agents used may increase systemic blood 
pressure and hence the driving pressure perfusing the flap, the associated vasoconstriction 
(assuming denervated flaps maintain such control), may paradoxically reduce flap perfusion 
resulting in flap ischaemia. As a result, many surgeons remain wary of using such agents.
74
 The 
optimal agent to maintain blood pressure without adverse effect on flap blood flow remains 
unclear.  
This section of the thesis concentrates on the peri-operative support of patients undergoing 
ablative surgery and free flap reconstruction in terms of blood pressure support. The section 
commences with a literature review, before review of the methodology and results in: 
1.  Eley KA, Young JD, Watt-Smith SR. Epinephrine, norepinephrine, dobutamine, and 
dopexamine effects on free flap skin blood flow. Plast Reconstr Surg 2012; 130(3):564-
70.
3
 
2. Eley KA, Young JD, Watt-Smith SR. Power spectral analysis of the effects of 
epinephrine, norepinephrine, dobutamine and dopexamine on microcirculation 
following free tissue transfer. Microsurgery 2013; 33(4):275-81.
4
  
3. Eley KA, Young D, Watt-Smith. Assessment of the effects of pressors on graft blood 
flow after free tissue transfer surgery: interim findings. Br J Oral Maxillofac Surg 2009; 
47(7): e41-42 [Published abstract].
5
 
4. Eley KA, Young D, Watt-Smith. Assessment of the effects of pressors on graft blood 
flow after free tissue transfer surgery: Phase I results. Br J Oral Maxillofac Surg 2010; 
48(Supp 1): S13 [Published abstract].
6
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3.1 Literature Review 
A comprehensive review of the literature was conducted to determine the current understanding 
of the effects of pressor agents following free tissue transfer. This was completed using NCBI 
Pubmed and Google Scholar with the following MeSH terms:  
(Free Tissue Flaps or Surgical Flaps [All fields]) and (“Cardiotonic agents” or 
“hemodynamics” or “Catecholamines” or “Ethylamines” or “Biogenic monoamines”). 
The titles and abstracts were reviewed to identify those papers with clinical relevance, with 
subsequent review of related citations and references.  
 
Free flap surgery results in the disruption of the autonomic nerves surrounding the feeder 
vessels of the flap. Lecoq et al
77
 investigated the early effects of surgical sympathectomy on the 
reactivity of cutaneous microcirculation when challenged by adrenergic agents. Using epigastric 
flaps in rats, they compared the effects of adventitiectomy to intact vessels following infusions 
of phenylephrine, adrenaline and prazosin (a specific α1 blocker) utilising laser Doppler 
flowmeter monitoring. The authors found that immediately after surgical adventitiectomy, the 
vasoconstriction produced by α-adrenergic agents was prevented without denervation induced 
hypersensitivity, however they only measured the response of each drug for 6 minutes. The 
authors concluded that this may result in protection of free flap microcirculation. This was 
further confirmed by McKee et al
96
 who examined the blood flow and pressure in the vessels 
supplying a free skin flap (inferior epigastric) in 25 mongrel dogs. They found that blood flow 
in the epigastric artery and vein increased significantly between exposure of the vessels and 
elevation of the flap. 
Further animal work was conducted by Massey et al,
73
 who evaluated the dose-dependent 
changes in the pedicle artery blood flow and microvascular perfusion of a porcine vertical rectus 
abdominis myocutaneous rotational flap with the systemic administration of phenylephrine and 
adrenaline. The microvascular perfusion to the skin of the flap in the 6 pigs was measured using 
a laser Doppler probe, with a further probe on the thigh to act as a control. The blood flow 
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through the pedicle artery was measured using an ultrasonic transit time flow probe on the 
superior epigastric artery. The effects of phenylephrine, adrenaline and sodium nitroprusside (a 
potent vasodilator) were investigated. Phenylephrine and adrenaline both increased systemic 
mean arterial pressures, whereas only adrenaline increased cardiac output. The microvascular 
perfusion of the flap decreased in a dose dependent fashion whilst that of the control increased, 
with phenylephrine. Pedicle artery blood flow was increased with increasing doses of adrenaline 
in all but one case. Conversely, Banic et al
52
 in their study of 9 pigs undergoing latissimus dorsi 
free flaps reported a 40% decrease in total flow in the flap with systemic sodium nitroprusside, 
and no change with systemic infusion of phenylephrine. Sun et al
97
 also explored the effects of 
sodium nitroprusside, phentolamine and phenylephrine on epigastric skin in rats. Power spectral 
analysis and laser Doppler flowmetry was performed. They found that sodium nitroprusside and 
phentolamine increased cutaneous perfusion, whilst phenylephrine decreased perfusion. 
Cordeiro et al
46
 examined the effects of vasoactive drugs on blood flow in island 
musculocutaneous flaps in pigs. They found that dobutamine had the most positive effect on 
flap flow. At increasing doses, it both increased cardiac output and flap flow. Hiltunen et al
98
 
reported that in their experiments looking at the effects of hypotension and noradrenaline on 
pedicled rectus abdominis myocutaneous flaps in pigs, that moderate normovolaemic 
hypotension or its correction with noradrenaline did not affect flap perfusion as assessed by 
microdialysis.  
Investigations into the effects on microvascular anastomoses includes that by Godden et al
99
 
who investigated the changes in sensitivity of rat femoral artery to phenylephrine after 
microvascular anastomosis, and if these changes could be blocked by the addition of 
phentolamine, an α-adrenergic blocker. Bilateral groin flaps were raised, with division and 
anastomosis of the femoral artery on one side only. They found that after microsurgery, the 
phenylephrine sensitivity of the anastomosed vessels was increased. The increased vascular 
sensitivity of the denervated rat femoral artery could be prevented by the addition of 
phentolamine. This therefore provides evidence for the survival of α-receptors following 
microvascular repair. However, anastomosis was performed to the donor vessel and not to an 
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alternative site, and it would appear that there was minimal ischaemic time between division 
and repair of the artery. 
Further investigation in living patients includes the work by Suominen et al.
100
 They assessed 
the effect of intra-operative administered inotropic agents on blood flow in the recipient and 
donor vessels during breast reconstruction with a muscle sparing transverse rectus abdominis 
myocutaneous (TRAM) flap. Patients were randomised into three groups, and received one of 
dobutamine, dopamine or saline (placebo) for 15 minutes. Dobutamine (8 µg/kg/min) was found 
to systemically increase CO and heart rate while it decreased SVR. A simultaneous increase in 
donor and recipient artery flow was noted with dobutamine, but not with dopamine which 
resulted in a mixed response with decreased flow seen in some patients.  
Dobutamine was further investigated by Scholz et al
74
 in patients following microvascular 
anastomosis. They investigated the effects of three infusion rates of dobutamine (2, 4 and 
6µg/kg/min) for a 10 minute period each, performed intra-operatively in 18 patients. Flow in the 
artery distal to the anastomosis was measured with a flowmeter. They found that with increasing 
doses of dobutamine there was a significant increase in heart rate, systolic blood pressure and 
cardiac index. Dobuamine at 4 and 6µg/kg/min significantly increased blood flow to the flap 
above baseline values.  
More recently, Chen et al
101
 retrospectively reviewed the medical records of 187 consecutive 
patients undergoing DIEP flaps, and free TRAM flaps for breast reconstruction. Of the patients 
studied, 102 received vasopressors (ephedrine and phenylephrine) during surgery. They found 
that there was no statistical difference in outcome, including flap loss and re-operation, between 
those who received vasopressors and those who did not. Additionally, they found no difference 
between the timing of vasopressor use intra-operatively, and outcome.  
 In most investigations researchers have utilised Doppler monitoring to assess the effects on the 
transplanted tissue or feeding vessels. Further analysis of the Doppler waveform provides 
information on the intrinsic control of the tissues. These effects were explored by Lansverk et 
al
102
 who examined the effects of pharmacological interruption of the sympathetic innervation 
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to the arm during brachial plexus blocks. Using two laser Doppler probes, they were able to 
compare the effects of brachial plexus block on one arm compared to the normal contralateral 
limb in 13 patients. They found that in the anaesthetised arm there were reduced relative 
amplitudes in the 0.021 to 0.052Hz and 0.0095 to 0.02Hz frequency intervals. These frequency 
intervals represent neurogenic and endothelial activity, respectively, and indicate an inhibitory 
effect on the sympathetic and endothelial activity, suggesting it is denervation rather than 
another operative factor that alters the low frequency oscillations in transplanted tissue.  
There are two previous studies of spectral analysis of free flap and control tissue blood flow 
signals. Liu et al
103
 examined the spectral analysis of 18 patients undergoing free latissimus 
dorsi transfer. The authors used a laser Doppler flowmeter to measure skin blood perfusion at 
the flap and a control site on the contralateral limb in patients with soft tissue injury of the lower 
extremity. They found that the spectral power and average amplitude of oscillations in the 
frequency range 0.0095-1.6Hz were dramatically lowered in the flaps. They concluded that a 
decrease in both the endothelial cell metabolic processes and sympathetic control, and an 
increase in the intrinsic myogenic activity occurred. Similar findings were reported by Sun et 
al
50
 who examined the spectral analysis changes prior to and following free radial forearm flap 
harvest and transplantation. They reported significantly increased high frequency (0.15-0.4Hz) 
and decreased very low frequency (0003-0.04 Hz) power fraction after flap transfer.  
In summary, of the pressor agents currently available, the studies to date demonstrate that 
dopamine and phenylephrine appear detrimental to flap flow. Noradrenaline appears to have 
limited effect on flap flow, whilst adrenaline and dobutamine are beneficial. Retrospective 
studies of ephedrine suggest that this agent does not have adverse effects on free flaps. There 
are no studies available in the literature that have explored the effects of dopexamine, 
metaraminol, or isoprenaline.  
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Overall, whilst these studies provide valuable information on the potential effects of pressor 
agents on transplanted tissues, they have failed to address the important clinical question of 
which agent should be utilised first line in patients undergoing free tissue transfer following 
ablative surgery for head and neck malignancy.  
The following section explores the methodology of the presented papers, with the aim of 
identifying the effects of four commonly utilised pressor agents on flap perfusion thus providing 
guidance on which agent should be utilised in the peri-operative period.   
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3.2 Materials & Methods 
A prospective study investigating the effects of four pressor agents was completed in patients 
presenting with head and neck malignancy between 2008 and 2010. In total 24 patients (16 
male; 8 female) were recruited to the study. One patient re-presented during the study period 
with a second primary tumour, and was recruited to the study on both occasions, resulting in 25 
sets of results. The inclusion criteria were patients undergoing free flap surgery for head and 
neck cancer resection with a planned post-operative intensive care unit admission for overnight 
sedation and ventilation, which is standard local practice. The only exclusion criteria were 
pregnancy or a bodyweight above 100kg.  
All patients had both a central venous line and an arterial line sited at the time of anaesthesia as 
part of routine clinical care. Intra- and post-operatively in the intensive care unit, fluid 
management was optimised with the aid of the LiDCO™ Rapid system, which uses a pulse 
contour analysis algorithm (“PulseCO”) to estimate stroke volume.104 Stroke volume variation 
below 10% was taken to indicate optimal fluid loading throughout the study. 
Free flap reconstruction was with a free radial forearm flap (n=16), latissimus dorsi (n=2), 
anterolateral thigh flap (n=1) or free fibula flap (n=2). In the remaining 4 cases reconstruction 
was with two simultaneous free flaps (ALT and fibula n=3, radial forearm and fibula n=1) 
(Table 2). At the end of the surgical procedure, two Transonic laser Doppler red blood cell 
velocimetry probes were attached to the skin – one central on the free flap skin paddle, and one 
acting as a control (Figure 16 & 17). To standardise the control site, and to minimise impact 
upon vascular access, the skin over the deltoid muscle was used in all cases. 
The Transonic device calculates skin blood flow as the product of the number of red cells 
moving in the illuminated field, and their mean velocity, to provide a measure of red cell flux 
(blood flow). This is expressed in tissue perfusion units (TPU), a unitless measure, as it is not 
possible to calibrate the probes. Flap skin blood flow was logged from the Transonic device 
using AcqKnowledge version 3.9.1.6 software on a personal computer at 40 samples per 
second.  
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Figure 17: Laser Doppler probe sited on the centre of a 
cheek flap.  
 
 
 
Figure 16: Equipment set up in the intensive care unit for the 
pressor study.  
Continuous Doppler monitoring of the flap and control sites was 
conducted using Transonic laser Doppler probes.  
Fluid management was optimised using LiDCO™ Rapid.  
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Red cell transfusion to maintain a haemoglobin concentration above 8.0g/dL was completed 
before the study commenced. Once the patient was stabilised on the intensive care unit, and if 
the mean arterial pressure (MAP) was below 80mmHg, the patients received four pressor drugs 
(adrenaline, noradrenaline, dobutamine and dopexamine) infused at four increasing doses 
(Table 3).  The order of drug administration was randomly pre-determined and concealed in an 
opaque envelope until commencement of the trial. The research and medical teams were 
unblinded to the infusion drug and rate.  
Each drug was administered for 5 minutes at each rate intravenously via the central line. The 
infusion was stopped if the MAP increased by more than 30mmHg, the heart rate reached 150 
beats per minute or there was an adverse effect. At the end of each infusion, 5ml of blood was 
aspirated and discarded from the central line, and the line flushed with 10ml of normal (0.9%) 
saline. A 20 minute period elapsed prior to commencing the next drug in the sequence to permit 
adequate time for physiological variables to return to baseline. Throughout the periods of 
baseline recording and drug infusions, sedation was maintained at a steady rate, and only 
maintenance fluids were administered.  
At the end of the trial, if the patient required continued pressor support, the drug producing the 
best increase in flap skin blood flow from the trial data was selected.  
The final two minutes of the five minute recording period of each drug rate was used for 
subsequent analysis. The time period was identified on the AcqKnowledge system, and the data 
transferred to a Microsoft Excel spreadsheet. The recording (in tissue perfusion units) over the 
two minute period was averaged to obtain a mean value for the flap and the control skin. This 
was completed for each of the four drugs for all of the four drug infusion rates, and at baseline 
prior to commencing any drug infusion. The fractional change from the baseline was calculated 
for each of the infusion rates.  
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Patient:  Age Sex BMI Resection  Free flap donor 
site  
1  67 M 25.3 Left hemiglossectomy  Radial  
2  62 F 24.9 Left hemiglossectomy  Radial  
3  62 F 23.4 Total glossectomy  Latissimus dorsi  
4  65 M 24.2 Hemi-mandibulectomy  Fibula  
5  58 M 32.8 Hemi-mandibulectomy  Fibula  
6  61 F 18.0 Resection floor of mouth/mandible  ALT + Fibula  
7  53 F 22.4 Left hemiglossectomy  Radial  
8  43 M 24.3 Maxillectomy and orbital enucleation  Latissimus dorsi  
9 * 68 M 25.0 Resection right buccal sulcus  Radial  
10  54 F 24.7 Left hemimandibulectomy  Radial + Fibula  
11  63 M 19.4 Resection right tongue/mandible  ALT + Fibula  
12  48 M 24.3 Left partial glossectomy  Radial  
13 * 69 M 24.7 Right hemimandibulectomy  ALT + Fibula  
14  60 F 24.7 Right hemiglossectomy  ALT  
15  47 M 26.3 Resection left buccal mucosa  Radial  
16  64 M 17.5 Resection floor of mouth  Radial  
17  57 F 25.4 Right hemiglossectomy  Radial  
18  64 M 26.0 Resection adhesions tongue  Radial  
19  54 M 27.1 Right hemiglossectomy  Radial  
20  69 M 23.9 Right hemiglossectomy  Radial  
21  67 M 30.4 Resection right tonsillar fossa  Radial  
22  56 M 17.8 Resection right posterior tongue  Radial  
23  66 M 24.7 Resection left tonsillar fossa  Radial  
24  57 M 24.7 Resection ventral tongue  Radial  
25  73 F 24.4 Right hemiglossectomy and partial maxillectomy  Radial  
 
Table 2: Demographics of the 25 patients recruited to the pressor study. 
(BMI=Body mass index ; ALT=anterolateral thigh flap).  
*Patient 9 & 13 are the same patient, enrolled in the study on two separate occasions, having 
presented with a second primary tumour during the study period. 
 
 
 
Drug  Concentration 
(mcg/ml)  
1st  
infusion rate  
(mcg/kg/min)  
2nd  
infusion rate  
(mcg/kg/min)  
3rd  
infusion rate  
(mcg/kg/min)  
Final  
infusion rate  
(mcg/kg/min)  
Adrenaline  20  0.05  0.1  0.15  0.2  
Noradrenaline  20  0.05  0.1  0.15  0.2  
Dobutamine  500  2  4  6  8  
Dopexamine  1000  1.25  2.5  3.75  5  
 
Table 3: Drug infusion rates for the four agents used in the pressor study 
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Corresponding data from LiDCO™ Rapid was entered onto the Microsoft Excel spreadsheet 
and corresponding flap conductance   
                      
                             
 ) calculated. This result was 
also converted to a fractional change from baseline.  
Spectral analysis (Figure 18) of the Doppler data was performed using Matlab version 
7.11.0.584 (R2010b). This was completed by using the last 4096 samples (102.4 seconds of 
recording). The total power (the amount of variation in blood flow) in the signal was calculated 
as the variance. A standard signal processing approach was used to determine the frequency 
components of the blood flow signal. Three 2048 sample (51.2 second) segments with 50% 
overlap were derived by dividing up the total period of 4096 samples. Each underwent linear 
trend removal (to remove baseline drift) and was then windowed with a Hamming window 
function (required to remove artefacts generated at the start and end of the recordings) before 
conversion to zero mean unit variance format, which allowed comparison between patients 
irrespective of the total blood flow.  
Power spectra (the plot of blood flow oscillations at each frequency) were computed using a 
standard fast Fourier transform algorithm, and the resulting three spectra averaged to give the 
final result. Only the frequencies below 3Hz were used for graphing. This analysis was 
performed for each of the four drugs and four drug concentrations, and prior to commencement 
of any drug infusion, for all 25 sets of results and both recording sites.  
For each patient the power in the baseline (pre-drug) period was used to normalise the 
subsequent results for both control and flap sites. The results from all patients were averaged. In 
addition for each patient and each dose the control site spectrum was subtracted from the flap 
site spectrum to highlight any differences between the sites.  
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Ethical Considerations 
Ethical approval was granted from the Oxfordshire Research Ethics Committee (08/H0606/31), 
and written informed consent obtained from all participants.   
Statistical Analysis 
Data was analysed using line graphs to identify trends in flow and conductance. Statistical 
analysis for differences in variance (variability) between control site and flap was completed 
using t-tests, with Šidák correction for multiple comparisons, on SPSS (Statistical Package for 
the Social Sciences). The probability of differences between regions of the normalised power 
spectra arising by chance could not be tested statistically and so differences reported are based 
on simple interpretation of the graphs.  
 
 
Figure 18: The Doppler waveform and spectral analysis.  
Shown above is an example of the Doppler waveform of the flap and control tissues. The 
waveform if visualised more closely, as shown below, is composed of oscillations representative 
of the intrinsic control. These are demonstrated via spectral analysis.  
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3.3 Results 
The mean values for each of the cardiovascular variables at baseline and for each infusion are 
shown in Table 4. Only five patients received the maximum noradrenaline infusion rate 
(0.15mcg/kg/min) as the others all reached the upper safety limit for blood pressure at a lower 
dose.  
All of the drugs except noradrenaline resulted in an increased heart rate. Noradrenaline and 
adrenaline caused an increase in mean arterial pressure, whilst dobutamine and dopexamine 
caused a modest decrease. All drugs increased cardiac output.  
Figure 19 shows graphically the mean and standard error of fractional change in skin perfusion 
from baseline for both the control and flap. For adrenaline and dopexamine tissue perfusion 
(flap flow) decreased, whilst that at the control site decreased and increased respectively. For 
noradrenaline and dobutamine flap flow increased at lower infusion rates, whilst the control site 
decreased and increased respectively. The greatest increase in flap skin blood flow occurred 
with 0.1-0.15mcg/kg/min noradrenaline.  
To examine the vasodilator or vasoconstriction effects of the drugs independent of the MAP, 
skin blood flow conductance was calculated (Figure 20), with an increase signifying 
vasodilatation. Only dopexamine caused an increase in conductance for both flap and control 
with increasing infusion rates. Adrenaline and noradrenaline were both vasoconstrictors 
(reduced conductance), though noradrenaline had less effect on the flap compared to control 
tissue.  
For the one patient recruited twice into the study, the findings on both occasions yielded similar 
results for flow and conductance, with all drugs except adrenaline. With adrenaline, it was noted 
that the first study for this patient (Patient 9) resulted in increased flow for both flap and control, 
which was not consistent with the repeat study (Patient 13) nor with the mean overall findings 
for all of the patients combined.   
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Figure 19: Graphs of mean fractional change in perfusion from baseline for each drug 
infusion for the flap and control tissues.  
Red indicates free flap flow, blue indicates control.  
 
 
Figure 20: Graphs of mean fractional change in conductance from baseline for each 
infusion. A decrease in conductance signifies vasoconstriction, as was seen with 
adrenaline and noradrenaline. Red indicates the free flap, blue indicates the control 
tissues.  
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Table 4: Mean cardiovascular variables at each pressor infusion rate.  
Results are shown as mean (SD). (HR=heart rate; MAP=mean arterial pressure; CO=cardiac 
output; CI=cardiac index.)  
 
 
 
Table 5: Drug infusion rates, cardiovascular variables and mean total power of the laser Doppler 
blood flow signal at both sites for all drug doses.  
The power has been normalised to the baseline (pre-drug) reading. Values are shown as mean± SD. 
 
  
Mean (SD) 
 
Concentration 
(mcg/kg/min)  
HR 
(beats/min) 
Systolic 
(mmHg) 
MAP 
(mmHg) 
CO 
(L/min) 
CI 
(L/min/m
2
) 
Baseline  -  77 (13) 113/57 (17/7) 76 5.2 (1.3) 2.9 (0.5) 
Adrenaline  0.05  86 (15) 116/53 (22/8) 73 6.7 (2.1) 3.7 (1.1) 
 
0.1  92 (16) 129/55 (24/7) 77 8.2 (2.7) 4.5 (1.4) 
 
0.15  99 (17) 139/57 (26/7) 80 9.5 (3.0) 5.2 (1.5) 
 
0.2  106 (17) 147/61 (24/8) 85 10.5 (3.5) 5.9 (1.8) 
Noradrenaline  0.05  76 (15) 136/66 (30/10) 89 5.7 (1.4) 3.1 (0.6) 
 
0.1  76 (14) 14871 (26/9) 98 6.2 (1.6) 3.38 (0.8) 
 
0.15  76 (16) 161/76 (21/9) 106 6.8 (1.6) 3.6 (0.8) 
 
0.2  84 (13) 168/72 (13/7) 103 6.9 (2.0) 3.9 (0.7) 
Dobutamine  2  84 (16) 126/58 (25/9) 80 6.5 (2.0) 3.6 (0.9) 
 
4  91 (18) 131/58 (21/11) 80 7.3 (2.5) 4.0 (1.1) 
 
6  99 (20) 132/56 (22/8) 78 8.2 (2.9) 4.5 (1.4) 
 
8  107 (18) 134/55 (23/7) 76 9.8 (3.2) 5.3 (1.4) 
Dopexamine  1.25  88 (15) 107/52 (20/9) 68 6.6 (2.0) 3.6 (0.9) 
 
2.5  95 (15) 105/48 (22/8) 66 7.6 (2.9) 4.2 (1.4) 
 
3.75  102 (16) 104/46 (22/8) 64 8.4 (2.9) 4.6 (1.3) 
 
5  109 (17) 103/45 (23/8) 62 9.2 (3.2) 5.0 (1.5) 
 
 
 
Infusion Rate 
(mcg/kg/min) 
Number of 
patients 
receiving 
dose 
Mean Flap Control 
HR 
(beats/min) 
MAP 
(mmHg) 
CI 
(l/min/m
2
) 
Mean 
normalised 
power 
Mean 
normalised 
power 
Baseline  -  77±13 76 2.9±0.5 1.00±0.00 1.00±0.00 
Adrenaline: 
25% 0.05  25 86±15 73 3.7±1.1 1.23±0.83 1.67±2.93 
50% 0.1  25 92±16 77 4.5±1.4 1.57±1.39 1.34±0.97 
75% 0.15 24 99±17 80 5.2±1.5 1.87±1.89 1.34±0.96 
100% 0.2 21 106±17 85 5.9±1.8 1.76±1.83 1.34±0.75 
Noradrenaline: 
25%  0.05 25 76±15 89 3.1±0.6 2.74±3.69 1.26±0.84 
50% 0.1 19 76±14 98 3.4±0.8 3.57±7.57 1.37±0.88 
75% 0.15 13 76±16 106 3.6±0.8 4.42±6.59 1.34±0.82 
100% 0.2 5 84±13 103 3.9±0.7 1.90±1.76 0.79±0.52 
Dobutamine: 
25% 2 25 84±16 80 3.6±0.9 1.55±1.10 1.24±0.53 
50% 4 23 91±18 80 4.0±1.1 1.50±1.08 1.75±1.93 
75% 6 23 99±20 78 4.5±1.4 1.48±1.19 1.48±0.99 
100% 8 22 107±18 76 5.3±1.4 1.28±0.77 1.71±1.34 
Dopexamine: 
25%  1.25 25 88±15 68 3.6±0.9 1.02±0.57 1.19±0.77 
50% 2.5 25 95±15 66 4.2±1.4 1.48±1.93 1.28±0.94 
75% 3.75 25 102±16 64 4.6±1.3 1.23±1.37 1.23±0.60 
100% 5 25 109±17 62 5.0±1.5 1.83±2.44 1.13±0.74 
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By analysing the power spectra contained within the Doppler waveform the effects of these 
agents on local tissue control could be determined. For each dose the average normalised power, 
standard deviation of the normalised power and the changes in the power of the blood flow 
signal (the variance of the signal) are shown in Table 5.  There was no statistically significant 
difference between the variability in the control site and flap at any drug dose (“t” tests, Šidák 
correction for multiple comparisons, all p values >0.05), despite the power spectra for the flap 
flow appearing to exhibit far more variability with noradrenaline.  Figure 21 shows the power 
spectrum from the control site of one of the patients in the study. The cardiac, respiratory and 
myogenic components are seen as discrete peaks, the neurogenic and local endothelial-based 
control cannot be separately distinguished in this example. 
The control (pre-drug) averaged power spectra is shown in Figure 22, and at maximum dose 
(adrenaline, dobutamine and dopexamine) and 75% maximum dose noradrenaline, (as only 5 
patients reached maximum dose) are shown in Figure 23. Intervening doses showed similar 
changes. Nearly all the oscillation in blood flow was in the range of 0-3Hz with almost none in 
higher frequency bands. Figure 22 shows the control (pre-drug) spectra. The power in the 
region below 0.1Hz was reduced. As the spectra were normalised there was a corresponding 
increase in the power in the 0.8-1.7Hz range representing the heart rate. The differing heart rates 
of the subjects broadened this peak. At the maximum adrenaline infusion rate the heart rate 
increased and the spread of heart rates also increased. As a result the heart rate dependent peak 
moved to higher frequencies and broadened. The proportion of the total power in the lower 
frequencies increased. At the maximum dobutamine infusion rate there was little effect on the 
distribution of the control of blood flow, though as with all drugs studied the cardiac related 
peak increased in frequency and broadened. Dopexamine demonstrated the same findings as 
dobutamine. However with noradrenaline at 75% of maximum dose, low frequency activity 
below 0.1Hz was higher in the flap compared to control, and the difference between flap and 
control in the 0.1-0.4Hz band was less marked than with other drugs.  
No adverse events or flap failures were noted in any of the patients as a result of the pressor 
infusions.  
 Page 70 of 217 
 
 
 
 
 
 
 
  
 
 
Figure 21: Power spectra at baseline. 
This demonstrates the characteristic peaks extracted from the Doppler waveform, 
corresponding to heart beat, respiration, intrinsic myogenic and neurogenic control.  
 
 
Figure 22: Power spectra for flap and control tissues at baseline.  
The flap tissues are shown in red, and the control tissues in blue. Inset: The differential 
between flap and control tissues (flap-control).  
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Figure 23: Power spectra for the flap and control tissues with pressor infusions. 
Shown are the power spectra for flap (red) and control (blue) tissues for (A) adrenaline 
0.2mcg/kg/min (B) dobutamine 8mcg/kg/min (C) dopexamine 5mcg/kg/min and (D), 
noradrenaline 0.15mcg/kg/min.  
Inset panels in each graph show the averaged differences (flap spectrum-control spectrum) to 
assist interpretation.  
Note that the spectra were all normalised (i.e. set to the same area under the curve) by the zero 
mean unity variance processing, so total power cannot be compared with these graphs. 
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3.4 Discussion 
It has been demonstrated that whilst noradrenaline results in vasoconstriction in both the flap 
and the control tissue, the effect is more marked in the control tissues. This vasoconstrictor 
effect on the flap is more than overcome by the resultant increase in blood pressure caused by 
noradrenaline, resulting in a significant increase in flap perfusion. Dobutamine also reliably 
increased flap and control site blood flow by about 10% (compared with the 30% maximum 
seen with noradrenaline) without causing a change in conductance and with little effect on blood 
pressure.  
The power spectra confirmed a number of anticipated findings following free tissue transfer. All 
drugs increased the power (overall variability) of the blood flow signal at both sites, and this 
was more marked for adrenaline and especially noradrenaline. At the maximum dobutamine 
infusion rate there was little effect on the distribution of the control of blood flow. However 
with noradrenaline at 75% of maximum dose, low frequency activity below 0.1Hz was higher in 
the flap compared to control, and the difference between flap and control in the 0.1-0.4Hz band 
was less marked than with other drugs. This suggests that the noradrenaline infusion increases 
the local myogenic control of blood flow in the free flap to a greater extent than the other drugs 
studied. 
 
Chapter Conclusion 
Noradrenaline most consistently elevated the mean arterial pressure and caused by far the 
largest increase in flap skin blood flow, making it the pressor agent of choice (of those studied), 
following free tissue transfer. This is supported by the finding that the control of blood flow 
shifts towards low frequency vasomotion where blood flow depends mostly on average blood 
pressure. 
  
 
 
4. Coagulation 
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4.0 Coagulation 
 
In 2005, the House of Commons Health Committee reported that an estimated 25,000 people in 
the UK die from preventable hospital-acquired venous thromboembolism (VTE) every year. 
105
  
The NICE guidelines on VTE state that any patient undergoing a surgical procedure with a 
general anaesthetic and surgical time of more than 90 minutes should be considered at increased 
risk of VTE. Patients with cancer, aged over 60 years, have a critical care admission, or have 
one or more significant medical co-morbidities are further risk factors.  
These risk factors are further compounded in patients with head and neck malignancy due to the 
procoagulant effects of malignancy.  
In combination with the significant risks of VTE in patients undergoing free flap surgery for 
head and neck malignancy, there remains an appreciable risk of anastomotic thrombosis, most 
notable within the first 48 hours, with resultant disastrous consequences.
106
 As a result, the 
majority of surgeons utilise pharmacological antithrombotic agents.
44,107,108
 However, such 
practice remains controversial since inappropriate anticoagulation may result in external 
haematoma formation and compromise of flap perfusion.  
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This section of the thesis focuses on peri-operative management of coagulation in patients 
undergoing ablative surgery and free flap reconstruction. The section commences with a 
literature review, prior to review of the methodology and results of:  
5. Parker RJ, Eley KA, Von Kier S, Pearson O, Watt-Smith SR. Functional fibrinogen to 
platelet ratio using thromboelastography as a predictive parameter for thrombotic 
complications following free tissue transfer surgery: a preliminary study. Microsurgery 
2012; 32(7): 512-9.
7
 
6. Eley KA, Watt-Smith SR. Low molecular weight heparin in patients undergoing free 
tissue transfer following head and neck ablative surgery: a review of efficacy and 
associated complications. Br J Oral Maxillofac Surg 2013; Oct;51(7):610-4.
8
  
7. Eley KA, Watt-Smith SR. Coagulopathies and the use of LiDCO Plus Rapid monitoring 
in patients following head and neck cancer resection and reconstruction. Br J Oral 
Maxillofac Surg 2010; 48(6): 466.
9
 
8. Eley KA, Parker R, Bond SE, Watt-Smith SR. Are routine prophylactic dalteparin doses 
appropriate in patients undergoing head and neck cancer resection? Int J Oral Maxillofac 
Surg 2009; 38(5): 584-5 [Published abstract].
10
 
9. Parker R, Eley KA, Bond SE, Watt-Smith SR. Is the ratio of functional fibrinogen to 
platelets as measured by thromboelastography a predictive parameter for thrombotic 
complications in free tissue transfer surgery? Int J Oral Maxillofac Surg. 2009; 38(5): 585 
[Published abstract].
11
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4.1 Literature Review 
A comprehensive review of the literature was conducted to explore the current practices in peri-
operative management of coagulation following free tissue transfer. This was completed using 
NCBI Pubmed and Google Scholar with the following MeSH terms:  
(Free Tissue Flaps or Surgical Flaps [All fields]) and (“Blood coagulation” or “Blood 
coagulation factors” or “Blood coagulation tests” or “Anticoagulants” ). 
The titles and abstracts were reviewed to identify those papers with clinical relevance, with 
subsequent review of related citations and references.  
 
Flap failure may occur due to vascular complications despite meticulous microvascular 
technique, with venous thrombosis being more common than arterial occlusion.
109
 This 
thrombogenic effect may be the result of several factors. Expression of the proteolytic enzyme 
CP (cancer procoagulant, a cysteine proteinase) by malignant tumour cells is known to directly 
activate factor X without interaction with the intrinsic or extrinsic coagulation pathways.
110-112
 
Increased levels of TF (tissue factor), PAI-1 (plasminogen activator inhibitor), the inflammatory 
cytokines TNF (tumour necrosis factor), IL1, IL8 (interleukins) and VEGF (vascular endothelial 
growth factor) are all associated with tumour related thrombosis.
112,113
 Additionally reduced 
expression of regulators of coagulation such as tPA (tissue plasminogen activator) and TM 
(thrombomodulin) on the endothelial surface and concomitant increased production and 
deposition of fibrin are also observed in tumour related thrombosis. Higher flap failure rates in 
malignancy cases would therefore be anticipated; however, reported rates do not appear to 
support this.
114-117
  
Fibrinogen is synthesised in the liver and forms the final step in the clotting cascade when it is 
converted to fibrin with formation of the clot. In addition to its well known roles in blood 
coagulation, recent studies have shown that fibrinogen plays important roles in a variety of 
processes, which include cell-to-cell interactions, inflammation, and cancer progression.
118
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Concentrations of fibrinogen can increase by as much as 200-400% during times of 
physiological stress, primarily due to the actions of macrophage-derived IL6.  
High plasma fibrinogen levels have been correlated with increased thromboembolic risk in 
patients with cancer or cardiovascular disease.
119
 Wayman et al
79
 noted that fibrinogen 
concentration was significantly higher in patients with oesophageal carcinoma than in age and 
sex matched control patients with benign disease. Fibrinogen concentration was also higher in 
patients who had a greater depth of tumour invasion and those with metastatic disease.  
Kuo et al
119
 investigated the impact of hyperfibrinogenemia on patency of microvascular 
anastomoses. Using a rodent model, they performed femoral artery and vein anastomosis with 
and without intravenous administration of fibrinogen. Laser Doppler flowmetry was used to 
assess the patency of the anastomosis pre-operatively and 2 hours post-operatively. Vascular 
patency was assessed 7 days post-operatively. They found that there was no statistical difference 
in patency of the femoral vessels after vessel division and re-anastomosis. This experimental 
data did not support their clinical findings that 20% of patients with hyperfibrinogenemia 
suffered post-operative thrombotic events resulting in flap failure. 
Wang et al
120
 highlighted the problems associated with free tissue transfer in hypercoagulable 
patients. Of the 2032 flaps performed over a 5 year period, 58 flaps were identified to have been 
performed in patients having thrombophilia or previous thromboembolic event. The rate of 
thrombosis was 20.7% (12 flaps), including those occurring intra-operatively, with a flap loss 
rate of 15.5%. Most of these flaps failed late, outside of the typical 48 hour window. Whilst the 
authors advocated careful pre-operative assessment to identify patients at risk, Davison et al
121
 
presented four patients in whom flap failure occurred due to unrecognised hypercoagulation, 
highlighting that no routine, inexpensive, specific screening test predicts for the development of 
hypercoagulopathy-related peri-operative complications.  
In their review of pharmacologic optimisation of microsurgery, Conrad and Adams
122
 following 
an extensive review of the literature, reported their experience with 500 free flaps. They found 
that Dextran resulted in several cases of volume overload and pulmonary oedema and therefore 
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advocated the use of low dose aspirin for two weeks post-operatively, and intra-operative 
heparin. Dextran impairs platelet function, prolongs bleeding time and destabilises fibrin 
polymerisation. It is related to anaphylactic reactions and systemic effects, making its use in 
patients over 50 years of age unadvisable. As recommended by Conrad and Adams
122
 aspirin 
and heparins are more suitable for patients with head and neck malignancy, who are typically of 
advanced age. Low molecular weight heparins (LMWH) have broadly replaced unfractionated 
heparin (UFH) due to more preferable pharmacokinetics and an improved safety profile.
123
 
Reiter et al
124
 reviewed the outcome and peri-operative complications of 137 free flap 
procedures using low molecular weight enoxaparin prophylaxis. The overall flap survival was 
97.1%, and the overall return to theatre rate was 15.3%. A similar retrospective study was 
completed by Chen et al.
125
 They reviewed 6,759 surgical procedures for oncologic 
reconstruction, with comparisons made between those undergoing head and neck reconstruction 
(n=1,591) with all other surgical procedures (n=5,168) during the same period. Of those 
undergoing free flaps to the head and neck (n=473), there were 4 cases of symptomatic DVT, 
and 7 cases of PE. Post-operatively head and neck free flap patients received aspirin and 
LMWH in addition to pneumatic compression devices; despite this the incidence of VTE was 
higher than in non head and neck patients.  
It is well documented that patients with malignant disease are at increased risk of VTE, with 
malignancy being the aetiological factor in 20% of VTE events in the community, and resulting 
in a 100-fold increase in incidence in hospitalised patients.
126-127
 In patients undergoing free 
tissue transfer, this risk is further compounded by immobility and prolonged surgical 
procedures.  
Locally, dalteparin is usually the preferred LMWH. Blackburn et al
128
 assessed the safety of a 
change in protocol in which the first dose of dalteparin was increased from 2500 to 5000 units 
12 hours pre-operatively in patients undergoing major head and neck surgery with 
microvascular reconstruction. In total they reviewed 68 patients evenly distributed across the 
two dalteparin regimens. The primary outcome measure was the bleeding index and the 
secondary outcome measure was post-operative return to theatre for bleeding or evacuation of a 
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haematoma. Pre-operative use of warfarin was considered a factor for exclusion. The bleeding 
index (BI) over 5 days (range 40–60) was used as an objective, surrogate measure of peri-
operative bleeding, where: 
BI = [pre-operative haemoglobin (g/L) - day 4-6 post-operative haemoglobin (g/L)] + number of 
units of packed cells transfused in the interim.  
They found no significant difference in the mean bleeding index between the two groups, and 
the authors concluded that an increased dose of dalteparin did not seem to increase bleeding 
complications. The efficacy of the increased dose was not studied. The benefit of commencing 
LMWH pre-operatively has been debated. Strebel et al
129
 in their systematic review of LMWH 
regimens in patients undergoing elective hip surgery found no convincing evidence that starting 
prophylaxis pre-operatively is associated with a lower incidence of VTE than starting post-
operatively.  
With only a moderate prolonging effect on the activated partial thromboplastic time, anti-Xa 
levels are preferentially used to monitor LMWH therapy.
130
 For dalteparin the recommended 
peak anti-Xa level is 0.5-1.0 IU/ml or 1.0–2.0 IU/ml for full anticoagulation with twice daily 
and once daily dosing, respectively, and 0.2-0.4 IU/ml for prophylactic VTE 
anticoagulation.
130,131
 The same dose regimen for prophylaxis is routinely used for all patients 
post-operatively, irrespective of their body mass index (BMI).    
In an attempt to predict risk there are various scoring systems available. In patients with head 
and neck malignancy, one such system, the Caprini score
132
 would result in the majority of 
patients being deemed high risk – since patients are mostly over the age of 60 years (2 points), 
have malignancy (2 points), are having major surgery (2 points), and depending upon the donor 
site, will have an immobilising plaster (2 points).
132
 In view of smoking and alcohol use, many 
will also score additional points for co-morbidity. 
Early identification of the failing flap is paramount for successful salvage. A method to reliably 
predict those patients most at risk would permit additional measures to be instigated in an 
attempt to minimise flap failure. 
 Page 80 of 217 
Thrombelastography (TEG
®
) has been used for many years to detect coagulopathy and 
hypercoagulable states, and is now widely used as a near-site haemostasis monitor.
133-135
 TEG
®
 
technology analyses the functional activities of the cellular elements, such as platelet 
cytoplasmic granules and platelet surfaces, in conjunction with plasma components. Because the 
TEG
®
 analyser monitors the shear elasticity of clotting blood, it is sensitive to all of the 
interacting cellular and plasmatic components. These include coagulation and fibrinolytic 
factors, activators, and inhibitors which may affect the rate or structure of a clotting sample and 
its breakdown. The TEG
®
 analyser can be used to calculate the ratio of functional fibrinogen to 
platelets (the “functional” component being only the fibrinogen which is biologically active) by 
utilising an additional reagent. There are no published findings in the literature (apart from the 
presented paper) exploring the use of TEG
®
 in free tissue transfer. 
The following section explores the methodology used in the presented papers, with the aim of 
determining: a) if the ratio of functional fibrinogen to platelets, as measured by TEG
®
, is a 
reliable predictor of intra- and post-operative thrombotic complications following free tissue 
transfer surgery, and b) the therapeutic response to standard LMWH dose in patients (using anti-
Xa levels) following ablative and reconstructive surgery for head and neck cancer.  
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4.2 Materials and Methods 
 
The methodology is divided into two discrete phases: 
4.2.1 TEG 
A retrospective review of patients undergoing surgery for head and neck pathology with free 
flap reconstruction, performed between April 2006 and June 2007 was conducted.  
Functional fibrinogen to platelet ratio was determined at induction of anaesthesia and this 
baseline result used for subsequent analysis. All patients, as per local routine practice, had 
regular TEG
®
 analyses (without the additional functional fibrinogen to platelet ratio) performed 
throughout the peri-operative period in addition to routine haematology and biochemistry 
investigations (including a coagulation screen).  
TEG
®
 analysis was completed using the TEG
®
 5000 haemostasis analyser (Haemoscope Corp, 
Niles, IL) (Figure 24). This measures the visco-elastic properties of blood, and the resulting 
haemostasis profile is a measure of the time it takes for the first fibrin strand to be formed, the 
kinetics of clot formation and the strength and dissolution of the clot (Figure 25). 
Approximately 80% - 90% of the strength of the maximum amplitude (MA) is related to platelet 
numbers and function. 
A “Clauss correlated” functional fibrinogen level (TEG-Fib) achieved through the addition of 
the monoclonal antibody c7E3 (abciximab (ReoPro®, Eli Lilly, Indiana, USA)) which binds the 
glycoprotein IIb/IIIa receptor on the platelet surface, was used to remove the platelet component 
of the clot to measure the fibrinogen contribution to clot strength, expressed as MAR.  
 
 
 
 
 
 
Figure 24: TEG haemostasis analyser.  
TEG analyses the viscoelastic properties of blood.  
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With the concurrent use of an unmodified TEG
®
 sample, the independent contribution of 
fibrinogen and platelets to the overall clot strength could be determined. For standard TEG
® 
analysis, a 1ml sample of whole blood was added to a kaolin activator vial. After inverting the 
vial to ensure adequate mixing, 360µgs of kaolin activated whole blood was transferred to the 
analyser. To test the functional fibrinogen level, 355µgs of the remaining kaolin activated whole 
blood was added to a second cup which contained 5µgs abciximab (Figure 26). Analytical 
software within the TEG
®
 software (version 4.2.3) was used to calculate the functional 
fibrinogen level (FLEV) through the transformation of the MA value.  
As the maximal amplitude (MA) of thromboelastography using whole blood (MAW) measures 
clot strength and represents the collective contribution of both fibrinogen and platelets it was 
possible to firstly inhibit the platelet function, and subsequently calculate the functional 
fibrinogen to platelet ratio using the equation:  
                                         
   
   
      
In total, 29 patients (male n=17; female n=12), with a mean age of 58 years (32 – 83 years) had 
functional fibrinogen to platelet ratios available (Table 6). Pre-operative anticoagulation in line 
with local protocol at the time of the study was not used. 
The functional fibrinogen to platelet results were compared to data previously obtained from a 
healthy adult control group (n=42). Participants in this group were freely consenting laboratory 
staff, who each donated 1ml of blood for baseline modified functional fibrinogen and standard 
TEG
®
 testing. This data was collected to permit familiarity with the methodology, and as such 
no demographic data was stored.   
Ethical Considerations 
Since blood analysis utilising TEG
®
 constitutes routine patient care (with no additional blood 
samples required), and the control group were laboratory staff, ethical approval was not 
considered necessary.   
Statistical Analysis  
Statistical analysis was performed with an Independent samples Mann Whitney U Test and 
Fishers Exact Test on SPSS version 17, with results displayed as mean±SD. 
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Figure 25: Schematic diagram of TEG trace.  
The TEG parameters illustrate the functional activity of clot initiation, kinetics, maximal 
strength and clot stability. 
 
 
 
 
 
 
 
 
  
 
Figure 26: Schematic diagram of the TEG trace. 
This shows: Large trace (red) the MA as a function of fibrinogen and platelet activity on whole 
blood (MAw); Small trace (pink) the MA as a function of fibrinogen contribution alone, after 
exposure to Reopro (MAR). Allowing for the determination of the independent contributions of 
fibrinogen and platelets to overall clot strength. MAR/MAw x100 
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Patient Sex Age Site of 
resection 
Flap(s) Baseline 
FF:Plt 
Thrombotic 
Complications 
1 M 83 Mandible Latissimus Dorsi, & 
Radial 
55 Intra-operative 
anastomotic thrombus 
2 M 43 Mandible Fibula & Latissimus 
Dorsi 
55 Arterial anastomotic 
thrombus 
3 M 34 Mandible Fibula 39  
4 M 59 Mandible Fibula & Radial 36  
5 M 83 Mandible Fibula & Radial 50 Intra-operative IJV 
thrombus 
6 F 61 Mandible Fibula & Radial 34 Arterial anastomotic 
thrombus 
7 M 32 Maxilla Radial 26  
8 F 63 Mandible Radial & Scapular 45 Venous anastomotic 
thrombus 
9 M 75 Floor of 
Mouth 
Radial 35  
10 M 57 Floor of 
Mouth 
Radial 50 Intra-operative IJV 
thrombus 
11 F 52 Tongue Radial 46  
12 F 57 Mandible Fibula 35  
13 M 48 Floor of 
Mouth 
Radial 44 Intra-operative IJV 
thrombus 
14 F 55 Mandible Radial 39  
15 F 32 Right 
cheek 
Groin 37  
16 M 69 Pharynx Radial 42  
17 M 53 Mandible Fibula 32  
18 F 79 Mandible Fibula 30  
19 F 73 Maxilla Radial 32  
20 M 75 Mandible Radial 44  
21 M 45 Mandible Fibula 39  
22 M 50 Floor of 
Mouth 
Radial 41  
23 F 77 Mandible Fibula 49 Arterial anastomotic 
thrombus 
24 M 49 Lateral 
tongue 
Radial 38  
25 F 76 Tonsillar 
fossa 
Radial 36  
26 M 55 Lateral 
tongue 
Radial 51  
27 F 54 Lateral 
tongue 
Radial 42  
28 M 50 Lateral 
tongue 
Radial 39  
29 F 46 Lateral 
tongue 
Radial 42 Venous anastomotic 
thrombus 
 
Table 6: Demographics for the patients included in the TEG study.  
Included are the baseline functional fibrinogen to platelet ratio (FF:Plt) and corresponding 
thrombotic complications 
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4.2.2 LMWH and Anti-Xa 
A retrospective review of all patients undergoing ablative surgery for head and neck cancer with 
free tissue transfer between 2006 and 2009 was completed. Patient medical records and the 
departmental database were utilised to obtain information relating to anticoagulation 
prescription, pre-operative weight, co-morbidity and post-operative morbidity. Co-morbidity 
was assessed using the Adult Co-morbidity Evaluation-27 (ACE-27) scoring system grading 
patients into four groups of no, mild, moderate or severe decompensation (Appendix B).
136
 The 
presenting tumour was not included in this scoring process.  
At the time of the study, routine prophylaxis included dalteparin 5000 IU once daily (od) with 
or without aspirin 75mg od post-operatively. The incidence of bleeding complications requiring 
return to the operating theatre was determined. In those cases where anti-Xa levels were 
available, these results were reviewed. An anti-Xa level 4 hours following administration of the 
initial dalteparin dose was requested (introduced at the end of 2008), and the dose adjusted to 
ensure optimal LMWH therapy. Only those anti-Xa results which could be confidently 
confirmed as being performed at the correct time interval were included for data analysis. The 
prophylactic range was considered a peak (4-hour) result of 0.2-0.4 IU/ml.  
Post-operative haematoma and bleeding complications, for which no cause was identifiable, 
were considered to be related to anticoagulation administration for the purpose of this study.  
Ethical Considerations 
This aspect of the thesis was considered to be an audit of clinical practice, and therefore formal 
ethical approval was not considered necessary. All patients included in the study had undergone 
surgical intervention, and had agreed to the use of their medical records for the purposes of 
research and audit during the formal written consent process.  
Statistical Analysis  
Statistical analysis was performed using SPSS. Descriptive analysis was first completed using 
histograms, box plots, and scatter plots. Statistical comparison was performed using paired 
Student’s t-tests and chi square tests. Probabilities of ≤0.05 were considered significant. 
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4.3 Results 
4.3.1 TEG 
The functional fibrinogen to platelet ratio results were significantly higher in the surgery group 
(40.8±7.4) compared to healthy controls (32.4±6.1) (p<0.05; Independent samples Mann 
Whitney U Test). Within the surgery group, patients with malignancy (n=26) had higher ratios 
compared to those with benign pathologies (n=3), with mean functional fibrinogen to platelet 
ratios of 41±7% and 38±2% respectively (Table 6). 
Of the 29 patients studied, 31% (n= 9) had some form of thrombotic event (Table 6). One 
patient had an early venous anastomotic thrombotic event, which was detected prior to wound 
closure, with no post-operative flap complications following thrombus removal and repeat 
anastomosis. Five patients experienced flap complications necessitating return to the operating 
theatre where anastomotic thrombosis was identified as the cause. Of these, 3 were arterial 
thromboses, with successful salvage in one case; two were venous thromboses, with both flaps 
ultimately lost. In the remaining 3 cases thrombosis within the internal jugular vein (IJV) was 
noted and removed at the time of primary surgery, with no further complication. There were no 
incidents of deep vein thrombosis or pulmonary emboli.  
The functional fibrinogen to platelet ratio results were stratified into 2 groups, based upon the 
apparent clustering of thrombotic complications in those with ratios above 42% (Table 7). In 
Group A (ratio < 42%) one patient experienced flap complications (ratio 34%), with ultimate 
loss of both fibula and radial flaps on post-operative day 11 (Figure 27).  
In Group B (ratio ≥42%) 8 patients experienced thrombotic complications; with three flap 
failures on days 1, 5 and 9 respectively. In the first case (ratio 45%) repeat surgery was 
complicated with further anastomotic thrombosis, but salvage successful. In the second patient 
(ratio 55%) both free flaps (fibula & latissimus dorsi) were lost, with subsequent failure of a 
repeat free flap. In the final patient (ratio 42%), repeat surgery was uneventful. The incidence of 
all thrombotic complications was statistically higher in Group B (p=0.003; Fishers Exact Test) 
(Figure 28). 
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The groups were similar for both age and BMI (Table 7). Only one patient had a previous 
history of VTE (deep vein thrombosis), and there were no prior incidences of anastomotic 
complications for any of the patients studied. The patient with a past history of DVT had a 
functional fibrinogen to platelet ratio of 46% at induction of anaesthesia for flap surgery, but did 
not experience any thrombotic complications at or following surgery.  
A functional fibrinogen to platelet ratio of ≥42% resulted in a sensitivity of 89% and specificity 
of 75% for predicting thrombotic events. 
During the study period, a further 19 free flaps were completed, resulting in 48 flap procedures 
by the same surgical team. In this group one patient underwent successful flap salvage for 
anastomotic venous occlusion. The overall free flap success rate for the study period was 92%. 
However, a free flap survival rate of 86% was achieved in the 29 patients studied, lower than 
would be expected. This discrepancy is likely to represent a combination of chance, and an 
increased request rate for a functional fibrinogen to platelet ratio in patients who may have been 
clinically perceived to be at increased risk of flap thrombosis.  
 
 
Group A B 
FF: Plt <42% ≥42% 
 n=16 n=13 
Age (years) 55±15 62±14 
BMI (kg m
-2
) 27±6 23±5 
Thrombotic events n=1 n=8 
Flap loss n=1 n=3 
 
Table 7: Comparison of thrombotic and flap complications with age and BMI for the two 
subgroups of functional fibrinogen to platelet ratio.  
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Figure 28: Graph of the functional fibrinogen to platelet ratios for the patients studied and the 
healthy controls. 
The functional fibrinogen contributions of the patient group are shown in green, and healthy 
controls in blue. Patients who experienced thrombotic events are highlighted in red.  
 
Figure 27: Flow diagram correlating flap outcomes with functional fibrinogen to platelet ratio. 
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4.3.2 LMWH and Anti-Xa 
 
During the 4 year period, 173 free flap procedures were completed following resection of 
primary or recurrent tumours of the head and neck, and were included in the study. This 
consisted of 153 patients, of whom 18 patients underwent more than one free flap procedure 
(two procedures n=16; three procedures n=2) as a result of tumour recurrence (n=3), a second 
primary tumour (n=3), to aid function (n=7) or due to flap failure (n=7) (Table 8). There were 
three further flap failures in the patient cohort, who subsequently underwent delayed or pedicled 
reconstruction. Successful flap salvage (including successful leech therapy n=1) was performed 
in 5 cases, with a further 2 patients experiencing an area of skin paddle loss.   
Fourteen patients required return to theatre because of bleeding complications. In 8 of these, an 
active bleed was identified secondary to loose vascular clips (n=1), bleeding from the 
anastomosis (n=1), erosion of a vessel by a drain (n=1) or another identified vessel bleed (n=5). 
However, in 6 cases, no active bleeding was identified, and a haematoma evacuated. The 
distribution of unexplained haematoma was similar for all dalteparin regimens (Table 9), with 
no significant difference between groups (p=0.712). The distribution in terms of ACE-27 score, 
age and weight for the three groups are displayed in Table 8. The majority of patients received 
dalteparin with or without aspirin (Table 10). Nine patients were managed with intravenous 
unfractionated heparin (UFH) post-operatively, with five patients ultimately being commenced 
on warfarin in view of thrombosis within the IJV and/or problematic flap salvage. There were 
no significant complications in those managed with UFH.  
Anti-Xa results were available in 47 cases, with a further test performed in 3 patients following 
dose adjustment (Figure 29). Of these, 44% (n=22) of the results were within the prophylactic 
range (≥0.2 U/ml) (Table 11). The average weight of patients with an anti-Xa <0.2 IU/ml was 
84kg ±24 (range 48.5 – 157kg), and for those ≥0.2 IU/ml 65kg±12 (range 45 – 86kg). Paired 
samples t test, demonstrated a strong negative correlation (p=0.01) with anti-Xa result with 
increasing patient weight. In the 3 patients with repeat anti-Xa results following dose 
adjustment, there was an improvement in anti-Xa result in 2 cases.  
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Of the 47 flap cases with anti-Xa results, there were 6 flap complications. This included 
successful flap salvage, in one case, but 5 flaps ultimately lost. All but two anti-Xa results were 
below 0.2 IU/ml, with patients receiving a dalteparin dose of 5000od. Of the 14 patients who 
required return to theatre because of bleeding/haematoma, anti-Xa results were available in 8. 
Of these, 5 were patients with identified vessel bleeding, in whom only 2 patients had an anti Xa 
in the prophylactic range (mean 0.13; range 0.01-0.24). For the remaining 3 patients with 
haematoma, 2 of the anti-Xa results were in range (mean 0.26; range 0.1 – 0.47). One patient 
was treated for suspected post-operative VTE (pulmonary embolism), although there was some 
doubt associated with the diagnosis. This was an 82 year old male weighing 70kg who 
underwent mandibulectomy, and a fibula free flap reconstruction. He had been prescribed a 
dalteparin dose of 5000 IU bd, with no adjuvant aspirin. An anti-Xa was not performed.  
 
 
Table 8: Patients’ details, co-morbidities, and free-flap reconstruction by bleeding complications 
 
 Return to theatre for bleeding 
complication (n=14) 
No bleeding 
complications 
(n=159) Cause of bleed 
identified (n=8) 
No cause for 
bleeding identified 
(n=6) 
Sex:    
Male n=5 n=3 n=93 
Female n=3 n=3 n=66 
Age (years) 54±16 66±16 61±14 
Weight (kg) 82±14 60±7 71±18 
ACE-27:    
0 n=3 n=2 n=55 
1 n=4 n=4 n=89 
2 n=1 n=0 n=15 
Free Flap:    
Radial n=4 n=4 n=93 
ALT n=1 n=1 n=18 
Fibula n=2  n=21 
Latissimus dorsi  n=1 n=9 
Fibula + Radial n=1  n=8 
Fibula + ALT   n=5 
Fibula + Latissimus 
dorsi 
  n=1 
Other   n=4 
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Dalteparin dose 
(IU) 
No bleeding 
complications 
(n=159) 
Active bleeding 
identified at return 
to theatre (n=8) 
Unexplained 
haematoma (n=6) 
2500 od 7 (5%) 0 0 
5000 od 100 (63%) 5 4 
5000 bd 34 (21%) 1 2 
7500 or more od 18 (11%) 2 0 
 
Table 9: Dalteparin prescription in patients with no bleeding or haematoma and those with 
unexplained post-operative haematoma. 
 
 Dalteparin dose  
2500od 5000od 5000bd ≥7500od Total 
with 
aspirin 
no 
aspirin 
with 
aspirin 
no 
aspirin 
with 
aspirin 
no 
aspirin 
with 
aspirin 
no 
aspirin 
No Problems 5 2 71 29 19 15 13 5 159 
Identified 
bleed 
0 0 4 1 1 0 2 0 8 
Haematoma 0 0 3 1 2 0 0 0 6 
Total: 5 2 78 31 22 15 15 5 173 
 
Table 10: Anticoagulation regimen and frequency of associated bleeding complications. 
 
Dalteparin dose (IU) Anti-Xa Concentration 
<0.2 ≥0.2 
2500 od 6 0 
5000 od 18 14 
5000 bd 2 5 
7500 od or more 2 3 
 
Table 11: Result of anti-Xa in 47 cases with varying doses of dalteparin (3 patients had repeat 
tests).  
 
Figure 29: Boxplot of anti-Xa results for varying doses of dalteparin. The prophylactic 
range is highlighted in green. 
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4.4 Discussion  
It has been demonstrated that anti-Xa results are strongly correlated with mean patient weight, 
consistent with studies examining the anti-Xa response to dalteparin in obese patients.
137
 This 
would imply that standard dose regimens of dalteparin are not suitable for all patients. However, 
despite a variable anti-Xa response to prophylactic dalteparin dose regimens, prescribing is 
rarely adjusted according to patient weight in routine clinical practice. 
In the presented cohort, 56% had anti-Xa results which were below 0.2 IU/ml, and therefore 
deemed insufficient for prophylaxis. The risk, in terms of bleeding/haematoma complications, 
did not appear to be influenced by dalteparin dose, or aspirin prescription.  
Targeting anticoagulant therapy to those patients most at risk of VTE or thrombotic flap events 
appears more complex than BMI alone. Functional fibrinogen to platelet ratio performed at 
induction of anaesthesia may therefore be a useful pre-operative predictor of patients likely to 
experience thrombotic complications. By identifying those in a cohort of patients all deemed 
“high risk” that are more likely to develop thrombotic flap complications additional measures to 
prevent or identify early flap failure can be instituted. These additional measures may include 
additional chemical thromboprophylaxis such as unfractionated heparin (particularly intra-
operatively), or monitoring devices such as Doppler probes or microdialysis.
138
  
However, patients included in this study had the functional fibrinogen to platelet ratio measured 
at the time of induction of anaesthesia (when the first routine TEG
®
 is ordinarily performed) to 
avoid the need for an additional blood sample, and as a result, high risk patients were not 
identified at a sufficiently early time to institute pre-operative additional anticoagulation. 
Whilst included as a thrombotic complication, the significance of thrombosis within the internal 
jugular vein seen at primary surgery is unclear. This was found in 3 patients, at the time of 
surgery, without subsequent flap complication. Where IJV thrombus was removed, additional 
anticoagulation measures, including intra-operative unfractionated heparin, were instigated with 
close clinical surveillance. This is likely to have reduced potential adverse sequelae in these 
patients. Certainly this represents an increased incidence of IJV thrombosis detected at primary 
surgery than is alluded to in the literature.
9,139
  
 Page 93 of 217 
Chapter Conclusion  
Standard prophylactic LMWH dosing appears inadequate in patients with head and neck cancer 
and dose adjustment with anti-Xa monitoring is advocated. Anticoagulation could be further 
guided by functional fibrinogen to platelet ratio levels which appear useful in identifying 
patients likely to experience post-operative thrombotic events.  
 
 
 
  
 
 
5. Nutritional Support 
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5.1 Nutritional Support 
 
Malnutrition occurs in 35 to 60% of patients with head and neck malignancy. Optimised 
nutritional support is vital for post-operative recovery, including wound healing and immune 
function.
140-143
 Despite improvements in reconstruction following ablative surgery, the 
impairment of post-surgical functions such as articulation, mastication and swallowing remain 
problematic for patients, compounded by oedema, trismus, loss of muscle, and reconstruction 
with nonsensate and nonmotile flaps.
144,145
  Radiotherapy adds to these problems through 
mucositis, xerostoma, trismus, and further alters swallowing dynamics often resulting in 
dysphagia.
146,147
 It is therefore often necessary to provide enteral feeding to bypass the oral 
cavity and pharynx to permit recovery of swallowing, and to allow the site to heal. In the early 
1990’s the use of Percutaneous Endoscopic Gastrostomy (PEG) tubes were popularised as the 
feeding method of choice in patients with head and neck malignancy; however, they carry 
significant morbidity and mortality risks.
148
  
This section of the thesis focuses upon the peri-operative management of nutrition in patients 
undergoing free tissue transfer following ablative surgery for head and neck malignancy. The 
section commences with a literature review before describing the methodology and results of: 
10. Eley KA, Shah R, Bond SE, Watt-Smith SR. A review of post-operative feeding in 
patients undergoing resection and reconstruction for oral malignancy and presentation of 
a pre-operative scoring system. Br J Oral Maxillofac Surg 2012; 50(7):601-5.
12
 
11. Eley KA, Watt-Smith SR. Routine use of percutaneous endoscopic gastrostomy (PEG) in 
head and neck oncology: benefits and pitfalls. Br J Oral Maxillofac Surg 2010; 48(Supp 
1): S20 [Published abstract].
13
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5.2 Literature Review 
A comprehensive review of the literature was conducted to explore the current practices in peri-
operative management of nutrition following free tissue transfer. This was completed using 
NCBI Pubmed and Google Scholar with the following MeSH terms:  
(“Free Tissue Flaps” or “Surgical Flaps” or “Mouth neoplasms” or “Head & neck 
neoplasms” [All fields]) and (“Enteral nutrition” or “Feeding methods” or “Nutritional 
support” or “intubation, gastrointestinal” or “Gastrostomy” ). 
The titles and abstracts were reviewed to identify those papers with clinical relevance, with 
subsequent review of related citations and references.  
 
It is recognised that patients with head and neck cancer are frequently affected with swallowing 
difficulties as a result of their primary tumour, surgical resection, reconstruction or adjuvant 
therapy. This results in malnutrition, and the potential sequelae of delayed wound healing. Early 
nutritional input is paramount to optimise enteral feeding, often with the need for nasogastric or 
gastostomy tubes.
149
 The main difficulties associated with nasogastric tubes include blockage or 
their inadvertent removal. They may additionally cause nasopharyngeal pressure and irritation 
that can interfere with recovery of independent swallowing function and possibly lead to septal 
necrosis and sinusitis.
150
 
It is hoped that swallowing function improves in the post-operative period to permit early 
removal of feeding tubes; however this belief is not supported in the literature. Tei et al
147
 
assessed the swallowing function in 25 patients pre- and post-operatively in patients undergoing 
resection of tongue, floor of mouth, lower gum and/or retromolar trigone carcinomas with free 
flap reconstruction. Of these, 21 patients underwent pre-operative radiotherapy. Swallowing 
performance was assessed pre-operatively, and at 1, 6, and 12 months after surgery. 
Assessments were completed using barium liquid and paste swallowing investigations. The 
authors reported that after surgery, as expected, swallowing worsened. Only 9 of the 25 
patients’ demonstrated improvement in swallowing at 24 months post surgery; function 
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appeared to remain unchanged 6 months following surgery. Those with the worst dysfunction 
were patients with tumours affecting the floor of mouth or tongue. It is therefore likely that any 
patient requiring nutritional support at 6 months post-surgery is likely to require this long term. 
It should be noted however, that the majority of patients included in Tei et al
147
 study had 
undergone pre-operative radiotherapy increasing the likelihood of post-operative swallowing 
difficulties.    
Gastrostomy provides a longer term route to maintain adequate nutrition in those patients with 
prolonged swallowing dysfunction, however this is not without risk. O’Dwyer et al151 reported 
their experience with percutaneous gastrostomy feeding in 55 patients with head and neck 
malignancy. In their cohort, gastrostomy was performed by a radiologist under fluoroscopy, 
following ultrasound confirmation of the absence of viscera between the stomach and anterior 
abdominal wall. Of the 55 patients, 1 died of peritonitis and septic shock 72 hours after the 
procedure, due to dislodgement of the tube with leakage of feed into the peritoneum. Perforation 
of the small bowel occurred in one further case, requiring laparotomy, and three further patients 
experienced minor complications. Whilst the authors concluded that percutaneous gastrostomy 
using the Seldinger technique under fluoroscopy was useful in patients with head and neck 
tumours, endoscopy is often preferred. Endoscopy provides direct confirmation of the siting of 
the gastrostomy tube, and provides adjunct investigation of the upper gastrointestinal tract in 
patients at risk of synchronous gastrointestinal tumours. However, as with radiologically 
inserted gastrostomy, endoscopic assisted gastrotomy insertion is associated with similar 
complications.  
Walton
152
 reported the complications of PEG in 40 patients with head and neck cancer. In the 
majority of cases PEG was placed by the “pull” method one week prior to surgery; where 
endoscopy was not possible, gastrostomy was placed under fluoroscopic control. Nine patients 
experienced major complications, including premature tube removal, migration of the 
gastrostomy tube through the stomach wall and pneumonia. Seven patients experienced minor 
complications, including wound site infections and leakage around the tube. The author 
concluded that whilst useful, PEG is not without potentially life-threatening complications and 
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careful pre-operative selection is required. Fewer complications were reported by Hujala et 
al.
153
 In their cohort of 79 patients with upper aerodigestive tract malignancies, PEG tubes were 
placed by the “pull” technique in the pre-operative period. In 5 cases open gastrostomy was 
needed mainly due to stricture or obstruction. There were no major complications, and the 
incidence of minor complications was low. 
The insertion of gastrostomy tubes in the pre-operative period results in patients requiring an 
additional procedure at a time when the airway may become compromised by tumour bulk. 
Oakley et al
154
 noted that peri-operative airway events in patients undergoing PEG insertion for 
head and neck cancer was reduced by the introduction of a tumour assessment protocol. In their 
initial audit cycle of 33 patients who had PEG insertion under sedation, there were two patients 
who had major airway complications resulting in one fatality. The protocol introduced included 
dynamic and static assessment of the tumour by endoscopy in addition to imaging review, prior 
to PEG to identify those tumours at risk of causing airway compromise. Following introduction 
of this protocol, 96 patients had PEG insertion under sedation, 16 under GA and 5 under 
radiological guidance, without complication.  
Cunliffe et al
155,156
 reported the benefits of PEG insertion at the time of tumour resection. They 
noted the significant risks associated with intravenous sedation in patients with advanced oral 
malignancy, with a requirement for the patient to be positioned supine. PEG placement at the 
time of definitive surgery once the airway was secured with an endotracheal tube, ensured that 
the airway was protected, and minimised the number of procedures for the patient. Lloyd and 
Penfold
142
 reported similar findings. PEG insertion was completed by the “pull” method, in 52 
patients over a 3 year period. Of these, the median duration of use was 18 weeks. There were no 
major complications, and 10 minor complications. The authors concluded that the insertion of a 
PEG could be performed safely at the time of surgical resection following intubation to secure 
the airway. In their study, Chandu et al
144
 reviewed the complication rate associated with PEG 
insertion in 49 patients undergoing resection of oral malignancy. In the majority of cases (n=41) 
PEG insertion was via the “pull” technique at the time of surgical tumour resection. Seven tubes 
were inserted pre-operatively and 2 post-operatively. In total, there were 4 major complications 
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and 5 minor complications. Major complications included accidental removal, tube migration 
and abdominal wall abscess. Endoscopy revealed Barrett’s metaplasia in one case and an ulcer 
on the greater curvature of the stomach in a second case, diagnosed as poorly differentiated 
adenocarcinoma. This again highlights the benefit of endoscopy in this patient group, with a 
similar complication rate associated with PEG insertion in the peri-operative period. Similar 
findings in terms of peri-operative morbidity have been reported by other authors with PEG 
insertion either at the time of tumour resection, or in the early pre-or post-operative period.
157-159
  
Available guidance
 160-163
 suggests that PEG tubes should be considered if it is anticipated that 
nutritional intake is likely to be inadequate for a period exceeding 2-3 weeks. Sobani et al
145
 
compared patients managed with nasogastric feeding with those provided with a gastrostomy 
tube. In their cohort of 32 patients, they reported lower mean weight loss in those managed with 
gastrostomy. The complication rate was higher in the nasogastric group, with aspiration 
pneumonia due to dislodged tubes being problematic.  
One of the key difficulties in patients with head and neck malignancy is identifying which 
patients are most likely to require longer term nutritional support, and who would therefore 
most benefit from the insertion of a PEG tube. Locher et al
164
 conducted a retrospective analysis 
of surveillance, epidemiology and end results data of 8306 patients with locoregionally 
advanced stage head and neck cancer. PEG tube was more likely in patients with cancer of the 
larynx or oropharynx compared with those with cancer of the nasopharynx or oral cavity, in 
patients who had regional rather than local cancer, and who did not receive surgery as part of 
treatment.  
Schweinfurth et al
150
 also attempted to identify the factors common to patients who require 
enteral feeding long after the immediate post-operative period. They reviewed the medical 
records of 142 patients treated by surgical resection of carcinomas of the sinus, oral cavity, 
tongue base, larynx and pharynx. They found that a heavy use of alcohol was an absolute risk 
factor for post-operative gastrostomy dependence. The addition of post-operative radiation also 
placed patients at increased risk for gastrostomy dependence. TNM staging was not predictive 
of significant risk. Mekhail et al
141
 retrospectively reviewed patients with SCC of the head and 
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neck treated with definitive radiation therapy or combined chemoradiotherapy; surgical 
resection was only used in those patients where non-operative management failed. As 
anticipated, there was a greater need for feeding tube placement in those patients with 
hypopharyngeal primary tumours, larger primary tumours, and after treatment with the more 
intensive chemoradiotherapy. Patients managed with a PEG were dependent upon their feeding 
tube longer than those managed with NG tube. This was speculated by the authors to be related 
to the discomfort and appearance of the NG tube producing a more aggressive and motivated 
swallowing rehabilitation. However, selection bias of patients being provided with a PEG 
because of a perceived increased requirement could not be excluded. Gardine et al
146
 reviewed 
109 patients treated surgically for SCC of the oral cavity, larynx or pharynx. 37.6% of their 
patients required tube feeding for more than 30 days post-operatively. The patient’s age, sex and 
pre-operative serum albumin levels did not predict which patients would require prolonged 
enteral supplementation. Stage IV cancers, combined treatment with surgery and radiotherapy, 
and pre-operative weight loss of more than 10 pounds were significantly associated with the 
need for long term post-operative nutritional support.  
Gibson et al
165
 reported that in patients with tonsil lesions, the hospital stay was 48 days for the 
nasogastric group, and 19 days for the PEG group; however there were only 20 patients with 
tonsil tumours. Similar claims have been made by other authors.
159
 Morton et al
166
 explored the 
impact upon quality of life of PEG in head and neck cancer patients receiving 
chemoradiotherapy. They found that longer PEG duration was associated with poorer 
swallowing function, anticipated as more severely affected patients are likely to require longer 
periods of tube feeding. Longer PEG duration also predicted poorer overall quality of life and 
speech.  
Whilst these authors have identified potential contributory factors to assist in the selection of 
enteral feeding tube in patients with head and neck malignancy, further guidance is required. 
The following section explores the methodology of the presented paper, with the aim of 
reviewing the complications associated with PEG and NG feeding in a local patient cohort, and 
developing a potential scoring system to aid tube selection.  
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5.3 Materials and Methods 
A retrospective review of all patients undergoing primary or secondary head and neck cancer 
resection with immediate free flap reconstruction between January 2006 and 2010 was 
conducted. In total 144 patients were identified, and their medical records, and the electronic 
reporting systems (Centricity PACS and CaseNotes
©
) were reviewed to obtain details on tumour 
type, co-morbidity, surgery, post-operative feeding method, length of feeding and associated 
complications.  
Routine practice at the time of the study included (where required) the insertion of a PEG by the 
upper gastrointestinal surgeons using the “pull” technique (which provides direct endoscopic 
visualisation of the upper gastrointestinal tract) immediately prior to surgery. PEG placement 
was performed once the anaesthetist had secured the airway. For patients managed with NG 
tubes, these were placed at the end of surgery with the aid of a flexible scope, with post-
operative radiological confirmation of position. 
Typically the operating surgeon selected a PEG rather than NGT when nutritional support was 
likely for ≥4 weeks, with consideration given to tumour volume, site and post operative 
adjuvant therapy. 
Patients were ventilated for the first post-operative night on the Intensive Care Unit (ICU) as per 
routine practice. All patients received standard post-operative antibiotic prophylaxis (usually a 
cephalosporin and metronidazole), and gastric protection (usually a H2 receptor antagonist).  
Ethical Considerations 
Patient consent for the use of medical records for audit and research purposes is routinely 
obtained as part of the consent process for surgical procedures. All patients included in this 
retrospective study had undergone surgical resection, with no objections given at the consent 
process for the use of their medical records for audit or research. As this work was considered to 
be part of an audit of clinical practice, with the aim of improving patient outcome, ethical 
approval was not considered necessary.  
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Statistical Analysis 
Data was collected using data collection sheets, with the information transferred to an Excel 
spreadsheet and Access database to aid data interrogation. Data was randomly cross-referenced 
to confirm accuracy. SPSS was used for statistical analysis, with preliminary interpretation 
completed with histograms and box plots, followed by binary logistic regression. 
Following data analysis, review of the decision making processes, and results of the literature 
review, the Key to Appropriate Replacement Enteral Nutrition (KAREN) scoring system was 
developed to assist in identifying those patients most likely to require prolonged nutritional 
support and who should receive a PEG tube. Whilst created retrospectively, this scoring system 
provides a basis for future prospective analysis.  
5.4 Results 
Of the 144 patients (male n=88; female n=56) the average age was 62 years (29 – 88 years). The 
pathology in all but 4 patients was squamous cell carcinoma (SCC); 3 were sarcomas and 1 
patient had a malignant ossifying fibromyxoid tumour. In 126 cases resection was performed for 
a primary tumour, 9 for second primary tumours, and 9 cases for recurrent tumours. The site of 
excision and method of reconstruction are shown in Table 12.  
Table 12: Tumour excision site and free flap used for reconstruction. 
 
 ALT Radial Fibula Latissimus  
Dorsi 
Scapular ALT + 
Fibula 
Radial +  
Fibula 
TOTAL 
Alveolus/Mandible/ 
Retromolar 
Trigone 
2 11 12 2 1 3 10 41 
Maxilla 0 1 0 1 0 1 0 3 
Floor of Mouth/ 
Ventral Tongue 
1 18 0 0 0 0 0 19 
Lateral/ Posterior 
Tongue 
6 48 0 3 0 0 0 57 
Buccal mucosa/ 
Cheek/Lip 
5 13 0 1 0 0 0 19 
Tonsillar fossa/ 
pharynx/soft palate 
0 5 0 0 0 0 0 5 
TOTAL 14 96 12 7 1 4 10 144 
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5.4.1 Nasogastric Tube Feeding 
In total, 24 patients were managed post-operatively with NGT. Of these, 3 patients ultimately 
required a PEG tube; 2 because of post-operative complications (unrelated to their NGT) 
prolonging their need for nutritional support (one case of hypoxic brain injury following a 
respiratory arrest and one post-operative pneumonia), inserted at 21 and 30 days respectively. 
The final patient had a PEG tube placed as a separate outpatient procedure following discharge, 
prior to commencing radiotherapy to the pharynx.  
The average length of NGT use was 13 days (5 – 63 days). In addition to the two patients 
ultimately progressing to PEG, 2 further patients were reliant upon NGT for longer than 28 days 
(33 and 63 days respectively). In the first case this was due to perforation of a colonic 
diverticulum unrelated to the primary surgery. The second patient had an NGT for 63 days, 
following resection of a commisure and cheek tumour with reconstruction using a radial 
forearm free flap and local rotation flap. Early return to oral nutrition was anticipated, but post-
operative recovery was eventful with return to the critical care unit due to respiratory failure. 
The use of NG feeding was discontinuous with times of full oral nutrition before succumbing to 
further complication.  
Patients required the insertion of a mean of 1.9 NGT’s (1 – 5 tubes per patient), as a result of 
accidental removal or dislodgement. Two patients experienced complications directly related to 
their NGT resulting in a prolonged in-hospital stay (aspiration pneumonia in both cases).  
5.4.2 Percutaneous Endoscopic Gastrostomy (PEG) 
The remaining 120 patients received PEG tubes. Five were inserted in the pre-operative period 
in the endoscopy suite at an average of 14 days pre-operatively (2 – 26 days), the remainder 
(n=115) at the time of surgery. This group included one patient requiring open jejunostomy in 
view of co-existing pancreatic disease.  
In the pre-operative insertion group (n=5) there were no serious PEG related complications. One 
patient experienced complex feeding problems (autonomic neuropathy related diabetic 
gastroparesis), ultimately requiring supplemental Total Parental Nutrition (for one month) in 
addition to jejunal gastrostomy extension.  
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Post-operative imaging of the abdomen was required in 10 patients (CT n=7; Fluroscopy n=3) 
having PEG or jejunostomy tubes inserted at the time of surgery. The indications for imaging 
included significant abdominal pain, early sepsis, and confusion, raising concern of a PEG leak. 
This occurred on an average of 6.3 days post insertion (3 – 12 days). In one case, CT revealed a 
colonic injury secondary to PEG insertion and the patient proceeded to laparotomy and removal 
of the PEG. A PEG leak was found on imaging in one patient and he also underwent 
laparotomy. In both cases subsequent recovery was uneventful. In a further 3 patients imaging 
identified an abdominal cause for their symptoms which was unrelated to their gastrostomy 
(ischaemic bowel, acute pancreatitis, and perforated colonic diverticulum). In the remaining 5 
patients imaging was normal.  
Of the 120 patients managed with PEG, 19 experienced minor complications (16%). These 
included abdominal pain not warranting investigation (n=4), problems associated with the feed 
(n=3), leakage of feed around the stoma (n=2), overgranulation of the stoma (n=7), skin site 
infection (n=2) and accidental removal of the tube (not requiring replacement or further 
intervention) (n=1).   
To date, 13 patients continue to use their PEG tube and their average length of use is currently 
795 days (310 – 1344). Thirty patients died with their PEG tubes still in use, resulting in an 
average length of use at the time of death of 186 days (2 – 654). The remaining 77 patients have 
had their PEG tubes removed as a separate outpatient endoscopic procedure or at the time of 
further surgery. The average length of use from insertion to request for removal was 141 days 
(13- 636), and to the date of actual removal 212 days (27 – 733).  
Selection of post-operative feeding route 
In those patients managed with a PEG tube, 9 patients used it for less than 28 days, and in these 
patients NGT may have been more appropriate. All nine patients had minimal co-existing 
medical problems, with ASA scores of I or II, and underwent partial glossectomy with a radial 
forearm free flap ≤ 6x4cm in size.  
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In the NGT group, the four patients who required prolonged nutritional support had 
unpredictable post-operative complications. The combination of co-morbidity and surgical 
excision site were not sufficient to predict these events pre-operatively.  
Development of a pre-operative scoring system 
The scoring system (Table 13) was devised from a combination of statistical analysis of the 
retrospective review, and additional information from the medical records. Not every patient 
required feeding for the whole period prior to radiotherapy commencing.  
Binary logistic regression between the NG and PEG groups, utilising only those patients who 
were deemed appropriately managed, revealed no statistical difference between the groups for 
age or sex. ASA score (grouped for ASA I-II, and III-IV), alcohol intake, and free flap type all 
met or approached 95% significance (p=0.063, p=0.012, p=0.092 respectively). 
ASA score, alcohol intake and free flap type were insufficient in isolation to accurately select 
the feeding method. Further factors typically utilised in the decision making process, including 
clinical tumour stage, tumour site, and planned radiotherapy (& number of sites) were therefore 
also included to improve the scoring system. Patient’s prescribed large numbers of oral 
medications frequently remain reliant upon their PEG tube for these medications despite almost 
full return to oral nutrition. The number of medications was therefore considered a further 
contributing factor in tube selection.   
 Using this method, all nine patients using their PEG tube for less than 28 days would have been 
identified as suitable for an NGT rather than a PEG. For the NG group, the KAREN score would 
have identified only one out of four of the patients who required prolonged nutrition. However, 
two patients suffered unpredictable post-operative complications (perforated colonic 
diverticulum, hypoxic brain injury). Taking these two patients into consideration, and applying 
the scoring system to the remaining 142 patients (Table 14), resulted in a prediction rate of 
92%.    
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Table 13: K.A.R.E.N (Key to Appropriate Replacement Enteral Nutrition) Score. 
 
 
 
 
Table 14: Application of KAREN scoring system to patient cohort.  
 
  Score 
K Known clinical tumour stage T3 or T4 3 
A ASA Grade: III-V 3 
 Alcohol Consumption: >40 units/week 3 
R Reconstruction:  
 Fibula / ALT / Latissimus dorsi 2 
 ≥ 2 simultaneous free flaps 3 
 Radiotherapy: More than one field following surgery planned  2 
E Excision of tumour:  
 Anterior 2/3 of tongue+/- Floor of mouth 1 
 Posterior 1/3 tongue 2 
 Total glossectomy 4 
 Mandibulectomy 2 
 Tonsillar fossa/ pharyngeal/ soft palate 2 
N Number of regular medications: >3 2 
Method of Nutritional Support: Total 
Score: 
Nasogastric Tube 0 - 3 
PEG Tube ≥ 4 
 Correctly 
Predicted 
Incorrect Total 
NGT 21 1 22 
PEG 110 10 120 
Total 131 11 142 
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5.5 Discussion 
The complication rate associated with NGT was low, with two cases of aspiration pneumonia 
most likely secondary to dislodgement of the NGT during feeding, despite confirmation of 
position prior to the commencement of feeding. A higher incidence of complications were noted 
in the PEG tube group, with two major complications directly related to the PEG tube (1.7%), 
and a minor complication rate of 16%, resulted in an overall complication rate of 18%. This is 
in keeping with previously reported rates in the literature.
148,167 
For the cohort of patients studied, the KAREN scoring method appears reliable, with the correct 
tube selection in 92% of patients, providing the basis for prospective review to permit 
refinement and the creation of a highly accurate and reliable tool.  
 
Chapter Conclusion 
Nutritional support in patients undergoing ablative surgery for head and neck cancer is 
paramount. Whilst the major complication rate associated with NGT and PEG is relatively low, 
careful selection of the most appropriate tube is required. The scoring system developed 
provides a novel and simple method of scoring the key factors which have been found to be 
related to requirement for prolonged nutritional support post-operatively.  
 
 
  
 
 
6. Fluid Balance & Cardiac Events 
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6.1 Fluid Balance & Cardiac Events 
 
The risk factors associated with head and neck cancer – tobacco and alcohol use, are also 
associated with coronary artery disease and myocardial infarction (MI). Myocardial injury is a 
common and major contributor to surgical morbidity and mortality.
168
 Patients experiencing an 
MI after non cardiac surgery have an in-hospital mortality rate of 15-25%, and non fatal peri-
operative MI is an independent risk factor for cardiovascular death and non fatal MI during the 
6 months following surgery.
169
 Cardiac troponin assays are highly sensitive and almost 
exclusively specific to myocardium, and have increased the detection rate of atypical and silent 
MI’s.  
Prolonged surgery for head and neck cancer involves large fluid shifts and blood loss. 
Complications resulting from inappropriate fluid management are thought to occur in as many 
as 50% of peri-operative patients, and their adverse outcome well documented.
68,170
 
Measurement of cardiac output or stroke volume has been regarded as a necessary facet of 
caring for critically ill patients.
171
 Previously only possible using invasive pulmonary artery 
catheters, the LiDCO
TM
 Rapid system is one method of minimally invasive monitoring that is 
now available.
172
 The Stroke Volume Variance (SVV) is derived directly from the arterial 
pressure waveform, providing reliable information regarding the filling status of the patient.   
Traditionally patients undergoing surgery were admitted in the pre-operative period to hospital 
where all necessary assessments and optimisation were completed. Hospital admission on the 
day of surgery was introduced as a means to increase patient throughput and produce efficiency 
savings. Initial reports about same day surgical admissions in vascular and colorectal surgery 
have been favourable.
173,174
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This section of the thesis focuses upon hospital admission route and peri-operative fluid balance 
in patients undergoing free tissue transfer following ablative surgery for head and neck 
malignancy. The section commences with a literature review before describing the methodology 
and results of: 
12. Eley KA, Watt-Smith SR. Myocardial infarction diagnosed by troponin concentration in 
post-operative patients with head and neck cancer admitted on the day of operation. Br J 
Oral Maxillofac Surg 2009; 47(3):245-6.
14
  
 
13. Eley KA, Watt-Smith SR. Re: Post-operative fluid balance in patients having operations 
on the head and neck. Br J Oral Maxillofac Surg 2009; 47(3):249.
15
 
 
14. Eley KA, Watt-Smith SR. Intra-operative use of LiDCO – is there an effect on the 
volume of intravenous fluids used by anaesthetists during free flap surgery for head and 
neck cancer? Br J Oral Maxillofac Surg 2009; 47(7):e15 [Published abstract].
16
 
 
15. Eley KA, Watt-Smith SR. Post-operative troponin positive cardiac events in patients 
undergoing head and neck cancer resection admitted on the day of surgery. Br J Oral 
Maxillofac Surg 2009; 47:e38 [Published abstract].
17 
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6.2 Literature Review 
A comprehensive review of the literature was conducted to explore the current practices in peri-
operative management of nutrition following free tissue transfer. This was completed using 
NCBI Pubmed and Google Scholar with the following MeSH terms:  
(“Free Tissue Flaps” or “Surgical Flaps” or “Mouth neoplasms” or “Head & neck 
neoplasms” [All fields]) and (“Fluid Therapy” or “Cardiovascular diseases” or 
“Physiological processes” or “surgery”) 
The titles and abstracts were reviewed to identify those papers with clinical relevance, with 
subsequent review of related citations and references.  
 
The World Health Organisation definition for diagnosis of myocardial infarction is two of: a) 
history of chest pain, b) diagnostic ECG, c) elevated biochemical markers. Arterial thrombosis 
is the underlying cause of the majority of non operative MI’s, however, the pathophysiology in 
the operative setting is less clear.
169
 Surgery initiates an inflammatory response due to increases 
in tumour necrosis factor-α, interleukin 1, IL6 and CRP. Surgical stress involves increased 
levels of catecholamines (adrenaline and noradrenaline) and cortisol.  
Cardiac troponins, which are structural proteins unique to the heart, are sensitive and specific 
biochemical markers of myocardial damage, often more reliable than electrocardiography.
175
 
Troponin I is a highly specific marker for cardiac injury with a sensitivity and specificity 
approaching 100%. Troponin I is elevated at 12 hours following a cardiac event and remains 
elevated for 5 days.   
Nagele et al
168
 completed a retrospective study of 378 patients undergoing major head and neck 
cancer surgery. They utilised Troponin I concentration as the primary outcome measure. 
Measurements were completed routinely in all patients immediately post-operatively, at 8 hours 
and at 16 hours. Of their patient cohort, 57 patients developed an elevated Troponin I, with 90% 
of these occurring within the first 24 hours post-operatively. The authors identified that pre-
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existing renal insufficiency, hypertension and preceding combined chemotherapy and radiation 
were predictive factors for post-operative MI. Patients with post-operative MI had a 
significantly longer stay in hospital and mortality. Only 30% of patients who developed a post-
operative Troponin I elevation had a pre-operative diagnosis of coronary artery disease.  
Troponin levels were utilised in a similar study by Nouraei et al
176
 who reviewed the incidence 
and risk factors for MI following head and neck surgery. They retrospectively reviewed 65 
patients undergoing surgery for upper aerodigestive tract SCC. Troponin I was performed on the 
3
rd
 post-operative day. Post operative elevated troponin I was found in 16 patients. Factors 
identified as independent predictors of post-operative myocardial injury were blood pressure 
level, intra-operative heart variability and degree of post-operative inflammatory response. 
Datema et al
177
 conducted a retrospective review of 135 patients undergoing extensive ablative 
and reconstructive surgery for SCC of the oral cavity or oropharynx. Medical records were 
reviewed for evidence of post-operative cardiovascular complications. The mean combined 
surgery and anaesthetic time was 11.3 hours. Of the 135 patients, there were 4 confirmed MI’s, 
18 patients with heart failure and 1 patient with ventricular fibrillation. The mean length of 
hospital stay was lengthened by 7 days in those experiencing cardiovascular complications 
compared to those who did not. ACE-27 score positively correlated with cardiovascular 
complications.  
Tanaka et al
178
 conducted a retrospective analysis of 1249 patients undergoing head and neck 
ablative surgery with free flap reconstruction to determine the mortality rate associated with 
surgery. The in-hospital mortality rate was 1.84%. The 30-day mortality rate was 0.88% and 
significantly correlated with age; however this was not the case for in-patient mortality. Only 
one of the 23 in-hospital deaths was attributed to acute MI. Similar findings were reported by 
Clark et al
179
 who identified an in-patient mortality rate of 1.6% in their study of 185 patients 
undergoing free flap reconstruction following ablative head and neck surgery. There was a 
major morbidity rate of 40%, including MI in 3.2% of all patients. Predictors for major 
complications including ASA grade 3 and 4, age greater than 65 years and current smokers. 
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Predictors for medical complications included crystalloid replacement of >130ml/kg over 24 
hours; volume of colloid replacement was a predictor for length of hospital stay.  
Optimising peri-operative fluid balance is important to minimise cardiovascular complications, 
and for maintaining flap survival. Excessive intra-operative fluid administration may jeopardise 
the success of free flap transfer by several mechanisms, including, contrary to what would be 
anticipated, enhancing coagulation.
180
 Flaps have a lack of lymphatic drainage, are denervated 
and have reduced ability to reabsorb excess interstitial fluid.
181
 Conversely, negative fluid 
balance is equally detrimental.  
Haughey et al
182
 in their retrospective review of 236 patients who had undergone free flap 
reconstruction to the head and neck found that more than 7L of crystalloid during surgery was 
significantly associated with major medical and flap complications. The duration of anaesthesia 
and use of blood products and pressors did not predict complications.  
Optimisation of fluid balance using Doppler ultrasound has been shown to improve stroke 
volume and cardiac output and speed of post-operative recovery; however, this is often 
impractical in head and neck surgery in view of the difficulty accessing the surgical field for 
repositioning of the Doppler probe.
183,184
 Routine invasive monitoring with central venous 
cannulation has been shown to be unreliable in head and neck surgery.
185
  
LiDCO™ Rapid derives stroke volume from the arterial pressure waveform using the pulseCO 
algorithm. Abdel-Galil et al
183
 reported their initial experience with LiDCO™ with plans for 
conducting a randomised controlled trial; these results are not yet available. Chalmers et al
181
 
conducted a survey of 32 head and neck units to ascertain the peri-operative monitoring in 
patients following free tissue transfer. They found that very few units currently use cardiac 
output monitoring, but reported that their own experience with LiDCO™ monitoring resulted in 
a mean reduction of 25% of intra-operative fluid administration.   
Pre-operative optimisation is equally important to minimise post-operative complications, 
particularly in terms of co-morbidity. As a result it has been traditional for patients to be 
admitted to hospital pre-operatively. In the 1990’s same day hospital admission (Theatre direct 
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admissions, TDA), whereby patients for elective operations attend a holding bay on the day of 
operation, became routine practice across the United States of America and Australia.  Boothe 
and Finegan
186
 assessed the cost-effectiveness of this process in patients undergoing 
laparoscopic cholecystectomy with discharge from hospital the day following surgery. One of 
the main benefits highlighted by the authors for same day admission was that pre-operative 
assessment by the anaesthetist in the outpatient clinic rather than on the night prior to surgery in 
hospital prevented inappropriate hospital admissions in patients not fit for anaesthesia and 
therefore in whom surgery would have been cancelled. They calculated an overall cost saving 
per patient of 18% for same day surgery. Similar findings were reported by Calligaro et al
174
 in 
their comparative study of patients undergoing elective infrarenal aortoilliac surgery. They 
reported a significant cost saving, with no differences in terms of post-operative mortality, 
complications or readmission rates. Interestingly post-operative stay was also shorter for those 
admitted on the day of surgery. However, patients admitted pre-operatively to optimise their 
medical status were excluded from the study, which may have biased the results. Vijay et al
187
 
reported their experience of such practice within the NHS using a dedicated elective surgery 
centre, concluding that this offered considerable cost-savings although these savings were not 
calculated.  
The only study identified in the literature exploring the use of same day admission in head and 
neck patients is by Kulasegarah et al.
188
 In their prospective review of 75 patients, 34% were 
oncology patients. The oncology group were significantly older than the non oncology group 
and were more likely to be delayed going to theatre; however, there was no difference in terms 
of post-operative complication rates. The authors however concluded that for major surgery 
same day admission is not appropriate for all patients.  
Whilst these authors have identified potential contributory factors to enhance care in head and 
neck patients, further guidance is required. The following section explores the methodology of 
the presented papers, with the aim of further evaluating the benefit of intra-operative LiDCO™ 
monitoring and same day hospital admission.  
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6.3 Materials and Methods 
The methodology is divided into two discrete phases evaluating firstly fluid balance and 
secondly same day hospital admission.  
6.3.1 Peri-operative fluid balance 
A retrospective review of all patients undergoing free flap procedures for head and neck cancer 
between January 2006 and April 2009 was conducted. During this period LiDO Rapid 
monitoring was introduced as part of the pressor study described in Chapter 3. LiDCO™ 
monitoring was additionally utilised in patients not recruited to the pressor study where it was 
deemed beneficial by the operating surgeon. Comparisons were made with those patients treated 
prior to the introduction of LiDCO™ monitoring.  
Medical records, including anaesthetic charts, were reviewed to determine the intra-operative 
fluid status, post-operative morbidity, and length of hospital stay. For patients in whom 
LiDCO™ Rapid monitoring was used the data was exported from LiDCO™ to a Microsoft 
Excel spread sheet to permit calculation of the mean intra-operative SVV.  
In total, 157 free flap procedures were completed during 140 surgical sessions. The notes for 7 
patients were unavailable for review, the anaesthetic chart missing in the notes of a further 
patient, and the LiDCO™ data corrupt in a further two patients. These patients were therefore 
excluded from the study. In total, 116 free flaps were completed during 103 surgical sessions on 
89 patients for primary head and neck cancer resection or reconstruction of associated problems. 
LiDCO™ monitoring was used for 27 free flap sessions (24 patients; 3 patients undergoing two 
separate surgical procedures).  
Ethical Considerations 
The study was considered to be an audit of clinical practice, for which ethical approval was not 
considered necessary. All patients underwent surgical intervention providing consent for the use 
of their medical records for audit and research.  
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Statistical Analysis 
Data collection sheets were used during review of the medical records, and the data transferred 
to a Microsoft Excel spreadsheet. Statistical analysis was completed with SPSS, with 
significance level set to 0.05.  
6.3.2 Theatre Direct Admission 
An audit of clinical practice was completed following a perceived increased risk of morbidity 
following the introduction of TDA in 2007 for patients with head and neck malignancy. All 
patients admitted via TDA underwent routine pre-operative assessment, and those deemed high 
risk were admitted in the traditional manner via the ward pre-operatively. 
A comparative study was completed between those admitted pre-operatively to the ward and 
those admitted via TDA.  
Myocardial infarction was used as the primary outcome measure of post-operative morbidity. 
Elevation in Troponin I was used to define MI to avoid potential bias associated with the 
documentation of chest pain or ECG changes.    
A retrospective review of all patients undergoing major operations for head and neck cancer 
between 2003 and 2007 was completed. During this time period 131 patients were admitted pre-
operatively to the ward in the traditional manner, and 15 patients were admitted via TDA. The 
electronic biochemistry results system (CaseNotes
®
) was interrogated for each patient to 
determine if a Troponin had been requested, and all subsequent results. Troponin was only 
requested by the clinical team where there was concern that the patient had suffered a cardiac 
event.   
Following a change of practice, the audit was repeated with a further 49 patients between 2007 
and 2008.  
Ethical Considerations 
As the study formed part of clinical practice with the intention of improving patient care, ethical 
approval was not considered necessary. All patients included in the study underwent surgical 
intervention, providing informed consent for the use of their medical records for audit and 
research purposes.  
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6.4 Results 
 
6.4.1 Peri-operative fluid balance  
Of the two patient groups, with and without LiDCO™ monitoring, the distribution in terms of 
free flap type, age, sex, weight and length of procedure (combined anaesthetic and surgical 
time) were similar (Table 15).  
On analysis of the intra-operative anaesthetic charts in the LiDCO™ group colloids were more 
frequently used (p<0.03) than in the non-LiDCO™ group where crystalloids were preferred. 
Overall, when urine output and procedure length were taken into account, the LiDCO™ group 
received less fluid per hour than the routine group (p<0.04).  
There were no in-hospital deaths in the 27 patients included in the LiDCO™ group. In the 103 
patients in the routine group, there were 7 post-operative deaths due to MI in two cases, an 
upper GI bleed (n=1), perforated sigmoid diverticulum (n=1), TB pneumonia (n=1) and 
ischaemic bowel (n=1).  
Post-operative hospital stay was significantly less in the LiDCO™ group (p<0.02), with a mean 
length of stay of 13.6±5 days in the LiDCO™ group, compared to 21.7±18 days in the routine 
group.  
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  LiDCO™  Routine 
Sex Male 52% 52% 
 Female 48% 48% 
    
 Age (years) 58 ± 9  62 ± 15 
 Weight (Kg) 76 ± 24  69 ± 14 
    
Free flap ALT n=15 n=12 
 Fibula n=7 n=16 
 Latissimus Dorsi n=19 n=5 
 Radial n=44 n=54 
 Other n=0 n=2 
 Combined two free flaps n=15 n=12 
    
 Procedure Length (Hours) 8 ± 1.3 7 ± 1.8 
 Average Hospital Stay (Days) 13.6 ± 5 21.7 ± 18 
    
Intra-operative 
Fluid Balance 
   
 Crystalloid (Litres) 6.0 ± 1.5 6.4 ± 1.9 
 Colloid (Litres) 0.7 ± 0.7 0.4 ± 0.8 
 Blood (Units) 0.7 ±  1 0.8 ± 1 
 Total Fluid In (Litres) 7.0 ±1.7 7.0 ± 2.1 
 Urine Output (Litres) 1.1 ± 0.7 1.2 ± 1.0 
 Balance (Litres) 5.9 ± 1.7 5.9 ± 1.8 
 Balance/procedure length (ml/hr) 728 ± 169 814 ± 250 
 
Table 15: Distribution of age, sex, weight and procedure length in the two groups in terms of 
LiDCO™ monitoring.  
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6.4.2 Theatre Direct Admission  
Of the 131 patients admitted to the ward pre-operatively, troponin concentrations were 
requested for 33 patients, and were significant in nine (7%). In the 15 patients admitted by 
TDA, troponin concentrations were requested in seven patients, and were positive in three 
(20%). During the period of TDA admission, 15 patients were also admitted pre-operatively via 
the ward, either because of patient factors, such as co-morbidity or lack of transport for the 
morning of surgery, or clinician factors, such as an inability to complete the required pre-
operative assessment prior to the date of surgery. Of these 15 patients, troponins were requested 
in 6 patients, and these were all negative (Table 16).  
As a result of these findings pre-operative ward admission for all patients undergoing ablative 
and reconstructive surgery for head and neck malignancy was reinstituted. Following full 
reintroduction of pre-operative ward admission a re-audit was completed. On re-audit, of the 49 
patients admitted via the ward, there were 12 troponin requests, with only 1 elevated result (2%) 
(Table 17).  
 
 2003-
2004 
2004-
2005 
2005-
2006 
2006-2007 2007-2008 2008 - 
    Ward TDA Ward TDA Ward Ward 
n 33 36 30 18 8 14 7 22 27 
Troponin 
Requests 
6 9 7 6 3 5 4 7 5 
 18% 25% 23% 33% 38% 36% 57% 32% 19% 
Troponin 
Positive 
4 2 2 1 1 0 2 0 1 
% 
Positive 
12 6 7 6 13 0 29 0 4 
 
Table 16: Frequency of troponin requests and percentage positive of whole group, per year between 
2003 and mid 2008.  
 
Cohort Admission 
Type 
Troponin Total 
Positive Negative Total 
Requests 
Total not 
requested 
1 Ward 
Admission 
9  
(7%) 
24 33 
(25%) 
 
98 131 
2 Theatre Direct 
Admission 
3 
(20%) 
 
4 
 
7  
(47%) 
 
8 15 
3 Ward 
Admission 
1  
(2%) 
 
11 
 
12 
(24%) 
 
37 49 
 
Table 17: Frequency of Troponin I request and results in the three cohorts of patients. 
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Overall, the timing for post-operative MI was at a median of day 3 post-operative (range 0-21 
days post-operative). This occurred at a mean of 3 days post-operative (range 1 – 6 days post-
operative) for those admitted via TDA, and a mean of 5 days (range 0 – 21 days post-operative) 
for those admitted via the ward.  
 
6.5 Discussion  
 
The results of these studies suggests that the intra-operative use of LiDCO™ Rapid monitoring 
results in an increased use of colloids and an overall decrease in fluid administration intra-
operatively. Post-operative in-hospital stay was significantly reduced in the LiDCO™ group, 
with an associated fall in post-operative complications.  
The high incidence of myocardial infarction associated with the TDA group may reflect a 
cluster that would have occurred at this time irrespective of the route of admission. However, 
subsequent repeat audit showed significant improvement in post-operative cardiac morbidity, 
when pre-operative ward admission was reinstituted. The combination of a patient’s anxiety 
associated with admission to hospital, and the serious stress response from an extensive 
operation, are probable contributory factors to post-operative complications such as myocardial 
infarction.
189
  
 
Chapter Conclusion 
LiDCO™ Rapid is an additional source of patient monitoring suitable for patients undergoing 
free flap surgery, permitting goal directed therapy, and resulting in decreased post-operative 
morbidity. Post-operative morbidity may be further reduced by careful attention to pre-operative 
factors including route of hospital admission, as TDA may not be appropriate for all patients 
having major operations. 
 
 
 
  
 
 
7. General Discussion & Conclusions 
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7.0 General Discussion 
The collection of publications which form the basis of this thesis highlight a number of factors 
which contribute to peri-operative mortality and morbidity in patients undergoing ablative and 
reconstructive surgery for head and neck malignancy.  
It has been demonstrated that operative risks in this patient group are compounded by co-
morbidity as a result of age, alcohol and tobacco use. A cardiovascular history is likely since the 
causative agents for oral malignancy and cardiovascular disease are largely the same. As a result 
patients are likely to require blood pressure support during the peri-operative period due to 
decreased vessel compliance and antihypertensive medications.  
Four commonly utilised pressor agents were studied for their effects on free tissue transfer. It 
was found that whilst noradrenaline resulted in vasoconstriction (demonstrated by a decreased 
conductance), in both the flap and the control tissue, the effect was more marked in the control 
tissues. This may suggest that the flap tissues have some level of protection, likely as a result of 
surgical sympathectomy. However, unlike the findings of Lecoq et al
77
 vasoconstriction did 
occur in the flap tissues. This vasoconstrictor effect on the flap was more than overcome by the 
increase in blood pressure, so that there was a significant increase in flap perfusion with the 
increased blood pressure up to a dose of 0.15mcg/kg/min of noradrenaline. The paradoxical 
results that were seen at 0.2mcg/kg/min of noradrenaline, whereby there was a sudden and 
profound decrease in flap perfusion, are likely to be unreliable. Only 5 patients received this 
maximal dose of noradrenaline with the remaining patients having already reached the 
maximum blood pressure increase permitted in the study (30mmHg MAP rise) at lower doses. 
This highlights one of the inherent problems of the analysis methods used for this study. It was 
noted on review of the individual patient results that half of the cohort demonstrated profound 
changes from baseline with noradrenaline, whilst the remainder of the group had more modest 
changes. This variable response may be due to varying levels of vessel compliance due to age 
and cardiovascular disease, or variable alpha receptor survival.  
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Dobutamine also reliably increased flap and control site blood flow by about 10% (compared 
with the 30% maximum seen with noradrenaline) without causing a change in conductance and 
with little effect on blood pressure. The effects on MAP with dobutamine were surprisingly 
variable. The sole reason for instituting pressor support in patients in the peri-operative period is 
to increase MAP; the potential benefits of improved flap flow are outweighed by an 
unpredictable effect on blood pressure. This is a recognised problem with dobutamine as despite 
increases in CO (on average this was increased by 50% in the patients studied), the reduction in 
SVR through β2 receptor and baroreceptor-mediated vasodilation results in BP being reduced or 
unchanged.
66
 A more concerning adverse effect of dobutamine in the patient group studied was 
the frequency with which it resulted in a tachycardic response requiring premature termination 
of the drug infusion. This effect is again in keeping with the known ino-dilator effects of 
dobutamine. Since patients with head and neck malignancy are already at high risk of cardiac 
ischaemia these side effects are likely to cause concern and dobutamine may therefore not be 
the most useful agent despite its positive flap effects.  
Adrenaline caused a decrease in both flap flow and conductance in spite of an increase in both 
blood pressure and cardiac output, and there was little difference between flap and control skin. 
It also resulted in a tachycardic response. Of the 25 patients studied, 21 received the maximum 
infusion rate of adrenaline, the remaining 4 patients having reached the safe limits at lower 
infusion rates.  
Dopexamine preferentially vasoconstricted the flap compared with the control skin, making it 
entirely unsuitable for maintaining flap perfusion. It was also ineffective at increasing blood 
pressure at the doses studied. Dopexamine is now a less popular agent in the ICU compared to 
the time at which the study was planned. This is an inevitable consequence of such studies due 
to significant time periods between designing the study, obtaining necessary approvals, 
including ethics, MHRA, and local research and development, and the completion of data 
collection.   
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However, the prolonged data collection period provided the opportunity to recruit the same 
patient to the study on two occasions, as a result of a second primary tumour which also 
required resection with free flap reconstruction. Consistency of findings on two separate 
occasions with different free flaps could therefore be explored. Overall, the results were largely 
consistent on both occasions and with the mean results for all patients with all of the drugs, 
except adrenaline. Adrenaline resulted in both increased flow and conductance for both flap and 
control on the first occasion, but decreased flow and conductance (consistent with the overall 
results) on the second study. This may simply reflect an erroneous result, but raises the 
possibility that there is some variability in free flap alpha receptor survival. On the first 
occasion reconstruction had been completed with a radial forearm free flap, and on the second 
by combined reconstruction with an ALT and fibula free flap, with the Doppler sited on the 
ALT. Anastomosis of the fibula free flap was completed whilst the ALT was raised, making 
prolonged primary ischaemia an unlikely contributor to alpha receptor survival. In the majority 
of the 24 patients studied, reconstruction had been completed with a radial forearm free flap, 
thus why the results were not consistent in this patient on the first occasion is more difficult to 
understand.  
It is postulated that the ischaemic time during free flap transplantation results in apoptosis of a 
proportion of alpha receptors. It is most likely that the intimal receptors survive this process, but 
the added contribution of denervation results in loss of the adventitial receptors. Age and co-
morbidity are also likely to be contributory factors in receptor survival. This would explain why 
the findings were not consistent in all of the patients studied. Since the ischemic time was not 
recorded in the patients studied it was not possible to correlate this with the results in this study.  
Certainly, the findings should be interpreted in light of the limitations of the study. In all cases 
the laser Doppler probe was sited at the centre of the flap, based upon the assumption that any 
changes in blood flow through the flap would be uniform. However, this may not be the case, 
and variabilities in flap flow, particularly in cases where the skin paddle of a fibula flap was 
used, may have resulted in discrepancies in the results.  
 Page 125 of 217 
The exclusion criteria for patient recruitment were largely limited to pregnancy and obesity, due 
to drug administration safety. As a result the patient cohort consisted of tumour resection from a 
range of oral cavity sub-sites, with varying patient BMI, age, sex and free flap types. Whilst it 
would have been particularly ideal to standardise the free flap across all patients, this would 
have resulted in difficulties in recruitment in a study which took over a year to complete the 
patient recruitment and data collection phases. Of the 25 datasets, 17 were from radial forearm 
free flaps, and only 2 required the Doppler probe to be sited on a skin paddle of a fibula flap. 
Any effects as a result of inconsistencies between flap types should therefore be minimal. As a 
result of the small numbers of each flap data analysis was completed for the whole group rather 
than sub-groups. Any sub-group analysis would have resulted in four groups, with as few as two 
patients in some of these groups. A power calculation demonstrated that a sample size of 25 was 
required to detect a difference, making sub-set analysis unlikely to approach significance.  
In four cases reconstruction had been completed with two simultaneous free flaps, with a fibula 
flap and either a radial forearm free flap or ALT. Arterial anastomosis was typically end to end 
for both of the flaps, with end to side venous anastomosis to the internal jugular vein. Since the 
flaps were not “piggybacked” to the same arterial supply it is unlikely that the effects of the 
pressor agents would have differed by using two rather than one free flap.  
Laser Doppler probes are both safe and convenient to use. The benefit of using a Doppler probe 
on the skin paddle of the flap was the ability to confirm positioning and permit easy removal 
following completion of data collection. Only the skin paddle of the flap was examined, which 
may not be representative of the entire free flap. In all cases the Doppler probe was sited at the 
centre of the flap; this occasionally resulted in the probe lying directly over the feeding vessels 
which, at the time of data collection, appeared to result in more pronounced variability of the 
Doppler reading on the monitor. However, such extreme variability was not seen at data 
analysis, and the overall consistency of the results is reassuring.   
Since the Doppler probe was sutured directly to the flap, they were simply removed without 
further requirement for surgery and without risk to the anastomosis. The simplicity of the 
technique and the good correlation with other measures of flap blood flow has made laser 
 Page 126 of 217 
Doppler monitoring a popular research and clinical monitoring technique. The laser Doppler 
device interrogates a hemisphere of about 1mm
3
 volume under the probe, and provides an 
output that is the product of the red cell velocity (from the Doppler shift in reflected light) and 
the number of red cells in motion (from the amount of reflected, Doppler-shifted light). The 
probe cannot be calibrated against a known blood flow, so the unitless “tissue perfusion units” 
are used to express blood flow. This means the use of a control tissue or stable comparator 
baseline is required. Laser Doppler monitoring of skin blood flow in free flap tissue transfer has 
been used successfully to assess changes in intra-oral flap perfusion over time.
47,190,191
 However, 
these studies used blood flow measured prior to flap elevation as a baseline rather than using a 
control area of normally innervated skin, and as a result could not determine if the responses 
were unique to free flaps or a global response to surgery and the recovery period. There are 
some inherent difficulties associated with using Doppler monitoring. Since measurements are in 
TPU, comparisons cannot be made across patients, thus necessitating calculation of change 
from baseline. The Doppler probes are sensitive to movement and light. As a result extra care 
was necessary to keep these factors constant throughout the data collection period. A good 
Doppler trace, as evidenced by the waveform, was ensured prior to commencing data collection 
in all cases. There was an inevitable learning curve associated with the method used to suture 
the probe to the flap; however this is unlikely to have impacted upon the results obtained. 
Between infusions the flap was monitored in the traditional manner (colour, warmth, 
consistency) to confirm viability. Any blood that had accumulated in the region was suctioned 
to ensure a good Doppler trace was maintained. A baseline recording period was completed 
before starting each drug infusion which was used for data analysis.  
Changes were calculated as a fractional change from baseline (prior to the infusion of any 
drugs) for each patient for both the control and flap sites, and a mean result obtained for the 
patient group. An alternative method of analysis would have been to standardise the results by 
determining the difference between the control and flap tissues (by subtracting one from the 
other), however, this would have eliminated the ability to compare the flap tissues to the control 
site. It may also have heightened inaccuracy, due to the effects of ambient temperature on the 
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peripheral control site. The control site in all cases was the deltoid region. This region was 
selected as it was remote from arterial and venous access sites. Being close to the operative site, 
any differences associated with temperature are likely to have been minimised. For comparative 
purposes, the tissue corresponding to the donor site on the opposite limb would be considered to 
be most representative of the flap tissues, however, access to these sites are likely be have been 
problematic in terms of confounding factors, such as temperature (due to ambient changes and 
as a result of infusion of fluids) and light. The effects of the pressor agents due to 
vasoconstriction of the peripheries is also likely to have been problematic had a more distal 
peripheral site been utilised for the control site.  
Skin blood flow was used as a surrogate measure of total flap blood flow. There is only one 
study of total blood flow to free flaps in human subjects, largely obtaining similar results to 
those seen in this study. Scholz et al
74
 investigated the effect of dobutamine on total blood flow 
of free tissue transfer flaps during head and neck surgery. Following completion of the 
anastomoses, the flow in the anastomosed donor artery was measured with an ultrasonic 
flowmeter. Dobutamine at rates up to 6µg/kg/min was infused. They found a doubling in flow 
from baseline to 6µg/kg/min accompanied by increased cardiac output, concluding that 
dobutamine may be useful in improving free flap perfusion. The authors noted that there was no 
significant increase in MAP with the three rates trialled. The maximum dobutamine infusion 
utilised in the presented study was 8µg/kg/min, a small increase in the doses used by Scholz et 
al; however, the often insignificant increase in MAP was also noted.  
Any effect on cardiovascular parameters and Doppler readings were considered to be solely the 
result of the pressor agent infused. However, there are numerous contributory factors. Despite 
the best efforts to achieve optimum fluid balance and maintain all variables constant during data 
collection, this was difficult to fully achieve during the immediate post-operative period being 
also reliant upon intra-operative fluid optimisation. The study was not commenced until patients 
had been adequately stabilised on the ICU, this included where required, transfusion to maintain 
haemoglobin above 8g/dL. A SVV of ≤10% was considered optimal filling and this was 
achieved in the majority of patients prior to the commencement of pressor infusions. The 
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accuracy of the LiDCO™ results were dependent upon achievement of a good arterial line trace.  
In one case the patency of the arterial line was lost during data collection necessitating the drug 
infusion to be recommenced. Difficulties also arose with sedation; whilst a constant level of 
sedation was achieved throughout the study period in the majority of cases, a small number 
required additional bolusing to prevent patient movement affecting the Doppler trace. The 
contributory effects of sedation and fluid administration on the overall results of the study are 
difficult to quantify. 
In addition to electronic recording of results, cardiovascular parameters and Doppler results 
were recorded manually throughout the baseline periods and drug infusions. This provided a 
further method to cross-reference the results obtained during data analysis to enhance accuracy. 
In one patient the LiDCO™ data was corrupt, and the manual dataset was utilised for analysis.  
Conducting such a study on the intensive care unit requires full understanding by the intensive 
care team to avoid any additional confounding factors. Patient care is paramount, and this was 
maintained throughout data collection by good communication with the nursing and medical 
staff on the ICU to ensure that necessary tasks, such as access to the arterial line for blood gases, 
were not conducted during pressor infusion periods which would have impacted upon the 
LiDCO™ results. As such, there were no adverse events for any of the patients during data 
collection.  
Overall, the most striking result found was the decreased sensitivity of the flap to the 
vasoconstrictor effects of noradrenaline when compared with control tissue. It was this that 
caused the increase in blood flow to the flap as the blood pressure increased with increasing 
noradrenaline doses, whilst in control tissue vasoconstriction dominated and the blood flow 
decreased as the noradrenaline dose increased. Chronic denervation of tissues is generally 
believed to lead to a heightened vasoconstrictor response to α adrenergic agents such as 
noradrenaline in the denervated tissue, which may begin as early as two days.
99,192-195
 As a result 
it would be anticipated that the control tissues would have demonstrated less vasoconstriction 
compared to the flap tissues. However, in this acute situation the ability of systemically-
administered noradrenaline to cause vasoconstriction in the denervated free flap was markedly 
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attenuated when compared with the control tissue. A similar effect has been observed when 
innervated and denervated pedicle flaps were raised in a rat model.
77
 Why this reduction in α1 
adrenergic receptor sensitivity occurs in acutely denervated vessels is unknown. It is possible 
that noradrenaline-induced vasoconstriction of fully vasodilated denervated vessels results in 
insufficient calibre reduction to significantly alter blood flow, though this is unlikely given the 
exquisite sensitivity of flow to vessel diameter. Reduced pulsatility in denervated, dilated 
vessels may reduce the secretion of endothelium-derived vasoconstrictive factors, or there may 
be a direct effect at the α1 adrenergic receptor level. Certainly, there was some inherent delay 
between completion of surgery and the stabilisation of the patient on the ICU prior to 
commencing the study equating to approximately 4 hours from the time of microsurgical 
anastomosis.  
 
Spectral analysis of the Doppler waveform was completed to further explore this. Examining 
the frequency components helps to distinguish local from humeral effects, and has been shown 
to be useful and accurate.
89,196
 Characteristic frequency peaks exist in signals of cardiovascular 
origin.
197
 The spectrum is conventionally divided into 5 frequency intervals centred on 1Hz, 
0.3Hz, 0.1Hz, 0.04Hz, and 0.01Hz.
103,197
 Of interest are those occurring at a slower rate than the 
oscillations caused by respiratory rate at about 0.3Hz. Studies have demonstrated that these slow 
oscillations are influenced by the sympathetic nervous system and microvascular wall 
activity.
102
 Blood flow is controlled by the combined effect of all of these periodic oscillations 
of both local and central origin, which are transduced to vascular smooth muscle cells, resulting 
in a specific vascular tone.
103
 
The power spectra confirmed a number of anticipated findings following free tissue transfer. 
Since the flaps were denervated the power in the region below 0.1Hz, which contains 
sympathetic activity, and in the respiratory frequencies centred on 0.2-0.3Hz (12-18 
breaths/minute) which are partially neurally mediated, were both reduced as expected.  
As the spectra were normalised (the area under the curve was fixed) there was a corresponding 
increase in the power in the 0.8-1.7Hz range representing the heart rate. As the results for the 
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cardiovascular variables demonstrated, there was a dose dependent increase in heart rate with 
adrenaline, dopexamine and dobutamine but an unchanged heart rate with noradrenaline until 
the maximum dose was reached. The differing heart rates of the subjects broadened the 
associated peak of the power spectra. At the maximum adrenaline infusion rate the heart rate 
increased and the spread of heart rates also increased, so the heart rate dependent peak moved to 
higher frequencies and broadened. The proportion of the total power in the lower frequencies 
increased, as local control of blood flow rather than global hemodynamics dominated blood 
flow control, though in general as with the control spectra, the effects of denervation were 
maintained.  
All drugs increased the power (overall variability) of the blood flow signal at both sites, and this 
was more marked for adrenaline and especially noradrenaline. As a result of the processing 
techniques any differences between flap and control spectra in one frequency band must have 
equivalent changes in the opposite direction at other frequencies. The difference spectra 
demonstrated this best, the area defined by the 0 baseline and the spectral difference above the 
baseline being matched by an equivalent area between the 0 baseline and the spectral difference 
below the baseline. The technique used for sampling and processing meant the frequency 
resolution was limited to 0.05Hz and thus the 0.04Hz, and 0.01Hz peaks corresponding to the 
neurogenic activity of the vessel wall and the endothelial cell metabolic processes could not be 
resolved independently. 
At the maximum dobutamine infusion rate there was little effect on the distribution of the 
control of blood flow, though as with all drugs studied the cardiac related peak increased in 
frequency and broadened. Dopexamine demonstrated the same findings as dobutamine. 
However with noradrenaline at 75% of maximum dose, low frequency activity below 0.1Hz was 
higher in the flap compared to control, and the difference between flap and control in the 0.1-
0.4Hz band was less marked than with other drugs. This suggests that the noradrenaline infusion 
increases the local myogenic control of blood flow in the free flap to a greater extent than the 
other drugs studied. 
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With increasing doses of adrenaline and noradrenaline there was increased dependence on local 
control, as evidenced by the increasing proportion of power in the 0-0.1Hz frequency band. This 
occurred in both control and flap tissue, though with noradrenaline the effect was more marked 
in the flap tissue. This would imply that there is survival of alpha receptor activity in the 
transplanted tissues, and possibly that these receptors are more sensitive to exogenous alpha 
agonists after denervation.  
The sampling period used limited the resolution of the spectral analysis to 0.05Hz, thus the two 
lower frequency bands could not be resolved independently. All the spectra were normalised to 
allow an averaged spectrum containing all patient data to be constructed with each patient 
contributing equally, but this normalisation causes increases in power in one frequency band to 
always be associated with a change in the opposite direction in other frequency bands, making 
interpretation more difficult. The probability of differences between regions of the normalised 
power spectra arising by chance could not be tested statistically. Changes in the power in the 
cardiac cycle frequency were made more difficult to interpret due to the increase in heart rate 
and the widening of the range of heart rates caused by the drugs. Drug infusion times were 
selected to minimise the effects of slow overall changes in the patient’s haemodynamics biasing 
the results. A minimum of 5 minutes (2-3 half-lives for the drugs studied
198-200
) was used to 
ensure a steady state drug effect.   
The β1 and β2 agonists dobutamine and dopexamine showed no change in the power spectrum 
from the control state, with the denervation effect preserved and no other changes. The known 
vasodilator properties of β2 agonists, at the doses studied, had no apparent effect on the local 
control mechanisms or the effects of global haemodynamics. Adrenaline and especially 
noradrenaline, have significant α1 agonist activity, and this did alter the relative effects of local 
and haemodynamic control on blood flow, with an apparent increase in local control. In the case 
of noradrenaline this seemed to overcome the effect of denervation, so there was more power at 
the very low frequencies in the denervated flap compared with the control site. It is postulated 
that the vasomotion at low frequencies became wholly dependent on exogenous α1 agonist, 
swamping any local neural or other effects. This is in agreement with the results from the 
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hydraulic conductance, which showed both flap and control tissue vasoconstriction. However, it 
was noted that overall flap blood flow increased with noradrenaline, as the increase in blood 
pressure more than compensated for the decreased conductance. This was not reflected as an 
increase in the power at cardiac frequencies in the power spectral studies. Coupled with the 
changes in power at low frequencies, this suggests the flap blood flow is more determined by 
the average blood pressure interacting with low frequency vasomotion, rather than the pulsatile 
(systolic/diastolic) component of blood pressure. 
As noted previously,
3
 there appears to be a brief period after denervation when tissue blood flow 
is less responsive to exogenous α1 agonists, but later the tissues become more sensitive. The 
results from this study may therefore not be generalised to longer term blood flow control. 
Furthermore, vasopressor drugs acting via pathways other than alpha-adrenergic receptors, such 
as vasopressin or nitric oxide antagonists, may produce different results.  
It was assumed that skin flow reflected changes in other tissues, but this could not be proven 
with the technology used. However, similar findings were seen for all of the flaps included in 
the study. It is likely that other drugs mediating activity through alpha receptors will produce 
similar improved perfusion in denervated flaps. 
 
It appears that noradrenaline is effective and safe in free flaps once the tissue has been 
denervated, with only the intimal alpha-adrenergic receptors being responsive to noradrenaline. 
This is supported by the finding that the control of blood flow shifts towards low frequency 
vasomotion where blood flow depends mostly on average blood pressure. It is, however, 
assumed that the flap skin paddle response to noradrenaline is representative of the remaining 
flap tissues. The results may not be generalisable to treatment in the longer term, when a 
heightened sensitivity of denervated vessels to α adrenergic agents has been reported. 
Indeed acceptance of a small vasoconstrictor effect in return for a significant improvement in 
flap perfusion will further validation before concerns about the adverse effects of α adrenergic 
agents on free tissue transfer are fully addressed. However, the enhanced effects of alpha 
receptor stimulation causing vasoconstriction of the flap vessels appears to be largely balanced 
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by the denervation of the flap vessels, which results in reduced vascular tone and small vessel 
dilatation, resulting in an overall increase in flap perfusion; although as previously discussed 
this is likely to represent a somewhat over simplified explanation.   
 
Metaraminol is a sympathomimetic agent with direct α and β1 effects, which also indirectly 
stimulates noradrenaline release. This agent was not in common use in the Trust when the study 
was planned, but is now frequently employed intra-operatively and in the ICU to elevate MAP. 
Metaraminol has three properties that set it apart from the inotropes and pressors used in the 
study. Metaraminol produces a reflex reduction in heart rate, and so avoids the tachycardia 
almost invariably caused by the sympathomimetic amines. It constricts the central venous 
circulation and so increases the central venous pressure and therefore cardiac output. Unlike the 
sympathomimetic amines it can be used as a peripheral venous infusion, which though not 
relevant to this study (all patients have central venous catheters) is relevant in other branches of 
reconstructive surgery. A comparative study further investigating dobutamine, noradrenaline 
and metaraminol was commenced and data collection completed in two patients, however it was 
not possible to complete the study as a result of departmental restructuring. Data from these two 
patients were not included in this thesis as the small number of patients would not permit any 
conclusions to be made. This work is vital to fully address the concerns relating to pressor 
effects on transplanted tissues.  
 
As already discussed, patients undergoing such extensive surgery frequently have significant 
co-morbidity that not only has an impact upon pressor selection, but also increases their general 
risk of post-operative morbidity. Co-existing cardiovascular disease is particularly prevalent as 
a result of the overlapping causative factors with oral malignancy. In combination with the 
surgical stress response cardiac ischaemia peri-operatively is likely, making adequate perfusing 
pressure vital. The surgical stress response is a systemic reaction to injury that includes 
endocrine, immunological, and haematological effects, with a magnitude and duration 
proportional to the injury.
201,202
 The route of hospital admission, whether pre-operatively to the 
ward, or on the day of surgery via theatre direct admission, was considered to be a potential 
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contributor to a heightened stress response. It is inevitable that patients undergoing ablative and 
reconstructive surgery for head and neck malignancy will have anxieties regarding surgery, 
post-operative recovery and their resultant appearance. The consenting process for such surgery 
includes the discussion of all potential peri-operative complications which will have a resultant 
impact upon mental state of the patient. Whilst pre-operative assessment is completed in the 
weeks preceding surgery, the structuring of junior doctor rotas, certainly in the Trust where 
these studies were conducted, resulted in the consent form being signed on the day of surgery 
for those patients admitted via TDA. This is compounded by the additional anxiety of travelling 
to the hospital on the day of surgery, finding the admission unit which is often unfamiliar, and 
awaiting surgery in an area very close to the operating theatres. Pre-operative hospital admission 
provides time for patients to become accustomed to being in hospital and usually on the same 
ward which they will return to post-operatively from ICU. The written consent is obtained on 
the night prior to surgery, providing further opportunity to ask any further questions. For the 
surgical team, it provides the opportunity to review investigations and complete a systematic up 
to date examination of the patient. Any potential cancellations due to the patient being unfit on 
the day prior to surgery does provide an opportunity, albeit short, to admit another patient on the 
waiting list for surgery. Conversely, some patients may prefer being admitted on the day of 
surgery, since it avoids being an in-patient during a time when they consider themselves to be 
well.  
The impact of TDA on patients undergoing ablative head and neck surgery was considered by 
review of post-operative troponin positive myocardial infarction. Between 2003 and 2004 there 
were 33 patients admitted pre-operatively via the ward, with a troponin requested in 6 cases. Of 
these, 4 were positive, resulting in a troponin positive MI rate for the year of 12%. Between 
2004 and 2006 this rate dropped, until the introduction of TDA when there was a troponin 
positive MI rate of 13% and 29% between 2006-7 and 2007-8, respectively. Most profound is 
that for those admitted to the ward between 2007-8, including those patients preferentially 
admitted via the ward despite TDA being operational, and following return to ward admission 
for all patients, the troponin positive MI rate was 0%.  
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The increased incidence of MI in patients admitted via TDA may reflect a cluster that occurred 
at this time, irrespective of admission method. This was a new method of admitting patients, 
and patients may not have been adequately optimised in the pre-operative period. In many 
centres, including the Trust where this work was conducted, pre-operative assessment is largely 
led by nursing staff with clinical examination by the medical team. The patients included in this 
cohort were at a time when the junior medical staff were dentally but not medically qualified. 
As a result it is likely that on the balance of probabilities co-morbidity was not adequately 
investigated nor optimised. As a result it is impossible to state if this increased incidence of MI 
was solely the result of patients being admitted via TDA. However, the results were of sufficient 
concern to change practice and return to pre-operative ward admission for all patients 
undergoing ablative and reconstructive surgery for head and neck cancer. Certainly on re-audit 
the incidence of MI returned to a more satisfactory level.  
Troponin measurements were used in isolation to diagnose MI for the purpose of the study. In 
clinical practice, the triad of chest pain, ECG changes and troponin levels are utilised with a 
diagnosis of MI being made when at least two of these factors are positive. Troponin is highly 
sensitive and specific and therefore considered to be more accurate than any attempt at both 
locating a history of chest pain and an ECG in the medical records, and identifying any changes 
on ECG. Incorrect timing of the ECG could result in detection of ST changes which signify 
reversible ischaemia rather than MI. Conversely, troponin levels may have been requested too 
early for elevation to be detected, thus resulting in an increased under-diagnosis rate. The 
electronic biochemistry reporting system was used to review the results of all troponin levels 
requested, with the majority of patients having more than one troponin result on the system. As 
a result, it is unlikely that an elevated result would have been missed since troponins remain 
elevated for 5 days after a cardiac event. Troponins were only requested by the medical team 
when there was concern that the patient had suffered a cardiac event. The frequency of requests 
therefore provided a further method to evaluate post-operative morbidity. The incidence of 
troponin requests increased between 2006-8, and subsequently decreased again in 2008. This 
may simply reflect an increased availability of the test, or its popularity at the time. Most 
striking is the request rate of 57% in the TDA group between 2007-8, compared to around 30% 
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in those admitted to the ward during the same time period. However, it should be noted that 
there were only 7 patients admitted via TDA during this time period.  
Previous studies have reported positive troponin rates following head and neck surgery to be as 
high as 46% when routinely measured.
176
 Conversely, reported rates of post operative MI have 
been as low as 3%.
177,179
 It is therefore likely that the incidence of post-operative MI is higher 
than reported in view of this patient cohort being at particular risk of silent MI. This raises the 
question of whether routine post-operative troponin monitoring should be utilised in routine 
practice. The main difficulty is identifying the optimal time, coinciding with the greatest risk, as 
to when the test should be conducted. Whilst it is reported that the majority of post-operative 
MI’s occur in the first 48 hours post surgery, in the cohort studied the range was between the 
day of surgery and 21 days post-operatively. The most frequent time interval appeared to be 
within 4 days of surgery. However, routinely measuring troponin levels would incur additional 
cost to the NHS. The overall benefit of routine testing is difficult to ascertain.  
One of the main limitations of the study is that retrospective note review was not formally 
conducted. Whilst there was some overlap of patients with the other studies reported in this 
thesis, it was not possible to calculate the in-hospital mortality rate for this particular cohort. It 
was therefore not possible to determine the incidence of silent MI or the longer term effects of 
MI in the post-operative period in this particular cohort. Reports suggest that MI following 
surgery results in an in-hospital mortality rate of 15-25%, and that non fatal peri-operative MI is 
an independent risk factor for cardiovascular death and nonfatal MI during the 6 months 
following surgery.
168
 The management of peri-operative MI includes the use of anti-platelet 
agents and anticoagulants, which can be problematic in the first 24 hours following surgery 
when flap complications may necessitate return to the operating theatre.  
Without review of co-morbidity and other potential contributory factors it is not possible to 
accurately determine if the increased MI rate was associated with TDA or due to patients 
already at risk of MI. Data available for the three patients admitted via TDA who experienced 
peri-operative MI demonstrates that only one of these patients had a history of claudication 
indicative of cardiovascular disease, but for which the patient was not on any treatment; the 
remaining patients were ASA I, with no past medical history of note and were not on any 
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medications. Their mean age was 66 years (range 58 – 71 years) at the time of surgery, with a 
mean BMI of 23 kg/m
2
 (range 19 – 28 kg/m2). However, they all had a positive smoking 
history, underwent resection with neck dissection (bilateral in two cases), with radial forearm 
free flap reconstruction. The mean combined anaesthetic and surgery time was 6 hours (range 5 
– 7 hours), with 6 – 8 L of crystalloid administered intra-operatively. None of these factors 
would identify these patients as being at high risk of MI. However, in one case it is likely that a 
PEG leak requiring laparotomy was a major contributory factor.  
To fully assess the potential risks associated with TDA, a randomised trial is required. However, 
there are potential ethical dilemmas associated with this approach as there are already concerns 
regarding the admission of patients on the day of surgery for major procedures.
188
  
As previously discussed there are many other potential contributory factors to the increased MI 
rate seen in the cohort of patients admitted via TDA. In patients with oral malignancy, where 
nutritional status is recognised to frequently be deficient, pre-operative ward admission provides 
the opportunity to optimise fluid and electrolyte balance, both of which are of significant 
importance in terms of peri-operative morbidity. The surgical stress response is further 
compounded by insulin resistance. The benefit of glucose loading pre-operatively on post-
operative outcome requires further investigation in head and neck malignancy.  
Complications resulting from inappropriate fluid management are thought to develop in as 
many as 50% of peri-operative patients, and their adverse outcomes are well documented.
68,170
 
Targeted fluid administration has been demonstrated to result in decreased post-operative 
morbidity. Following resection and reconstruction of oral cancer, patients typically remain 
intubated and ventilated for the first post-operative night. Hypotensive episodes are common as 
a consequence of anaesthesia maintained with propofol and morphine or other similar agents. 
Potential consequences of this are inadequate flap perfusion and fluid overload secondary to 
fluid boluses given in an attempt to normalise blood pressure. The unresolved dilemma is the 
relation between flap perfusion, systemic blood pressure, cardiac output, and which drugs have 
the most influence on flap perfusion. The work on pressor support has gone someway to address 
this, however, adequate fluid filling is required to optimise the effects of pressor agents and 
maintain flap perfusion; a fine balance between adequate fluid input and overload resulting in 
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pulmonary and flap oedema. The pressor study in view of the introduction of LiDCO™ based 
stroke volume variance monitoring, provided the opportunity to evaluate the effects on intra-
operative fluid balance. Only the intra-operative period was utilised for analysis as post-
operative LiDCO™ monitoring was not routinely used outside of the pressor study, and with 
multiple clinicians involved in the care of patients post-operatively, significant variability was 
likely. However, surgery was largely completed by the same surgical and anaesthetic team all of 
whom were familiar with LiDCO™ Rapid. Arterial cannulation is routine for such surgery, and 
a good trace ensured optimal LiDCO™ monitoring. The system calculates the variations in 
pulse pressure, systolic pressure, and stroke volume that occur through the respiratory cycle, 
providing reliable information regarding the patient’s response to fluids. The system does not 
require calibration, which resulted in set up in the operating room without any delays; however, 
the utilisation of a pulse contour analysis without formal calibration does raise question of 
accuracy. The consistency of findings in the studies reported suggests that this is not 
problematic.
171,172
 Patients’ height and weight are required to obtain accurate results, and as is 
often the case, some patients did not have a recent record of these in their medical records at the 
time of surgery, which may have resulted in some error, albeit small.  
At the time of the study of the 130 major cases included in the retrospective review LiDCO™ 
monitoring had only been used in 27 cases intra-operatively. However, the key factors including 
age, sex, flap type, weight and length of the combined surgical and anaesthetic procedure were 
largely consistent between the two groups. Of the 27 patients included in the LiDCO™ group, 
13 of these were patients recruited to the pressor study.  
Whilst the fluid balance and urine output appeared consistent between the two groups, colloids 
were more frequently used in the LiDCO™ group, and in terms of hourly fluid balance this 
group received less fluid. For the LiDCO™ group the mean intra-operative crystalloid volume 
was 6.0±1.5L and for the routine group not using LiDCO™ it was 6.4±1.9L. Haughey et al182 
reported that in their retrospective review of 236 patients that more than 7L of crystalloid intra-
operatively was significantly associated with major medical and flap complications. However, 
in our patient group a number of patients received more than 7L of crystalloid intra-operatively 
without complication. This included 9 out of 27 patients (33%) in the LiDCO™ group, and 45 
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of the 103 patients (44%) of the routine group. Utilising the volume of crystalloid in isolation is 
not an accurate method to assess intra-operative fluid balance. There are multiple factors that 
influence the volume of fluid given intra-operatively including the patient’s pre-operative status; 
it is well recognised that patients with oral malignancy are frequently malnourished and 
probably dehydrated pre-operatively. Other factors include the length of the procedure, the size 
of the patient, and the fluid output. A more accurate assessment is to incorporate as many of 
these factors as possible, by calculating the fluid balance per hour. In the patient cohort studied, 
this demonstrated that for the LiDCO™ group less fluid per hour was administered when urine 
output had been deducted (728±169ml/hr compared to 814±250ml/hr).   
Most striking was a significant reduction in length of hospital stay from a mean of 21.7±18 days 
to 13.6±5 days. Whilst this is likely to be multi-factorial, it should be noted that LiDCO™ 
monitoring was utilised in patients outside of the pressor study generally when there was 
concern regarding the impact of co-morbidity on fluid balance. As such it would be expected 
that this patient group would have a longer hospital stay, which was not the case. However, of 
the 27 patients studied in the LiDCO™ group 13 were also in the pressor study, which may 
have impacted upon their post-operative recovery. Anecdotally it was noted that patients in the 
pressor study had improved post-operative recovery; it is postulated that this was the result of 
the continuing fluid optimisation of the patient during data collection on the ICU. The pressor 
study took on average 5 hours to complete, and during this time I was present at the patient 
bedside, and co-ordinated all patient interventions. Certainly, the provision of a personal doctor 
for the patient is not possible for patients post-operatively, however the fluid balance results 
provide further evidence that intra-operative fluid optimisation has a significant effect in 
reducing post-operative morbidity.  
The use of LiDCO™ monitoring provides an additional indicator to clinicians in management 
of fluid status and is particularly useful intra-operatively when routine methods, such as central 
venous pressure monitoring can be more problematic. The introduction of LiDCO™ monitoring 
on the ICU for the first post-operative night may be particularly useful in helping to prevent 
fluid overload. This is frequently a problem compounded by hypotension, avoidance of pressor 
agents, and crystalloid rather than colloid bolusing. However, it should be noted that the system 
 Page 140 of 217 
is not infallible, significant changes, for example, in SVV can be seen just by the infusion of a 
pressor agent.  
The reduction in hospital stay seen in this preliminary work provides evidence for routine 
LiDCO™ monitoring in all patients undergoing ablative and reconstructive head and neck 
surgery. The main limiting factor to routine use is the associated cost of the required access 
cards; however, this would be more than compensated for by the cost saving of earlier post-
operative discharge. Further confirmation is undoubtedly required with a larger cohort study 
with a full cost analysis.  
Despite patient optimisation unpredictable flap complications may result in discharge delay. 
Early detection of a failing flap is vital to maximise successful flap salvage potential. Loss of a 
free flap has significant impact upon the patient, in terms of associated morbidity and delayed 
hospital discharge, with a further long operative procedure usually required. The financial 
consequences of flap failure are profound. Pre-selecting patients with the lowest risk factors is 
often not an option in head and neck malignancy. The cohort as a whole is often of advanced 
age with significant co-morbidity and the options in terms of local and pedicled reconstruction 
are limited with poorer outcomes in terms of cosmesis and function.  
If patients who are at increased risk of flap failure due to anastomotic thrombosis can be 
identified in the pre-operative period, the patient can be further counselled in terms of their 
increased risk, and if still deemed appropriate to proceed with free tissue transfer, additional 
methods can be instigated to both minimise and identify flap failure early.  
It has been demonstrated in the novel work on thromboelastography that functional fibrinogen 
to platelet ratio performed at induction of anaesthesia may be a useful pre-operative predictor of 
patients likely to experience thrombotic complications.  
Of the 29 patients studied the majority of cases of thrombotic complications could have been 
predicted in the immediate pre-operative period with high functional fibrinogen to platelet 
ratios. One of the 16 patients (6%) in Group A (Ratio <42%), and eight of the 13 patients (62%) 
patients in Group B (Ratio ≥42%) experienced thrombotic flap complications. It should be noted 
that this patient group was small, and the overall flap complication rate was far higher than 
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would ordinarily be anticipated (86%), most likely due to inadvertent pre-selection of patients 
most at risk. During the study period, a further 19 free flaps were completed in addition to those 
included in the study, resulting in 48 flap procedures. In this additional group one patient 
underwent successful flap salvage for anastomotic venous occlusion, and the overall free flap 
success rate for the entire study period was 92%. Certainly the discrepancy may have been the 
result of chance, but it is more likely that there was an increased request rate for functional 
fibrinogen to platelet ratio in patients who may have been clinically perceived to be at increased 
risk of flap thrombosis.  
Functional fibrinogen to platelet ratio was only measured at the time of induction of anaesthesia 
(when the first routine TEG
®
 is ordinarily performed) to avoid the need for an additional blood 
sample. As a result, high risk patients were not identified sufficiently early enough to institute 
pre-operative additional anticoagulation. It would be interesting to determine if performing the 
test on the day prior to surgery yields similar results thus permitting preventative measures to be 
implemented.  
The main limitation was the small number of patients included in the study. Further validation 
in a prospective study is required, with recruitment of consecutive patients. However, the 
difference between the cohort of surgical patients, particularly those with thrombotic 
complications, and normal controls was marked. The mean functional fibrinogen to platelet 
ratio in the control group was 32.4, but 40.8 in the surgical group. Even excluding those patients 
who experienced thrombotic flap complications, the mean functional fibrinogen to platelet ratio 
was 37.9. This finding is consistent with the procoagulant effects of malignancy.  
No demographic data were available for the healthy control group. Age, sex and ethnicity have 
been demonstrated to impact upon TEG
® 
 results,
203,204
 and it is likely that the age distribution of 
the control group was lower than the study group. Two patients in the control group had ratios 
above 42% defined as the limit at which adverse thrombotic flap complications were likely. 
With no data available for the control group it is impossible to draw any conclusions regarding 
these two controls. It is of course possible that these volunteers had contributory morbidity 
resulting in a procoagulant state. There are indeed a wide range of conditions predisposing 
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patients to increased risk of thrombosis, including Protein C and Factor V Leiden deficiencies. 
However, there is no information regarding the individual effects of any of these conditions 
specifically on functional fibrinogen to platelet ratio. This finding does highlight the fact that 
patients with seemingly no risk factors for thrombosis can have unrecognised reasons for flap 
complications. Whilst the difference between surgical patients and healthy controls is of 
interest, it is the correlation of a high ratio with thrombotic complications, rather than 
comparison to healthy controls which is of most importance.  
Although all patients undergoing free tissue transfer have standard TEG
®
 analysis, functional 
fibrinogen to platelet ratios (which is an additional test) were not routinely obtained. Full pre-
operative screening for hereditary thrombophilia is not routinely undertaken, and often the first 
indication of problems is a failing flap. The short time to obtain a functional fibrinogen to 
platelet ratio at the induction of anaesthesia is one of the key benefits of the test.  
Whilst included as a thrombotic complication, the significance of thrombosis within the internal 
jugular vein seen at primary surgery is unclear, and may simply be the result of central line 
insertion at the time of anaesthesia. This was found in 3 patients, at the time of surgery, without 
subsequent flap complication. Where IJV thrombus was removed, additional anticoagulation 
measures, including intra-operative unfractionated heparin, were instigated with close clinical 
surveillance. This is likely to have reduced potential adverse sequelae in these patients. Overall, 
an increased incidence of IJV thrombosis was detected at primary surgery than appears to be 
reported literature.
9,139
 Such finding at surgery raises suspicion for post-operative flap 
complications.  
The main benefits of TEG
®
 analysis include performing the test near the bedside, with a result 
obtained more quickly than routine laboratory analyses. TEG
®
 analysis also provides 
information of clot formation taking into consideration all of the constituents involved in its 
formation.  
Flap failure may occur as a result of extrinsic compression of the pedicle, interpositional vein 
grafts, or technical error.
109
 However, despite sound surgical technique, a hypercoagulable state 
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may still predispose a patient to thrombotic events that may ultimately jeopardise the 
microvascular anastomosis.
119
 It has been reported that 96% of microsurgeons routinely use 
anticoagulants in an attempt to minimise post-operative thrombotic complications.
205
 Without a 
mechanism to detect high risk patients, targeted therapy is not possible, subjecting all patients to 
the potential adverse effects of these measures. The recognised risk factors for thrombosis are 
related to one or more elements of Virchow’s triad – stasis, vessel injury and 
hypercoagulability; factors frequently encountered in oncology patients undergoing free tissue 
transfer. High plasma fibrinogen levels have been correlated with increased thromboembolic 
risk in patients with cancer or cardiovascular disease.
119
 Kuo et al
119
 investigated the impact of 
hyperfibrinogenemia on patency of microvascular anastomoses. Using a rodent model, they 
performed femoral artery and vein anastomoses with and without intravenous administration of 
fibrinogen. Laser Doppler flowmetry was used to assess the patency of the anastomosis pre-
operatively and 2 hours post-operatively. Vascular patency was assessed 7 days post-
operatively. They found that there was no statistical difference in patency of the femoral vessels 
after vessel division and re-anastomosis. This experimental data did not support their clinical 
findings of 20% of patients with hyperfibrinogenemia suffering post-operative thrombotic 
events resulting in flap failure. The increased functional fibrinogen to platelet ratio seen in those 
patients experiencing thrombotic complications in this study is consistent with the finding of 
microvascular complications associated with hyperfibrinogenemia; elevated fibrinogen being a 
recognised finding in patients with malignancy.
206
 
Wang et al
207
 reviewed the outcome of 58 flaps in patients with recognised hypercoaguability. 
They reported an increased flap thrombosis rate of 20.7% compared to the average for all flap 
cases of 4.2%. In their patient cohort, none of the failing flaps were salvageable. The authors 
discussed the potential of flap complications being amenable to mechanical thrombolytics, 
systemic anticoagulation and change of the target donor vessels, making pre-operative 
identification of at-risk patients of key importance. In the presented cohort, the only successful 
post-operative successful salvage was in the case of an arterial thrombus on post-operative day 
2, in whom the baseline functional fibrinogen to platelet ratio was 49%. As a result, functional 
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fibrinogen to platelet ratio levels may be a useful tool to identify patients likely to experience 
post-operative thrombotic events.  
Whilst TEG
®
 is increasingly being utilised in post-operative surgical management, the current 
study is the first to highlight the potential predictive benefit of the technique in free flap surgery. 
Further prospective validation is required, however, the results of this preliminary study suggest 
that this method may aid clinicians in targeting additional anticoagulation methods and close 
surveillance to those patients most at risk, reducing patient morbidity. This is particularly 
relevant in the NHS, where due to financial constraints, it is necessary to target therapy to those 
most in need. These additional measures may include additional chemical thromboprophylaxis 
such as unfractionated heparin (particularly intra-operatively), or monitoring devices such as 
Doppler probes or microdialysis.
138
 Using unfractionated heparin needs to be fully justified, and 
the use of devices such as implantable Dopplers are expensive, and are a luxury which cannot 
be afforded to every patient. By identifying those in a cohort of patients all deemed “high risk” 
that are more likely to develop thrombotic flap complications additional measures to prevent or 
identify early flap failure can be instituted.  
Patients who are at increased risk of thrombotic flap complications due to the procoagulant 
effects of malignancy or alternative cause are additionally at increased risk of VTE. There are 
numerous scoring methods to identify patients at high risk for VTE; however such methods are 
often unreliable in patients undergoing resection and reconstructive surgery for head and neck 
malignancy. Certainly, the use of the Caprini score in such a patient cohort would result in the 
majority of patients being deemed high risk – since they are mostly over the age of 60 years (2 
points), have malignancy (2 points), are having major surgery (2 points), and depending upon 
the donor site, will have an immobilising plaster (2 points).
132
 In view of smoking and alcohol 
use, many will also score additional points for co-morbidity.  
Despite the increased risk of VTE in patients with malignancy, standard prophylactic LMWH 
dosages are the same for all patients. It is therefore unsurprising to find that dalteparin doses are 
inadequate in terms of anti-Xa response in a large number of patients. Anti-Xa results were 
strongly correlated with mean patient weight, consistent with studies examining the anti-Xa 
 Page 145 of 217 
response to dalteparin in obese patients.
137
 However, despite a variable anti-Xa response to 
prophylactic dalteparin dose regimens, prescribing is rarely adjusted according to patient weight 
in routine clinical practice. The results available from the manufacturer state a mean peak (4 
hour) levels of anti-Xa level in trials following single doses of 2500, 5000 and 10,000 IU of 
0.19±0.04, 0.41±0.07 and 0.82±0.10 IU/ml, respectively.
208
 However, it was found that a dose 
of 2500 IU was rarely sufficient to bring the anti-Xa result into the prophylactic range.  
Anti-Xa measurement is the only method to accurately determine the effect of LMWH; 
however, routine testing is not advocated in clinical practice. Whilst in healthy patients without 
malignancy this routine prophylactic dosing regimen is likely to be adequate, this is not the case 
in patients with malignancy.  
The measurement of anti-Xa levels in patients, with subsequent dose adjustment, appears a safe 
and reliable method to ensure efficacy. In the presented cohort, 56% had anti-Xa results which 
were below 0.2 IU/ml, and therefore deemed insufficient for prophylaxis. The potential 
consequences of this include significant peri-operative morbidity. Whilst adjustment in 
dalteparin dose was undertaken in those patients with sub-prophylactic levels, few patients had 
a repeat anti-Xa performed to determine the resultant effect. In the 3 patients that did, 1 still 
failed to bring the anti-Xa level into range.  
The findings should be interpreted with the limitations of the retrospective nature in which it 
was conducted. The accuracy of the anti-Xa level was reliant upon clear documentation of both 
the time of dalteparin administration, and venepuncture. Whilst the majority of patients were 
cared for on the ICU which utilises electronic administration records, it is anticipated that some 
anti-Xa levels were not perfectly timed. Venepuncture too soon after administration would 
result in an artificially high anti-Xa result, and too long following administration, an artificially 
low result. In most cases venepuncture timing was overseen by a coagulation practitioner, thus 
enhancing the accuracy.  
Despite a high proportion of patients having sub-prophylactic anti-Xa results, the incidence of 
VTE in this cohort was low, with only one case identified. However, since an anti-Xa was not 
performed in this patient, it is impossible to ascertain if the dalteparin dose was appropriate. It is 
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possible that the incidence of VTE was under reported as a result of patients being treated at 
peripheral hospitals following hospital discharge, although it would be expected that such 
treatment would be reported to the operating surgeon and documented in the medical records. 
Further contributing factors reducing VTE in this cohort include the intra- and early post-
operative use of pneumatic compression devices, antithrombotic stockings, and where possible, 
early mobilisation.  
The adverse outcomes in patients with acute coronary syndrome with subtherapeutic anti-Xa 
levels have been reported,
209
 however no such relationship has yet been reported following flap 
surgery. A number of factors may interfere with the effectiveness of subcutaneous administered 
LMWHs in head and neck cancer patients, including low cardiac output, decreased peripheral 
blood flow, or subcutaneous oedema during the early post-operative period.
210
 This further 
highlights the benefit of routine anti-Xa monitoring.  
Whilst LMWH reduces the risk of VTE, the benefits for free flaps remain uncertain. Animal 
studies have demonstrated that LMWH dalteparin prevents arterial thrombosis as effectively as 
UFH.
211-212
 Of the ten flap losses, anti-Xa results were available in 5, with only 2 of these being 
in the therapeutic prophylactic range. In the majority of cases, flap failure occurred after the 
critical 48 hour post-operative period. Potential contributing factors leading to failure include 
pregnancy, diabetes mellitus, and cardio-respiratory diseases. Olsson et al
206
 noted that of the 
two patients experiencing anastomotic thrombotic events in their patient cohort, both had an 
anti-Xa level below 0.3 IU/ml, and that pre-operative anticoagulation with 2500-5000 IU was 
unreliable.  
The ideal anticoagulant for free flap surgery would not only effectively reduce pedicle 
thrombosis, but would do so with minimal adverse side effects. The literature is replete with 
recommended regimens with such aims. Statins, in view of their vasoprotective action, 
anticoagulation and anti-inflammatory properties, are potential alternatives to traditional 
anticoagulants; however, there are currently no intravenous preparations available. In the cohort 
studied, 20% of patients (n=35) were on statins, and of these 5 experienced flap and/or 
haematological complications (flap loss n=2; identified bleed n= 2; haematoma n=1). In view of 
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the small numbers the data fails to yield any statistically significant correlations, but certainly 
provides scope for future research.  
The risk, in terms of bleeding/haematoma complications, did not appear to be influenced by 
dalteparin dose, or aspirin prescription. Since all patients received heparin in some form, with 
only a very small number of patients managed with UFH, it is not possible to compare these 
findings with what would be encountered with UFH or in the absence of anticoagulation. 
Previous studies have reported that LMWH carries a substantially reduced risk of adverse side 
effects, including haematoma formation when compared to UFH.
213
  However small, the use of 
LWMH carries risk, but this risk appears to be outweighed by the prophylactic benefits.  
In a recent amendment of the hospital protocol for the pre-operative management of surgical 
patients it has been decided that all patients should now receive a dose of 2500 IU of dalteparin 
the night prior to surgery. The benefit of this small additional dose is questionable. Certainly in 
their systematic review of elective hip surgery patients Strebel et al
129
 found no convincing 
evidence that starting prophylaxis pre-operatively was associated with a lower incidence of VTE 
than starting post-operatively.  
Whatever dose of LMWH is used, the response should be measured by an anti-Xa 
concentration. Patients should be encouraged to mobilise as soon as possible to minimise the 
risk of VTE. In order to facilitate early mobilisation, patients need to be free of as many 
intravenous lines and feeding tubes as possible, and their nutritional status should be adequate 
enough to provide the calorific intake to permit post-operative recovery, wound healing and 
mobilisation.   
Such early mobilisation is only possible in patients who are physically able. Patients with oral 
malignancy are frequently malnourished, both as a result of their primary tumour and secondary 
effects of malignancy. Extensive surgery and delayed recovery often results in patients losing 
further weight during their hospital stay. Optimisation of nutrition is therefore vital. As a result 
of surgical resection and reconstruction a method to bypass the oral cavity is required. 
Nasogastric and gastrostomy feeding tubes are often the preferred methods since they maintain 
the gastrointestinal tract; total parental nutrition carries significant risks, is highly expensive 
 Page 148 of 217 
with potentially high complication rates, and is rarely required following head and neck cancer 
resection.  
The main problems associated with NG tubes are displacement. Patients required a mean of 1.9 
tubes post-operatively in the cohort studied, a finding similar to those previously reported.
148
 
Reinsertion of an NGT in patients following head and neck cancer resection and reconstruction 
can be challenging. The swallow mechanism is often inhibited, in combination with anaesthesia 
of the tissues and post-operative swelling obstructing passage of the tube. Other reported 
problems include nasal irritation, pharyngeal and mucosal ulceration.
141
 The diameter of the 
NGT is relatively small, making the administration of medication through them more 
difficult.
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 This is particularly problematic in head and neck cancer patients who frequently 
have multiple co-morbidities requiring multiple medications. For patients requiring only short 
term support NGT is the ideal method for nutritional support. The potential social stigma of a 
NGT in situ has been suggested as a factor for early return to oral feeding.  
Only 24 patients were included in the study that were initially managed with NGT, with 3 of 
these ultimately requiring the insertion of a gastrostomy. Whilst the mean duration of use of 
NGT was 13 days, well within the recommended period of less than 3 weeks, the range was 
wide (between 5 and 63 days). However, only 2 patients were dependent upon NGT for longer 
than 28 days; in both cases this prolonged requirement could not have been predicted. Both 
patients experienced post-operative complications which resulted in their increased dependence. 
With such a small number of patients included in this cohort it is difficult to make any direct 
comparisons between the NGT and PEG groups.  
In total, 120 patients were reviewed who were managed with gastrostomies. All but 5 of these 
were inserted at the time of surgery. The small number of patients who underwent insertion of 
gastrostomy in the pre-operative period was not sufficient enough to permit comparison 
between pre-operative insertion and insertion at the time of surgery. Insertion at the time of 
surgery does have significant benefits for the patient, this includes insertion only after the 
airway has been secured and minimises the number of procedures the patient has to undergo. 
Insertion at the time of surgery reduces demand on the routine endoscopy lists, and can be 
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completed with only minimal prolonging of the anaesthetic time. The main disadvantages are 
that any upper gastrointestinal pathology that is detected cannot be fully investigated or treated 
prior to surgery. The seeding of malignant cells as a result of upper GI endoscopy prior to oral 
cancer resection is a potential risk but is not one encountered in any of the patients studied.  
Iatrogenic injury to the colon at the time of PEG insertion is particularly rare, and in reported 
cases may not present for many weeks following PEG insertion.
214
 Two patients experienced 
major complications – a colonic injury, and a PEG leak, both requiring laparotomy. The minor 
complication rate of 16% resulted in an overall complication rate of 18%. This is lower than 
previously reported in the literature.
148,167
 It is likely there are a number of contributory factors 
to this. PEG insertion is only completed by a senior member of the surgical team, and only after 
the airway is secured. The nursing staff follow a protocol of flushing prior to use of the tube, 
and the patient is taught how to manage their PEG as soon as they are able. Patients are closely 
followed up in the outpatient department following discharge, with support from the Dieticians 
and Clinical Nurse Specialists. This ensures that the stoma site is frequently inspected, and 
preventative mechanisms put in place to avoid wound complications. However, it should also be 
noted that minor complications, such as local infection may have been treated by general 
practitioners and not documented in the patient medical records. By combined use of data from 
retrospective note review and both a database and records held by the dieticians it is hoped that 
these inaccuracies were minimised.  
The mean time of PEG use to removal request was 141 days, and to actual removal 212 days. 
This represents an average of 71 days from the point of referral to removal – a significant delay. 
Subsequent changes have been instigated in the patient pathway, with resultant reduction in 
waiting times for endoscopic PEG removal. In addition, the requirement for endoscopic removal 
may be reduced with the use of “cut and push” tubes which are currently being evaluated. All 
patients are assessed and followed up by the dietician and speech and language teams. The 
decision for PEG removal is multi-factorial, and whilst discussion of PEG removal may have 
occurred sooner during patient follow-up care, the date of referral for removal was considered to 
be more accurately documented.  
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Further concern related to PEG use is a delay in return to normal feeding which may result from 
protracted disuse of the muscles of deglutition.
141,215
 Rogers et al
216
 reported decreased quality 
of life scores in patients continuing to use their PEG compared to those who had undergone 
removal or had not used a PEG tube at all. However, the cohort continuing to use their PEG 
were also more likely to have undergone adjuvant therapy with more advanced disease; both 
significant contributors for quality of life scores. The impact on quality of life of a delay in 
reestablishing oral nutrition is difficult to quantify. It is difficult to accurately compare patient 
satisfaction between NG tubes and PEG tubes since this would entail randomisation of feeding 
tubes, which would be inappropriate in a number of cases.  
The correct selection of feeding tube in patients with head and neck cancer can be particularly 
problematic, as identifying patients who require longer enteral support can be difficult. It was 
demonstrated that the key factors likely to result in prolonged nutritional support include tumour 
size, location, method of reconstruction, and extent of planned post-operative radiotherapy. In 
the cohort of patients studied, the KAREN scoring method was reliable, with the correct tube 
selection in 92% of patients.  
The main limitations of the study are related to its retrospective nature. Only those patients who 
underwent free tissue transfer surgery were included, and as such, tumour volume was much 
greater than those undergoing local resection and local flaps/mucosal grafts. As a tertiary 
referral centre large volume disease is frequently encountered which contributed to the 
increased frequency of PEG selection. The scoring system was developed and assessed only on 
retrospective data at one centre thus it is heavily biased to local practice. The scores were 
arbitrarily assigned and it must be noted that a significant proportion of patients would be 
provided with a PEG based upon this system. Whilst useful for the local population, mainly as a 
result of being consistent with local practices, the scoring system was developed on a relatively 
small patient cohort and may not be transferrable to other head and neck units. Indeed the 
definition of “correct” selection of feeding tube for the patients included in the study was based 
upon their length of use, whilst important this is not the only consideration in tube selection. 
Often the decision for adjuvant therapy is only made once the results of pathological analysis of 
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the resected specimen are available, as a result it is not always possible to assign a score pre-
operatively for the number of planned radiotherapy fields. Prospective application of the scoring 
system is required for further validation with a larger patient cohort and subsequent refinement 
to permit the creation of a highly accurate and reliable tool.  
Potential factors to improve peri-operative care of patients following ablative and reconstructive 
surgery for head and neck malignancy have been investigated. There was a certain amount of 
overlap between the patient cohorts studied and certainly a full retrospective study on a larger 
cohort of patients would now be possible.  
The departmental database was established through some of the early preliminary studies 
included in this thesis. The retrospective review of medical records and maintaining the 
accuracy of this data with regard to investigations and outcome is an extensive task fraught with 
many challenges. As a result of the growing amount of data available it has been possible in this 
thesis to cross-reference patients from the published studies, such as that on MI following 
admission via TDA to further assess causative factors.  
However, as previously stated these comparisons are only as accurate as the data collected and 
stored. The fundamental difficulty associated with all retrospective medical record reviews is 
the accuracy and completeness of the contemporaneous notes. Certainly for the Trust at which 
these studies were conducted, filing of medical records provided additional challenges since the 
notes were often not arranged in chronological order, had sections missing or were illegible.  
The factors included in this thesis provide a good basis on which to improve peri-operative care 
in terms of pressor support, fluid management, nutrition, coagulation and hospital admission 
route. However, there are numerous other factors in the care of patients undergoing ablative and 
reconstructive head and neck surgery that could also be considered, such as management of the 
airway, effects of insulin resistance, and the benefits of a dedicated head and neck surgery unit. 
This provides further scope for study, for which comparisons can be made between patients 
cared for on combined surgical wards, and following the recent transfer of head and neck 
services to the cancer centre, where all head and neck patients under the care of the 
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Otolaryngologists, Plastic Surgeons and Maxillofacial Surgeons will be cared for on a combined 
head and neck ward.  
The studies discussed also provide further scope for additional investigation and research. In 
terms of selecting the optimal pressor agent following free tissue transfer, metaraminol requires 
further investigation. Discussions are currently underway to permit completion of this second 
phase of the study. Prospective studies are required to further assess the potential of fibrinogen 
to platelet ratio as measured by TEG
®
 as a screening tool to identify patients at risk of 
thrombotic complications, and also to determine the accuracy of the Key to Aid Replacement 
Enteral Nutrition.   
 
Conclusion 
This thesis has explored a number of factors in the peri-operative management of patients 
undergoing ablative surgery for head and neck malignancy with free flap reconstruction. Of the 
factors studied, fluid optimisation with LiDCO™ monitoring is advocated in patients 
undergoing ablative and reconstructive surgery and where pressor support is required, low dose 
noradrenaline should be used. Careful anticoagulation prescribing should be undertaken, with 
anti-Xa monitoring of LMWH to ensure adequate response, in combination with TEG
®
 
monitoring to identify patients most at risk of thrombotic flap complications. These 
recommendations may improve patient outcome with significant long term benefits for both 
patients and the NHS.   
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Appendix A: Staging of head & neck malignancy 
The current staging system for head and neck malignancy is by the TNM classification of Malignant Tumours, by the 
International Union Against Cancer (UICC), Seventh Edition.  
Lip & Oral Cavity 
The classification applies to carcinomas of the vermilion surfaces of the lips and of the oral cavity, including those of 
minor salivary glands.
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Anatomical Sites and Subsites 
Lip (C00) 
1. External upper lip (vermilion border) (C00.0) 
2. External lower lip (vermilion border) (C00.1) 
3. Commissures (C00.6) 
Oral Cavity (C02-06) 
1. Buccal mucosa 
a. Mucosa of upper and lower lips (C0.3, 4) 
b. Cheek mucosa (C06.0) 
c. Retromolar areas (C06.2) 
d. Bucco-alveolar sulci, upper and lower (vestibule of mouth) (C06.1) 
2. Upper alveolus and gingival (upper gum) (C03.0) 
3. Lower alveolus and gingival (lower gum) (C03.1) 
4. Hard palate (C05.0) 
5. Tongue 
a. Dorsal surface and lateral borders anterior to vallate papillae (anterior two thirds) (C02.2) 
b. Inferior (ventral) surface (C02.2) 
6. Floor of mouth (C04) 
TNM Classification 
T – Primary Tumour 
T1 ≤ 2cm 
T2 >2-4 cm 
T3 >4cm 
T4a Oral Cavity: through cortical bone, deep/extrinsic muscle of tongue, maxillary sinus, skin of face 
  Lip: through cortical bone, inferior alveolar nerve, floor of mouth, skin 
T4b Masticator space, pterygoid plates, skull base, internal carotid artery 
N - Regional Lymph Nodes 
N0 No regional lymph node metastasis 
N1 Ipsilateral single ≤3cm 
N2  
a. Ipsilateral single >3-6cm 
b. Ipsilateral multiple ≤6cm 
c. Bilateral, contralateral ≤6cm 
N3 >6cm 
M – Distant Metastasis 
 M0 No distant metastasis 
 M1 Distant metastasis 
Stage Grouping 
Stage 0  Tis  N0  M0 
Stage I  T1  N0  M0 
Stage II  T2  N0  M0 
Stage III  T3  N0  M0 
   T1, T2, T3 N1  M0 
Stage IVA  T4a  N0, N1  M0 
   T1, T2, T3, T4a N2  M0 
Stage IVB  Any T  N3  M0 
   T4b  Any N  M0 
Stage IVC  Any T  Any N  M1 
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Nasal Cavity and Paranasal Sinuses 
Anatomical Sites and Subsites 
Nasal Cavity (C3.0) 
Septum  
Floor 
Lateral wall 
Vestibule 
Maxillary Sinus (C31.0) 
Ethmoid Sinus (C31.1) 
 
TNM Classification (Maxillary Sinus) 
T – Primary Tumour 
T1 Mucosa 
T2 Bone erosion/destruction, hard palate, middle nasal meatus 
T3 Posterior bony wall maxillary sinus, subcutaneous tissues, floor/medial wall of orbit, pterygoid 
fossa, ethmoid sinus 
T4a Anterior orbit, cheek skin, pterygoid plates, infratemporal fossa, cribiform plate, sphenoid or 
frontal sinuses 
T4b Orbital apex, dura, brain, middle cranial fossa, cranial nerves other than V2, nasopharynx, clivus 
N – Regional Lymph Nodes 
N1 Ipsilateral single ≤3cm 
N2  
a. Ipsilateral single >3-6cm 
b. Ipsilateral multiple ≤6cm 
c. Bilateral, contralateral ≤6cm 
N3 >6cm 
Stage Grouping 
Stage 0  Tis  N0  M0 
Stage I  T1  N0  M0 
Stage II  T2  N0  M0 
Stage III  T3  N0  M0 
   T1, T2, T3 N1  M0 
Stage IVA  T1, T2, T3 N2  M0 
   T4a  N0, N1, N2 M0 
Stage IVB  T4b  Any N  M0 
   Any T  N3  M0 
Stage IVC  Any T  Any  N  M1 
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RECONSTRUCTIVE
Epinephrine, Norepinephrine, Dobutamine,
and Dopexamine Effects on Free Flap Skin
Blood Flow
Karen A. Eley, M.R.C.S.,
M.Sc.
J. Duncan Young, B.M.,
D.M.
Stephen R. Watt-Smith,
F.D.S.R.C.S., M.D.
Oxford, United Kingdom
Background: The optimal sympathomimetic drug to support blood pressure
without adverse vasoconstriction of free flap circulation remains unknown. This
study examined the effects of four agents (epinephrine, norepinephrine, do-
butamine, and dopexamine) on free flaps following resection of head and neck
cancer.
Methods: Twenty-four patients (25 data sets) were recruited into the study. Each
patient received an infusion of the four drugs in a random order, with an
intervening washout period between drugs, at four infusion rates. Continuous
free flap skin blood flow monitoring was performed using laser Doppler ve-
locimetry, with a second sensor on normal skin acting as a control. Global
cardiovascular variables were monitored using the LiDCO Rapid Pulse Contour
Analysis System (LiDCO Ltd., Cambridge, United Kingdom).
Results: Dose-dependent, increased free flap skin blood flow was observed with
norepinephrine and dobutamine. Both dopexamine and epinephrine infusions
decreased blood flow. Flap skin blood conductance decreased (vasoconstric-
tion) with norepinephrine, but markedly less than in control tissue, so overall
the flap skin blood flow increased with increasing arterial blood pressure.
Dobutamine increased flap skin conductance, without significantly increasing
blood pressure, and modestly increased flap blood flow.
Conclusions: Both dobutamine and norepinephrine had beneficial effects on
flap skin blood flow. The maximal improvement in flow occurred with norepi-
nephrine,making it the optimal pressor to use in patients with hypotension after
free flap surgery. (Plast. Reconstr. Surg. 130: 564, 2012.)
Free flap reconstruction following ablativesurgery for intraoral and perioral malig-nancy has become routine practice. Patients
with these malignancies are frequently of ad-
vanced age and have chronically abused tobacco
and alcohol, with resulting comorbidities.1–3 Many
patients require blood pressure support both in-
traoperatively and during the early postoperative
recovery period to counteract the hypotensive ef-
fects of sedation or anesthesia compounded by
comorbidities and concurrent medication. Al-
though the sympathomimetic pressor agents used
may increase systemic blood pressure and hence
the driving pressure that perfuses the flap, the
associated vasoconstriction (assuming denervated
flaps maintain such control) may paradoxically
reduce flap perfusion, resulting in flap ischemia.
As a result, many surgeons remain wary of using
such agents.4 The best agent to maintain blood
pressure without adverse effect on flap blood flow
remains unclear. This study investigated the ef-
fects on flap skin perfusion of four common sym-
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pathomimetic agents routinely used in intensive
care practice.
PATIENTS AND METHODS
After ethical approval from the Oxfordshire
Research Ethics Committee, 24 patients (16 men
and eight women) were recruited into the study,
and written consent was obtained. One patient
re-presented during the study period with a sec-
ond primary tumor and was recruited into the
study on both occasions, resulting in 25 sets of
results. The inclusion criteria were patients un-
dergoing free flap surgery for head and neck can-
cer resection with a planned postoperative inten-
sive care unit admission for overnight sedation
and ventilation (standard practice at our institu-
tion). The only exclusion criteria were pregnancy
or a body weight above 100 kg. All patients had a
central venous line and arterial line sited at the
time of anesthesia as part of routine clinical care.
Intraoperatively and postoperatively in the inten-
sive care unit, fluid management was optimized
with the aid of the LiDCO Rapid system (LiDCO
Ltd., Cambridge, United Kingdom), which uses a
pulse contour analysis algorithm (PulseCO) to es-
timate stroke volume.5 Stroke volume variation
below 10 percent was taken to indicate optimal
fluid loading throughout the study. At the end of
the surgical procedure, two Transonic laser Dopp-
ler red blood cell velocimetry probes (Transonic
Systems Inc., Ithaca, N.Y.) were attached to the
skin—one central on the free flap skin paddle and
one acting as a control. To standardize the control
site, and to minimize impact upon vascular access,
the skin over the deltoid muscle was used in all
cases. The Transonic device calculates skin blood
flow as the product of the number of red cells
moving in the illuminated field and their mean
velocity to provide a measure of red cell flux
(blood flow). This is expressed in tissue perfusion
units, a unitless measure, as it is not possible to
calibrate the probes. Flap skin blood flow was
logged from the Transonic device using Acq-
Knowledge version 3.9.1.6 software (Biopac Sys-
tems Inc., Goleta, Calif.) on a personal computer
at 40 samples per second.
Red cell transfusion to maintain a hemoglobin
concentration above 8.0 g/dl was completed before
the study commenced. Once the patients were sta-
bilized in the intensive care unit, and if the mean
arterial pressure was below 80 mmHg, the patients
received four pressor drugs (epinephrine, nor-
epinephrine, dobutamine, and dopexamine) in-
fused at four increasing doses (Table 1). The
order of drug administration was randomly pre-
determined and concealed in an opaque enve-
lope until commencement of the trial. The re-
search and medical teams were unblinded to the
infusion drug and rate.
Each drug was administered for 5 minutes at
each rate. The infusion was stopped if the mean
arterial pressure increased by more than 30
mmHg or there was an adverse effect. At the end
of each infusion, 5 ml of blood was aspirated and
discarded from the central line and the line
flushed with 10 ml of normal (0.9%) saline. A
20-minute period elapsed before commencing the
next drug in the sequence to permit adequate
time for physiological variables to return to base-
line. Throughout the periods of baseline record-
ing and drug infusions, sedation was maintained
at a steady rate, and only maintenance fluids were
administered.
At the end of the trial, if the patient required
continued pressor support, the drug producing
the best increase in flap skin blood flow from the
trial data was selected. The final 2 minutes of the
5-minute recording period of each drug rate was
used for subsequent analysis. The time period
was identified on the AcqKnowledge system and
the data were transferred to a Microsoft Excel (Red-
mond,Wash.) spreadsheet. The recording (in tissue
perfusion units) over the 2-minute period was aver-
aged to obtain a mean value for the flap and the
control skin. This was completed for eachof the four
drugs for all of the four drug infusion rates and at
baselinebefore commencinganydrug infusion.The
fractional change from the baseline was calculated
for each of the infusion rates. Corresponding data
fromLiDCORapid were entered onto theMicrosoft
Excel spreadsheet and corresponding flap conduc-
Table 1. Drug Infusion Rates
Drug
Concentration
(g/ml)
First Infusion Rate
(g/kg/min)
Second Infusion Rate
(g/kg/min)
Third Infusion Rate
(g/kg/min)
Final Infusion Rate
(g/kg/min)
Epinephrine 20 0.05 0.1 0.15 0.2
Norepinephrine 20 0.05 0.1 0.15 0.2
Dobutamine 500 2 4 6 8
Dopexamine 1000 1.25 2.5 3.75 5
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tance  Tissue Perfusion TPUMean Arterial Pressure mmHg was calcu-
lated. This result was also converted to a fractional
change from baseline.
RESULTS
Of the 24 patients recruited into the study, the
majority had reconstruction completed with a ra-
dial forearm free flap (n  17) (Table 2). All
patients were American Society of Anesthesiolo-
gists grade II to IV, with a mean age of 60 years
(range, 43 to 73 years). Patient demographics are
shown in Table 2.
The mean values for each of the cardiovascu-
lar variables at baseline and for each infusion are
shown in Table 3. All of the drugs except norepi-
nephrine resulted in an increased heart rate. Nor-
epinephrine and epinephrine caused an increase
in mean arterial pressure, whereas dobutamine
and dopexamine caused a modest decrease. All
drugs increased cardiac output. Figure 1 shows a
mean (SE) fractional change in skin perfusion
from baseline for the control and flap. For epi-
nephrine and dopexamine, tissue perfusion (flap
flow) decreased, whereas that at the control site
decreased and increased, respectively. For norepi-
nephrine and dobutamine, flap flow increased at
lower infusion rates, whereas the control site de-
creased and increased, respectively. The largest
increase in flap skin blood flow occurred with 0.1
to 0.15 g/kg/minute of norepinephrine.
To examine the vasodilator or vasoconstric-
tion effects of the drugs independent of the mean
arterial pressure, skin blood flow conductance was
calculated (Fig. 2), with an increase signifying va-
sodilatation.Only dopexamine caused an increase
in conductance for both flap and control with
increasing infusion rates. Epinephrine and nor-
epinephrine were both vasoconstrictors (reduced
conductance), though norepinephrine had less
effect on the flap compared with control tissue.
For the one patient recruited twice into the
study, the findings on both occasions yielded sim-
ilar results for flow and conductance, with all
drugs except epinephrine. With epinephrine, it
was noted that the first study for this patient (pa-
tient 9) resulted in increased flow for both flap
and control, which was not consistent with the
repeat study (patient 13) or the overall results for
all patients.
DISCUSSION
It has been demonstrated that whereas nor-
epinephrine results in decreased conductance
(vasoconstriction) in both the flap and the control
Table 2. Patient Demographics
Patient Age (yr) Sex BMI Resection
Free Flap
Donor Site
1 67 M 25.3 Left hemiglossectomy Radial
2 62 F 24.9 Left hemiglossectomy Radial
3 62 F 23.4 Total glossectomy Latissimus dorsi
4 65 M 24.2 Hemimandibulectomy Fibula
5 58 M 32.8 Hemimandibulectomy Fibula
6 61 F 18.0 Resection floor of mouth/mandible ALT  fibula
7 53 F 22.4 Left hemiglossectomy Radial
8 43 M 24.3 Maxillectomy and orbital enucleation Latissimus dorsi
9* 68 M 25.0 Resection right buccal sulcus Radial
10 54 F 24.7 Left hemimandibulectomy Radial  fibula
11 63 M 19.4 Resection right tongue/mandible ALT  fibula
12 48 M 24.3 Left partial glossectomy Radial
13* 69 M 24.7 Right hemimandibulectomy ALT  fibula
14 60 F 24.7 Right hemiglossectomy ALT
15 47 M 26.3 Resection left buccal mucosa Radial
16 64 M 17.5 Resection floor of mouth Radial
17 57 F 25.4 Right hemiglossectomy Radial
18 64 M 26.0 Resection adhesions tongue Radial
19 54 M 27.1 Right hemiglossectomy Radial
20 69 M 23.9 Right hemiglossectomy Radial
21 67 M 30.4 Resection right tonsillar fossa Radial
22 56 M 17.8 Resection right posterior tongue Radial
23 66 M 24.7 Resection left tonsillar fossa Radial
24 57 M 24.7 Resection ventral tongue Radial
25 73 F 24.4 Right hemiglossectomy and partial maxillectomy Radial
BMI, body mass index; M, male; F, female; ALT, anterolateral thigh flap.
*Patients 9 and 13 are the same patient, enrolled in the study on two separate occasions, having presented with a second primary tumor during
the study period.
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Fig.1. Mean fractional change inperfusion frombaseline for eachdrug infusion for flapandcontrol.Red indicates free flap, andblue
indicates control.
Table 3. Mean Cardiovascular Variables at Each Infusion Rate
Concentration
(g/kg/min)
Mean (SD)
HR (Beats/min) Systolic (MmHg) MAP (MmHg) CO (Liter/min) CI (Liter/min/m2)
Baseline — 77 (13) 113/57 (17/7) 76 5.2 (1.3) 2.9 (0.5)
Epinephrine 0.05 86 (15) 116/53 (22/8) 73 6.7 (2.1) 3.7 (1.1)
0.1 92 (16) 129/55 (24/7) 77 8.2 (2.7) 4.5 (1.4)
0.15 99 (17) 139/57 (26/7) 80 9.5 (3.0) 5.2 (1.5)
0.2 106 (17) 147/61 (24/8) 85 10.5 (3.5) 5.9 (1.8)
Norepinephrine 0.05 76 (15) 136/66 (30/10) 89 5.7 (1.4) 3.1 (0.6)
0.1 76 (14) 14871 (26/9) 98 6.2 (1.6) 3.4 (0.8)
0.15 76 (16) 161/76 (21/9) 106 6.8 (1.6) 3.6 (0.8)
0.2 84 (13) 168/72 (13/7) 103 6.9 (2.0) 3.9 (0.7)
Dobutamine 2 84 (16) 126/58 (25/9) 80 6.5 (2.0) 3.6 (0.9)
4 91 (18) 131/58 (21/11) 80 7.3 (2.5) 4.0 (1.1)
6 99 (20) 132/56 (22/8) 78 8.2 (2.9) 4.5 (1.4)
8 107 (18) 134/55 (23/7) 76 9.8 (3.2) 5.3 (1.4)
Dopexamine 1.25 88 (15) 107/52 (20/9) 68 6.6 (2.0) 3.6 (0.9)
2.5 95 (15) 105/48 (22/8) 66 7.6 (2.9) 4.2 (1.4)
3.75 102 (16) 104/46 (22/8) 64 8.4 (2.9) 4.6 (1.3)
5 109 (17) 103/45 (23/8) 62 9.2 (3.2) 5.0 (1.5)
HR, heart rate; MAP, mean arterial pressure; CO, cardiac output; CI, cardiac index.
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tissue, the effect is more marked in the control
tissues. The vasoconstrictor effect on the flap is
more than overcome by the increase in blood
pressure, so a significant increase in flap perfusion
arises with the increased blood pressure up to a
dose of 0.15 g/kg/minute. The paradoxical re-
sults at 0.2 g/kg/minute may be unreliable, as
only five patients received this dose, the remaining
patients having reached themaximumblood pres-
sure increase permitted in the study (30-mmHg
mean arterial pressure rise) at lower doses. Do-
butamine also reliably increased flap and control-
site blood flow by about 10 percent (compared
with the 30 percent maximum seen with norepi-
nephrine) without causing a change in conduc-
tance and with little effect on blood pressure. It,
however, frequently resulted in a tachycardia, re-
quiring premature termination of the drug infu-
sion in a number of cases, and increased the car-
diac output by 50 percent on average. These
effects are all in keepingwith the known inodilator
effects of dobutamine. With this patient group at
high risk of cardiac ischemia, these side effects
might cause concern. Epinephrine caused a de-
crease in both flap flow and conductance, despite
an increase in both blood pressure and cardiac
output, and there was little difference between
flap and control skin. Dopexamine preferentially
vasoconstricted the flap compared with the con-
trol skin, making it entirely unsuitable for main-
taining flap perfusion.
The recruitment of the same patient on two
occasions has provided a unique opportunity to
examine the consistency of findings on two sepa-
rate occasions with different free flaps. The results
were largely consistent on both occasions and with
the overall results for all patients in all drugs ex-
cept epinephrine. This resulted in both increased
flow and conductance for both flap and control on
the first occasion but a decreased flow and con-
ductance (consistent with the overall results) in
the second study. This may simply reflect an
Fig. 2. Mean fractional change in conductance frombaseline for each infusion. Red indicates free flap, and blue indicates control.
Plastic and Reconstructive Surgery • September 2012
568
172
erroneous result but raises the possibility that
there is some variability in free flap  receptor
survival.
The findings should be interpreted with re-
gard to the limitations of the study. The laser
Doppler probes were sited at the center of the flap
in all cases, based on the assumption that any
changes in blood flow through the flap would be
uniform. Only the skin paddle of the flap was
examined, and there was variability in the free flap
type. In addition, despite best efforts to achieve
optimal fluid balance and maintain all variables
constant during the study, this is difficult to fully
achieve during the immediate postoperative
period.
Doppler laser blood flow probes are both safe
and convenient to use. Because the Doppler
probes are sutured directly to the flap, they can
simply be removed without further requirement
for surgery, unlike probes attached around the
flap vessels. The simplicity of the technique and
the good correlation with other measures of flap
blood flow have made laser Doppler monitoring a
popular research and clinical monitoring tech-
nique. The laser Doppler device interrogates a
hemisphere of about 1-mm3 volume under the
probe and provides an output that is the product
of the red cell velocity (from the Doppler shift in
reflected light) and the number of red cells in
motion (from the amount of reflected, Doppler-
shifted light). The probe cannot be calibrated
against a known blood flow, so the unitless “tissue
perfusion units” are used to express blood flow.
This means the use of a control tissue or stable
comparator baseline is required. Laser Doppler
monitoring of skin blood flow in free flap tissue
transfer has been used successfully to assess
changes in intraoral flap perfusion over time.6–8
These studies, however, used blood flowmeasured
before flap elevation as a baseline rather than
using a control area of normally innervated skin
and, as a result, could not determine whether the
responses were unique to free flaps or a global
response to surgery and the recovery period.
The most striking result in this study was the
decreased sensitivity of the flap to the vasocon-
strictor effects of norepinephrine when compared
with control tissue. It was this that caused the
increase in blood flow to the flap as the blood
pressure increased with increasing norepineph-
rine doses, whereas in control tissue, vasoconstric-
tion dominated and the blood flow decreased as
the norepinephrine dose increased. Chronic de-
nervation of tissues is generally believed to lead to
a heightened vasoconstrictor response to  adren-
ergic agents, such as norepinephrine, in the de-
nervated tissue, which may begin as early as 2
days.9–13 In this acute situation, however, the ability
of systemically administered norepinephrine to
cause vasoconstriction in the denervated free flap
was markedly attenuated when compared with the
control tissue. A similar effect has been observed
when innervated and denervated pedicle flaps
were raised in a rat model.14 In these studies, the
denervated flaps had an increase in blood flow
after norepinephrine or phenylephrine (1 ago-
nist) administration, with a simultaneous reduc-
tion in flow in the innervated flap. The effect was
blocked by prazosin, a selective blocker of 1 re-
ceptors on vascular smoothmuscle, suggesting the
effect was due to a decreased sensitivity to 1 ago-
nists. In this study, epinephrine was also studied,
a drug that has 1 agonist activity at high doses but
that showed parallel changes in flap and control
tissue perfusion in this study, suggesting the 
effects of epinephrine were predominating at the
doses used.
Why this reduction in 1 adrenergic receptor
sensitivity occurs in acutely denervated vessels is
unknown. It is possible that norepinephrine-in-
duced vasoconstriction of fully vasodilated dener-
vated vessels results in insufficient caliber reduc-
tion to significantly alter blood flow, though this
is unlikely given the exquisite sensitivity of flow to
vessel diameter. Reduced pulsatility in dener-
vated, dilated vessels may reduce the secretion of
endothelium-derived vasoconstrictive factors, or
there may be a direct effect at the 1 adrenergic
receptor level. Examining the frequency compo-
nents of the blood flow signal may at least help
distinguish local from humeral effects.15
Dopexamine is a synthetic analogue of dopa-
mine that causes systemic vasodilatation through
the stimulation of 2 adrenoceptors and periph-
eral dopamine receptors, and weak inotropic
properties through the stimulation of 1 adreno-
ceptors. In this study, dopexamine increased con-
trol-site conductancemore than flap conductance
and, coupled with a modest reduction in blood
pressure caused by 2 adrenoceptor stimulation
systemically, caused a reduction in flap flow. As
dopaminergic stimulation causes local release of
norepinephrine, this differential effect on control
tissue and flap conductance might be mediated
through the same mechanism as norepinephrine.
Dobutamine is predominantly a 1 adrenergic
agonist, with weak 2 and 1 activity and is there-
fore primarily an inotropic and chronotropic
drug. It had little effect on either flap conductance
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or flow and was of limited practical value due to
the 1-induced tachycardia it caused.
This study used the skin blood flow as a sur-
rogate measure of total flap blood flow. There is
only one study of total blood flow to free flaps in
human subjects. Scholz et al.4 investigated the ef-
fect of dobutamine on total blood flow of free
tissue transfer flaps during head and neck surgery.
After completion of the anastomoses, the flow in
the anastomosed donor artery was measured with
an ultrasonic flow meter. Dobutamine at rates up
to 6 g/kg/minute was infused. They found a
doubling in flow frombaseline to 6g/kg/minute
accompanied by increased cardiac output, con-
cluding that dobutamine may be useful in improv-
ing free flap perfusion. The authors noted that
there was no significant increase in mean arterial
pressure with the three rates trialed. Similar find-
ings, but of much less magnitude, were obtained
in this study.
Acceptance of a small vasoconstrictor effect in
return for a significant improvement in flap per-
fusion will require further validation before con-
cerns about the adverse effects of  adrenergic
agents on free tissue transfer are fully addressed,
and the pure 1 adrenergic agents, phenylephrine
and metaraminol, require further investigation.
This study was limited to the perioperative period,
and the results may not be transferable to treat-
ment in the longer term, when a heightened sen-
sitivity of denervated vessels to adrenergic agents
has been reported.
CONCLUSION
Norepinephrine most consistently elevated
the mean arterial pressure and caused by far the
largest increase in flap skin blood flow, making it
the pressor agent of choice (of those studied),
following free tissue transfer.
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University of Oxford
John Radcliffe Hospital
Headley Way
Oxford OX3 9DU, United Kingdom
karen.a.eley@gmail.com
ACKNOWLEDGMENTS
This work was funded by a research grant and
research fellowship from the Oxfordshire Health Services
Research Committee. The fellowships are supported by
funds from the Oxford Biomedical Research Council and
Merck (Hoddesdon, United Kingdom). The authors thank
Dr. Jon Salmon, Intensive Care Unit, Oxford University
Hospitals National Health Service Trust, for his help with
this study.
REFERENCES
1. BlotWJ, McLaughlin JK,WinnDM, et al. Smoking and drink-
ing in relation to oral and pharyngeal cancer. Cancer Res.
1988;48:3282–3287.
2. Marshall JR, Graham S, Haughey BP, et al. Smoking, alcohol,
dentition and diet in the epidemiology of oral cancer. Oral
Oncol Eur J Cancer 1992;28B:9–15.
3. Rothman K, Keller A. The effect of joint exposure to alcohol
and tobacco on risk of cancer of the mouth and pharynx.
J Chron Dis. 1972;25:711–716.
4. Scholz A, Pugh S, Fardy M, Shafik M, Hall JE. The effect of
dobutamine on blood flow of free tissue transfer flaps during
head and neck reconstructive surgery. Anaesthesia 2009;64:
1089–1093.
5. Jonas M, Fennell J, Brudney CS. Haemodynamic optimisa-
tion of the surgical patient revisited. Anaesthesia Int. 2008;2:
1–5.
6. Yoshino J, Nara S, Endo M, Kamata N. Intraoral free flap
monitoring with a laser Doppler flowmeter. Microsurgery
1996;17:337–340.
7. Ho¨lzle F, Loeffelbein DJ, Nolte D, Wolff KD. Free flap mon-
itoring using simultaneous non-invasive laser Doppler flow-
metry and tissue spectrophotometry. J Craniomaxillofac Surg.
2006;34::25–33.
8. Ho¨lzle F, Rau A, Loeffelbein DJ, Mu¨cke T, KestingMR,Wolff
KD. Results of monitoring fasciocutaneous, myocutaneous,
osteocutaneous and perforator flaps: 4-year experience with
166 cases. Int J Oral Maxillofac Surg. 2010;39:21–28.
9. Banbury J, Siemionow M, Porvasnik S, Petras S, Zins JE.
Muscle flaps’ triphasic microcirculatory response to sympa-
thectomy and denervation. Plast Reconstr Surg. 1999;104:730–
737.
10. Rizzoni D, Perlini S, Mircoli L, Porteri E, Franzelli C, Cas-
tellano M, et al. Enhanced vascular reactivity in the sym-
pathectomized rat: Studies in vivo and in small isolated re-
sistance arteries. J Hypertens. 2000;18:1041–1049.
11. Godden DRP, Little R, Weston A, Greenstein A, Woodwards
RTM.Catecholamine sensitivity in the rat femoral artery after
microvascular anastomosis. Microsurgery 2000;20:217–220.
12. Bickel A, Axelrod FB, Schmelz M, Marthol H, Hilz MJ. Der-
mal microdialysis provides evidence for hypersensitivity to
noradrenaline in patients with familial dysautonomia. J Neu-
rol Neurosurg Psychiatry 2002;73:299–302.
13. Moore GK, Trachy RE, Cummings CW. The effect of alpha-
adrenergic stimulation and blockade on perfusion of myo-
cutaneous flaps.Otolaryngol Head Neck Surg. 1986;94:489–496.
14. Lecoq JH, Joris JL, Nelissen XP, Lamy ML, Heymans OY.
Effect of adrenergic stimulation on cutaneous microcircu-
lation immediately after surgical adventitiectomy in a rat skin
flap model. Microsurgery 2008;28:480–486.
15. Young JD, Cameron EM. Dynamics of skin blood flow in
human sepsis. Intensive Care Med. 1995;21:669–674.
Plastic and Reconstructive Surgery • September 2012
570
174
POWER SPECTRAL ANALYSIS OF THE EFFECTS OF EPINEPHRINE,
NOREPINEPHRINE, DOBUTAMINE AND DOPEXAMINE ON
MICROCIRCULATION FOLLOWING FREE TISSUE TRANSFER
KAREN A. ELEY, M.B.C.H.B., M.R.C.S.(ED), M.Sc.,1* JOHN DUNCAN YOUNG, B.M., D.M., F.R.C.A.,2 and
STEPHEN R. WATT-SMITH, M.B.B.S., F.D.S.R.C.S., M.D.1
Background: The use of pressor drugs after microsurgical free tissue transfer remains controversial because of potential vasoconstrictor
effects on the free flap. Noninvasive monitoring of free flaps with laser Doppler flowmetry may provide further information regarding the
local regulation of blood flow in the flap tissues during pressor infusions. This study evaluated the effects of four commonly used pressor
agents. Methods: Twenty four patients (25 data sets) undergoing head and neck cancer resection and free flap reconstruction were
recruited. Epinephrine, norepinephrine, dopexamine, and dobutamine were infused in a random order at four infusion rates, after surgery,
with free flap and control area (deltoid region) laser Doppler skin blood flow monitoring. Frequency analysis of the Doppler waveform was
performed utilizing the time period immediately before the first drug infusion for each patient as baseline. Results: At baseline there was
less power at the 0.002–0.6 Hz frequency in the flap compared with control tissue consistent with surgical denervation. At maximum epi-
nephrine infusion rates, the control of blood flow moved toward (i.e., proportion of power increased in) the lower frequencies, as smooth
muscle mediated (myogenic) control began to dominate blood flow, an effect most marked with norepinephrine. Dobutamine and dopex-
amine had little effect on control of blood flow. Conclusions: Denervation of free flap tissue is demonstrable using spectral analysis of laser
Doppler blood flow signals. With norepinephrine the control of blood flow shifts toward low frequency vasomotion where blood flow
depends mostly on average blood pressure, making it potentially the most suitable agent following free tissue transfer. VC 2013 Wiley Peri-
odicals, Inc. Microsurgery 33:275–281, 2013.
Microsurgical free tissue transfer has become routine
practice for reconstruction after the excision of peri-oral
malignancies. Patients undergoing surgery for these
malignancies frequently require blood pressure support
(pressor drug infusions) both intraoperatively and during
the early post-operative recovery period to counteract the
hypotensive effects of sedation or anaesthesia com-
pounded by co-morbidities and concurrent medication.
However, pressors may have vasoconstrictor effects on
the transplanted tissues, raising concerns about flap
ischaemia, which may contribute to the free flap failure
rates of 3% reported by high-volume centres.1,2 Salvage
of a failing flap depends on early detection and interven-
tion with reported success rates between 33 and 83%.3
Laser Doppler flowmetry provides a measure of microcir-
culatory blood flow in a small area of tissue illuminated
by a laser. This noninvasive method of monitoring blood
flow in free flaps is increasingly used in clinical practice
to assess changes in intraoral flap perfusion over time.4–6
As well as providing a convenient method to monitor
changes in flap blood flow over time, spectral analysis of
the variations in laser Doppler flowmetry signal may
provide further information on changes in the regulation
of blood flow in the superficial flap tissues and help
explain the differing effects of pressor agents on flap
blood flow.7
The human microcirculation shows rhythmic varia-
tions (oscillations) in blood flow produced by central
(brain stem) and local (tissue) effects. The most obvious
oscillations are caused by the heart rate and respiration.8
Several studies performed using laser Doppler flowmetry
have shown there are an additional three periodic compo-
nents with varying amplitudes and frequencies, which can
be extracted from the Doppler waveform. The five com-
ponents are centered around 1 Hz (60 cycles per minute),
0.3 Hz (18 cycles per minute), 0.1 Hz (six cycles per
minute), 0.04 Hz (2.4 cycles per minute), and 0.01 Hz
(six cycles in 10 min) corresponding to heartbeat, respira-
tion, intrinsic myogenic activity of vascular smooth
muscle, the neurogenic activity of the vessel wall and the
endothelial cell metabolic processes, respectively.9
The aim of this study was to determine the effects of
epinephrine, norepinephrine, dobutamine, and dopexamine
on the local control of blood flow in transplanted tissues
using spectral analysis of the laser Doppler flowmetry
waveform.
PATIENTS AND METHODS
Following ethical approval from the Oxfordshire
Research Ethics Committee, 24 patients (16 male; eight
female) undergoing resection of head and neck cancers
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with free flap reconstruction were recruited to the study
and written informed consent obtained. One patient repre-
sented during the study period with a second primary
tumor, and was recruited to the study on two occasions,
resulting in 25 sets of results. Free flap reconstruction
was with a free radial forearm flap (n 5 16), latissimus
dorsi (n 5 2), anterolateral thigh (ALT) flap (n 5 1), or
free fibula osteocutaneous flap (n 5 2). In the remaining
four cases, reconstruction was with two simulatenous free
flaps (ALT and fibula n 5 3, radial forearm and fibula n
5 1). At the end of the surgical procedure, a Transonic
laser Doppler probe (Transonic type R; Transonic Sys-
tems, Ithaca, NY) was sutured to the centre of the free
flap, utilizing the soft tissue free flap in cases of more
than one flap, and the skin paddle on fibula free flaps. A
second Doppler probe was sutured to the skin in the
deltoid region to provide a control site. All patients were
admitted to the intensive care unit (ICU) and were artifi-
cially ventilated overnight as part of the local care path-
way. Once the patients had been stabilized on the ICU
they received four drugs (epinephrine, norepinephrine,
dobutamine, and dopeximine) in increasing concentrations
for a period of 5 min at each rate (Table 1). The order of
drug administration was random and contained in a
sealed envelope, which was opened shortly prior to com-
mencing the trial. The infusions were administered via a
syringe pump using weight-based rates. The maximum
safe parameters for increase in mean arterial pressure
(MAP) and absolute heart rate were set at 30 mmHg and
150 bpm, respectively; with the infusions stopped if these
limits were reached. A 20 min wash-out period was
allowed before commencing the next drug in the
sequence. Continuous Doppler monitoring was performed
using a Doppler flow meter (model Transonic BLF—
21D, Transonic Systems, Ithaca, NY) with the waveform
recorded using analogue-to-digital conversion and Acq-
Knowledge software (BIOPAC Systems, Goleta, CA) at a
sampling frequency of 40 samples per second.
The final 2 min of each drug infusion rate and the 2
min period prior to the commencement of the first drug
(baseline) were used for subsequent analysis. Each time
period was identified on the AcqKnowledge software and
the data exported to Microsoft Excel for further analysis.
Spectral analysis of the Doppler data was performed using
Matlab version 7.11.0.584 (R2010b) (Mathworks, Natick,
MA). This was completed using the last 4,096 samples
(102.4 second of recording). The total power (the amount
of variation in blood flow) in the signal was calculated as
the variance. A standard signal processing approach was
used to determine the frequency components of the blood
flow signal. Three 2,048 sample (51.2 second) segments
with 50% overlap were derived by dividing up the total
sample of 4,096 samples. Each underwent linear trend
removal (to remove baseline drift) and was then win-
dowed with a Hamming window function (required to
remove artefacts generated at the start and end of the
Table 1. Drug Infusion Rates, Cardiovascular Variables, and Mean Total Power of the Laser Doppler Blood Flow Signal at Both Sites for
All Drug Doses
Infusion rate
(mcg/kg/min)
Number of patients
receiving dose
Mean Flap Control
Heart rate
(beats/min)
Mean arterial
blood pressure
(mmHg)
Cardiac index
(l/min/m2)
Mean
normalized
power
Mean
normalized
power
Baseline – 77 6 13 76 2.9 6 0.5 1.00 6 0.00 1.00 6 0.00
Epinephrine
25% 0.05 25 86 6 15 73 3.7 6 1.1 1.23 6 0.83 1.67 6 2.93
50% 0.1 25 92 6 16 77 4.5 6 1.4 1.57 6 1.39 1.34 6 0.97
75% 0.15 24 99 6 17 80 5.2 6 1.5 1.87 6 1.89 1.34 6 0.96
100% 0.2 21 106 6 17 85 5.9 6 1.8 1.76 6 1.83 1.34 6 0.75
Norepinephrine
25% 0.05 25 76 6 15 89 3.1 6 0.6 2.74 6 3.69 1.26 6 0.84
50% 0.1 19 76 6 14 98 3.4 6 0.8 3.57 6 7.57 1.37 6 0.88
75% 0.15 13 76 6 16 106 3.6 6 0.8 4.42 6 6.59 1.34 6 0.82
100% 0.2 5 84 6 13 103 3.9 6 0.7 1.90 6 1.76 0.79 6 0.52
Dobutamine
25% 2 25 84 6 16 80 3.6 6 0.9 1.55 6 1.10 1.24 6 0.53
50% 4 23 91 6 18 80 4.0 6 1.1 1.50 6 1.08 1.75 6 1.93
75% 6 23 99 6 20 78 4.5 6 1.4 1.48 6 1.19 1.48 6 0.99
100% 8 22 107 6 18 76 5.3 6 1.4 1.28 6 0.77 1.71 6 1.34
Dopexamine:
25% 1.25 25 88 6 15 68 3.6 6 0.9 1.02 6 0.57 1.19 6 0.77
50% 2.5 25 95 6 15 66 4.2 6 1.4 1.48 6 1.93 1.28 6 0.94
75% 3.75 25 102 6 16 64 4.6 6 1.3 1.23 6 1.37 1.23 6 0.60
100% 5 25 109 6 17 62 5.0 6 1.5 1.83 6 2.44 1.13 6 0.74
The power has been normalized to the baseline (pre-drug) reading. Values are shown as mean 6 SD.
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recordings) before conversion to zero mean unit variance
format, which allows comparison between patients irre-
spective of the total blood flow. Power spectra (the plot
of blood flow oscillations at each frequency) were com-
puted using a standard fast Fourier transform algorithm,
and the resulting three spectra averaged to give the final
result. Only the frequencies below 3 Hz were used for
graphing. This analysis was performed for each of the
four drugs and four drug concentrations, and prior to com-
mencement of any drug infusion, for all 25 set of results
and both recording sites. For each patient the power in
the baseline (pre-drug) period was used to normalize the
subsequent results for both control and flap sites. The
results from all patients were averaged. In addition for
each patient and each dose, the control site spectrum was
subtracted from the flap site spectrum to highlight any dif-
ferences between the sites. Only five patients received the
maximum norepinephrine infusion rate (0.15 mcg/kg/min)
as the others all reached the upper safety limit for blood
pressure at a lower dose.
Statistical analysis for differences in variance
(variability) between control site and flap was completed
using t-tests, with Sˇida´k correction for multiple compari-
sons, on Statistical Package for the Social Sciences. The
probability of differences between regions of the normal-
ized power spectra arising by chance could not be tested
statistically and so differences reported are based on
simple interpretation of the graphs.
RESULTS
The cardiovascular variables are shown in Table 1.
For each dose the average normalized power, standard
deviation of the normalized power, and the changes in
the power of the blood flow signal (the variance of the
signal) are shown in Table 1.
There was no statistically significant difference
between the variability in the control site and flap at any
drug dose (‘‘t’’ tests, Sˇida´k correction for multiple com-
parisons, all P values >0.05), despite the power spectra
for the flap flow appearing to exhibit far more variability
with norepinephrine.
Figure 1 shows the power spectrum from the control
site of one of the patients in this study. The cardiac, re-
spiratory, and myogenic components are seen as discrete
peaks, the neurogenic and local endothelial-based control
cannot be separately distinguished in this example.
The control (pre-drug) averaged power spectra is
shown in Figure 2, and at maximum dose (epinephrine,
dobutamine, and dopexamine) and 75% maximum dose
norepinephrine, (as only five patients reached maximum
dose) in Figure 3. Intervening doses showed similar
changes. Nearly all the oscillation in blood flow was in
the range of 0–3 Hz with almost none in higher fre-
quency bands.
Figure 2 shows the control (pre-drug) spectra. The
power in the region below 0.1 Hz was reduced. As the
spectra were normalized there was a corresponding
increase in the power in the 0.8–1.7 Hz range represent-
ing the heart rate. The differing heart rates of the subjects
broadened this peak.
At the maximum epinephrine infusion rate the heart
rate increased and the spread of heart rates also
increased, so the heart rate dependent peak moved to
higher frequencies and broadened. The proportion of the
total power in the lower frequencies increased. At the
maximum dobutamine infusion rate there was little effect
on the distribution of the control of blood flow, though
as with all drugs studied the cardiac related peak
increased in frequency and broadened. Dopexamine dem-
onstrated the same findings as dobutamine. However,
Figure 1. Power spectra at baseline demonstrating the characteris-
tic peaks extracted from the Doppler waveform, corresponding to
heart beat, respiration, intrinsic myogenic, and neurogenic control.
[Color figure can be viewed in the online issue, which is available
at wileyonlinelibrary.com]
Figure 2. Power spectra for flap (red) and control (blue) tissues for
baseline. [Color figure can be viewed in the online issue, which is
available at wileyonlinelibrary.com]
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with norepinephrine at 75% of maximum dose, low
frequency activity below 0.1 Hz was higher in the flap
compared to control, and the difference between flap and
control in the 0.1–0.4 Hz band was less marked than
with other drugs.
No adverse events or flap failures were noted in any
of the patients as a result of the pressor infusions.
DISCUSSION
The power spectra confirmed a number of anticipated
findings following free tissue transfer. As the flaps were
denervated the power in the region below 0.1 Hz which
contains sympathetic activity, and in the respiratory
frequencies centered on 0.2–0.3 Hz (12–18 breaths/min)
which are partially neurally mediated, were both reduced
as expected.
As the spectra were normalized (the area under the
curve was fixed) there was a corresponding increase in
the power in the 0.8–1.7 Hz range representing the heart
rate. As the results for the cardiovascular variables dem-
onstrated, there was a dose dependent increase in heart
rate with epinephrine, dopexamine, and dobutamine but
an unchanged heart rate with norepinephrine until the
maximum dose were seen. The differing heart rates of
the subjects broadened the associate peak of the power
spectra. At the maximum epinephrine infusion rate the
heart rate increased and the spread of heart rates also
increased, so the heart rate dependent peak moved to
higher frequencies and broadened. The proportion of the
total power in the lower frequencies increased, as local
control of blood flow rather than global hemodynamics
dominated blood flow control, though in general as with
the control spectra the effects of denervation were main-
tained.
All drugs increased the power (overall variability) of
the blood flow signal at both sites, and this was more
marked for epinephrine and especially norepinephrine. As
noted above, as a result of the processing techniques any
differences between flap and control spectra in one
frequency band must have equivalent changes in the
opposite direction at other frequencies. The difference
spectra demonstrated this best, the area defined by the 0
baseline and the spectral difference above the baseline is
matched by an equivalent area between the 0 baseline
and the spectral difference below the baseline. The
technique used for sampling and processing meant
the frequency resolution was limited to 0.05 Hz and
Figure 3. Power spectra for flap (red) and control (blue) tissues for (A) epinephrine 0.2 mcg/kg/min, (B) dobutamine 8 mcg/kg/min, (C)
dopexamine 5 mcg/kg/min, and (D), norephineprine 0.15 mcg/kg/min, and inset, the differential results (flap-control). Inset panels in each
graph show the averaged differences (flap spectrum-control spectrum) to assist interpretation. Note that the spectra were all normalized
(i.e., set to the same area under the curve) by the zero mean unity variance processing, so total power cannot be compared with these
graphs. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com]
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thus the 0.04 Hz, and 0.01 Hz peaks corresponding to
the neurogenic activity of the vessel wall and the
endothelial cell metabolic processes could not be resolved
independently.
At the maximum dobutamine infusion rate, there was
little effect on the distribution of the control of blood
flow, though as with all drugs studied the cardiac related
peak increased in frequency and broadened. Dopexamine
demonstrated the same findings as dobutamine. However,
with norepinephrine at 75% of maximum dose, low
frequency activity below 0.1 Hz was higher in the flap
compared to control, and the difference between flap and
control in the 0.1–0.4 Hz band was less marked than
with other drugs. This suggests that the norepinephrine
infusion increases the local myogenic control of blood
flow in the free flap to a greater extent than the other
drugs studied.
With increasing doses of epinephrine and norepineph-
rine there was increased dependence on local control, as
evidenced by the increasing proportion of power in the
0–0.1 Hz frequency band. This occurred in both control
and flap tissue, though with norepinephrine the effect was
more marked in the flap tissue. This would imply that
there is survival of alpha receptor activity in the trans-
planted tissues, and possibly that these receptors are more
sensitive to exogenous alpha agonists after denervation.
The laser Doppler flow meter measures red cell flux
in the skin by illuminating an approximately 1 mm3
hemisphere of skin with monochromatic (laser) light, and
determining the amount of light reflected from moving
erythrocytes and the Doppler shift (change in wavelength)
of the reflected light.10 The product of the two represents
red cell flux, a measure of tissue blood flow. Laser Dopp-
ler flowmetry records the velocities and concentrations of
erythrocytes in the arterioles located in the dermis and in
the subepidermal papillary loops. The absolute value
recorded depends on the adjacency of one of these ves-
sels to the illuminated area, and is therefore dependent
on probe position so it is not possible to convert the
Laser Doppler signal to ‘‘conventional’’ bulk blood flow
units of blood flow per unit mass of tissue per minute.
Instead the laser Doppler device gives results as ‘‘tissue
perfusion units’’ derived from the voltages generated by
the photodetector in the instrument. For these reasons
laser Doppler flowmetry results are usually expressed rel-
ative to a baseline state.11 Spectral analysis of laser
Doppler flowmeter signal has been shown to be useful
and accurate.12 It has been shown that characteristic fre-
quency peaks exist in signals of cardiovascular origin.13
The spectrum is conventionally divided into five fre-
quency intervals centered on 1, 0.3, 0.1, 0.04, and 0.01
Hz.9,13 Of interest are those occurring at a slower rate
than the oscillations caused by respiratory rate at about
0.3 Hz. Studies have demonstrated that these slow
oscillations are influenced by the sympathetic nervous
system and microvascular wall activity.8 Blood flow is
controlled by the combined effect of all of these periodic
oscillations of both local and central origin, which are
transduced to vascular smooth muscle cells, resulting in a
specific vascular tone.9
This study has a number of methodological limita-
tions. The sampling period used limited the resolution of
the spectral analysis to 0.05 Hz, thus, the two lower fre-
quency bands could not be resolved independently. All
the spectra were normalized to allow an averaged spec-
trum containing all patient data to be constructed with
each patient contributing equally, but this normalization
causes increases in power in one frequency band to
always be associated with a change in the opposite direc-
tion in other frequency bands, making interpretation more
difficult. The probability of differences between regions
of the normalized power spectra arising by chance could
not be tested statistically. Changes in the power in the
cardiac cycle frequency were made more difficult to
interpret due to the increase in heart rate and the widen-
ing of the range of heart rates caused by the drugs. Drug
infusion times were selected to minimize the effects of
slow overall changes in the patient’s haemodynamics
biasing the results. A minimum of 5 min (2–3 half-lives
for the drugs studied14–16) was used to ensure a steady
state drug effect.
There are two previous studies of spectral analysis of
free flap and control tissue blood flow signals. Liu et al9
examined the spectral analysis of 18 patients undergoing
free latissimus dorsi transfer. The authors used a laser
Doppler flowmeter to measure skin blood perfusion at the
flap and a control site on the contralateral limb in
patients with soft tissue injury of the lower extremity.
They found that the spectral power and average ampli-
tude of oscillations in the frequency range 0.0095–1.6 Hz
were dramatically lowered in the flaps. They concluded
that a decrease in both the endothelial cell metabolic
processes and sympathetic control, and an increase in the
intrinsic myogenic activity were found. Similar findings
were reported by Sun et al.17 who examined the spectral
analysis changes prior to and following free radial fore-
arm flap harvest and transplantation. They reported signif-
icantly increased high frequency (0.15–0.4 Hz) and
decreased very low frequency (0003–0.04 Hz) power
fraction after flap transfer. The results of the current
study are in general agreement with the findings of Liu
et al.9 and Sun et al.,17 though the effects observed in
this study were less pronounced.
Landsverk et al8 examined the effects of pharmaco-
logical interruption of the sympathetic innervation to the
arm during brachial plexus blocks. Using two laser Dopp-
ler probes, they were able to compare the effects of
brachial plexus block on one arm compared to the normal
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contralateral limb in 13 patients. They found that in the
anaesthetized arm there were reduced relative amplitudes
in the 0.021–0.052 Hz and 0.0095–0.02 Hz frequency
intervals. These frequency intervals represent neurogenic
and endothelial activity, respectively, and indicate an
inhibitory effect on the sympathetic and endothelial
activity, suggesting it is denervation rather than another
operative factor that alters the low frequency oscillations
in transplanted tissue.
We have previously reported the effects of the drug
infusions on flap and control site blood flow and overall
hydraulic conductance (average blood flow/MAP).7 In
brief, dobutamine caused little change in conductance,
dopexamine preferentially vasoconstricted the flap com-
pared with the control skin, epinephrine caused a
decrease in both flap and control flow and conductance,
and norepinephrine resulted in decreased conductance in
both the flap and the control tissue, with the effect more
marked in the control tissues. These four agents were
selected for investigation in view of their widespread use
within the ICU locally. It appears that norepinephrine is
effective and safe in free flaps once the tissue has been
denervated, with only the adventitial alpha-adrenergic
receptors being responsive to norepinephrine. It is
assumed that the flap skin paddle response to norepineph-
rine is representative of the remaining flap tissues.
The b1 and b2 agonists dobutamine and dopexamine
showed no change in the power spectrum from the control
state, with the denervation effect preserved and no other
changes. The known vasodilator properties of b2 agonists,
at the doses studied, had no apparent effect of the relative
effects of the local control mechanisms or the effects of
global haemodynamics. Epinephrine, and especially nor-
epinephrine, has significant a1 agonist activity, and this
did alter the relative effects of local and haemodynamic
control on blood flow, with an apparent increase in local
control. In the case of norepinephrine, this seemed to
overcome the effect of denervation, so there was more
power at the very low frequencies in the denervated flap
compared with the control sites. It is postulated that the
vasomotion at low frequencies became wholly dependent
on exogenous a1 agonist, swamping any local neural or
other effects. This is in agreement with the results from
the hydraulic conductance, which showed both flap and
control tissue vasoconstriction. However, it was noted that
overall flap blood flow increased with norepinephrine, as
the increase in blood pressure more than compensated for
the decreased conductance. This was not reflected as an
increase in the power at cardiac frequencies in the power
spectral studies. Coupled with the changes in power at
low frequencies, this suggests the flap blood flow is more
determined by the average blood pressure interacting
with low frequency vasomotion, rather than the pulsatile
(systolic/diastolic) component of blood pressure.
As noted previously,7 there appears to be a brief
period after denervation when tissue blood flow is less
responsive to exogenous a1 agonists, but later the tissues
become more sensitive. The results from this study may
therefore not be generalized to longer term blood flow
control. Furthermore, vasopressor drugs acting via path-
ways other than alpha-adrenergic receptors, such as vaso-
pressin or nitric oxide antagonists, may produce different
results. We measured skin flow and assumed that this
reflected changes in other tissues, but this could not be
proven with the technology used. However, similar find-
ings were seen for all of the flaps included in the study.
It is likely that other drugs mediating activity through
alpha receptors will produce similar improved perfusion
in denervated flaps.
CONCLUSION
This study has confirmed that denervation of free flap
tissue is demonstrable using spectral analysis of laser
Doppler blood flow signals. It appears from these findings
that norepinephrine may be the best agent to preserve
flap blood flow in spite of its vasoconstrictor effect,
supported by the finding that the control of blood flow
shifts toward low frequency vasomotion where blood
flow depends mostly on average blood pressure. Further
research to confirm this, and that the effect is common to
all flap tissues, would probably require flow measurement
at the flap pedicle rather than on the skin surface. Statis-
tical analysis may be possible by adjustment of the meth-
ods to avoid normalization of the power spectra.
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Is the ratio of functional ﬁbrinogen to platelets as mea-
suredby thromboelastographyapredictive parameter for
thrombotic complications in free tissue transfer surgery?
Karen Ann Eley ∗, Rachel Parker, S.R. Watt-Smith
Oxford Radcliffe Hospitals NHS Trust, United Kingdom
The risk of total flap loss after free microvascular tissue trans-
fer is estimated to be between 2 and 6%. Flap failure is most
frequently due to anastomotic thrombosis, occurring in the
early postoperative period. The exact causes of events leading
to thrombotic occlusion are not clear, although authors have
observed detrimental effects of increased platelet counts,
platelets aggregation, and fibrinogen levels on flap survival.
In patients with hyperfibinogenemia related to oral cancer,
the safety of performing a successful microsurgical procedure
for complex tissue defects has been debated, and the correla-
tion between hyperfibrinogenemia and vascular thrombosis
in microsurgery remains unclear.
We retrospectively reviewed 42 patients undergoing free
tissue transfer following head and neck cancer resection. The
ratio of pre-operative fibrinogen to platelet was calculated
for each patient pre-operatively. A control group of normal
fibrinogen to platelet ratio results were obtained from 49
healthy volunteers. Fibrinogen to platelet ratios in patients
with head and neck cancer preoperatively were significantly
higher (p < 0.001) than this control group.
In total, seven patients (17%) experienced major graft fail-
ure secondary to thrombotic events. Two of these patients had
intraoperative thrombotic events. The pre-operative fibrino-
gen to platelet ratio was above 50% in six patients, correctly
identifying their increased thrombotic tendency. In the one
patient with a pre-operative ratio of 34%, post-operative
results demonstrated continuing elevating ratios, that may
have highlighted forthcoming flap failure.
These preliminary results suggest that the use of pre-
operative fibrinogen to platelet ratios may aid in identifying
patients at increased risk of anastomotic thrombosis.
doi:10.1016/j.bjoms.2009.06.044
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Reducing post-operative blood loss in sagittal synostosis:
the role of ﬁbrin glue
Dilip Srinivasan ∗, D. Rodrigues, N. White, E. Carver, M.S.
Dover, H. Nishikawa, S. Magdum, G. Solanki
Birmingham Children’s Hospital, United Kingdom
Aims and objectives: Fibrin’s haemostatic properties are well
known and we report its application prior to scalp closure in
order to reduce post-operative blood transfusion.
Patients and methods: Prospective study of 16 calvarial
remodellings for sagittal synostosis were performed by the
same surgical team. Data collected included post-operative
wound drainage at 8 and 48 h. Group A had scalp closure
alone (10 cases), while Group B had scalp closure with fibrin
(Tisseel) glue (6 cases).
Results: The two groups were comparable with a sim-
ilar mean age at surgery, peri-operative blood loss and
intra-operative blood transfusion. In group A, post-operative
drainage in the first 8 h was 246 mls compared to 172 mls in
group B (p = 0.02) The total post-operative drain volume was
441 mls compared to 301 mls (p = 0.01). The fibrin glue group
did not require post-operative transfusion (0/6) compared to
2/10 in the untreated group.
Conclusion: Fibrin glue application is associated with
reduced post-operative bleeding and post-operative blood
transfusion.
doi:10.1016/j.bjoms.2009.06.045
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Assessment of the effects of pressors on graft blood ﬂow
after free tissue transfer surgery: interim ﬁndings
Karen Ann Eley ∗, D. Young, S.R. Watt-Smith
Oxford Radcliffe Hospitals NHS Trust, United Kingdom
Patients with intra-oral carcinoma frequently require support
to mitigate the hypotensive effects of sedation in the early
recovery period. Sympathomimetic agents may increase the
systemic blood-pressure but the resulting vasoconstriction
may paradoxically reduce flap perfusion and result in flap
failure (Suominem 2004). The aims of this study are to iden-
tify the optimal agent to improve systemic blood pressure
whilst maintaining flap perfusion.
All patients presenting with head and neck cancer, requir-
ing free flap surgery, and consenting to participate in the trial
are recruited. Following surgery Doppler probes are sited on
the flap and at a control site, providing continuous record-
ing of tissue perfusion. All patients remain intubated and
ventilated overnight, and are monitored using LiDCO Plus
to optimise fluid balance. Four drugs (Dobutamine, Dopex-
amine, Adrenaline and Noradrenaline), in random order and
with an intermediary wash out period, are infused at increas-
ing rates to institute a rise in mean arterial blood-pressure of
15 mmHg.
Interim findings show that both Noradrenaline and
Adrenaline reliably increase systemic blood pressure, but
unpredictably maintain, elevate or lower tissue perfusion.
Dopexamine has so far failed to increase blood pressure in
any of our patients, and has always resulted in significant
tachycardia. Dobutamine currently appears to be the drug of
choice; although it too often results in a tachycardic patient,
it reliably elevates blood pressure and elevates or maintains
tissue perfusion.
The implications of these initial findings are discussed.
The end point of this trial has implications for all tis-
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sue transfer surgery including free flap procedures and
transplantation.
doi:10.1016/j.bjoms.2009.06.046
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Factors associated with blood loss and transfusion
requirements in craniofacial surgery: a 5 year single-
institution review
Dilip Srinivasan ∗, E. Carver, D. Rodrigues, R. Vemaraju, R.
Marcus, G. Solanki, H. Nishikawa, M.S. Dover
Birmingham Children’s Hospital, United Kingdom
Introduction: Blood loss remains a major challenge in cran-
iofacial surgery. Despite major advances in both craniofacial
surgery and replacement of blood products, this area of prac-
tice remains challenging.
Aims and objectives: To delineate factors associated with
blood loss and transfusion by reviewing practice at a desig-
nated craniofacial unit in the UK.
Patients and methods: 189 Children operated on between
2002 and 2007 were the subjects of this retrospective review.
108 Fronto-orbital advancement and remodelling (FOAR)
and 81 sagittal synostosis corrections were performed. Patient
demographics, surgery details and estimate of blood loss
were collected. Surgical technique was refined to reduce
blood loss. Adjuvant methods were employed to reduce post-
operative drainage and transfusion requirements. A specific
protocol for blood transfusion was developed.
Results: Mean age at surgery for FOAR was19 months
with an upward trend (15 ≥ 25months) during the period of
review. Blood loss decreased from 120% to 80% of blood
volume during this period.
In sagittal synostosis, 83% of children undergoing correc-
tion were under 18-months. Age at surgery decreased over
5 year. Mean blood loss was 80% of blood volume.Blood
loss increased from 60% to 80% coinciding with a change in
practice from strip-craniectomy to calvarial remodelling.
Conclusions: Surgical technique, age at surgery, type of
surgery and use of fibrin glue influence amount of blood loss.
Cell salvage in FOAR helps reduce blood requirements.
doi:10.1016/j.bjoms.2009.06.047
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Microdialysis: have we found the ideal ﬂap monitoring
device?
Jolie Scannell ∗, Andrew Lyons
Guy’s Hospital, London, United Kingdom
Introduction: Flap monitoring should be reliable, safe, accu-
rate and easy to use in any clinical setting. Microdialysis is
a method of monitoring interstitial tissue metabolism of free
flaps. Previous studies have shown a 77% flap salvage rate
with use of microdialysis monitoring1 and ischaemia pre-
diction 1–2 h before it became evident clinically.2 The aim
of this study was to assess the usefulness and reliability of
microdialysis for continual free flap monitoring.
Methods: 20 Free Microvascular flaps carried out follow-
ing oral cancer resection were monitored from January 2008
to January 2009 with microdialysis for a 72 h postoperative
period. A microdialysis catheter was inserted into the skin
or muscle part of the flap at the end of operative procedure.
A bedside analyser was used with hourly dialysate samples
providing continual trace on the screen showing trends for
glucose, lactate and lactate/pyruvate ratio. The readout could
be photographed and sent by mobile phone. Flap ischaemia
is represented by a falling glucose, increased lactate and lac-
tate/pyruvate ratios.
Results: Successful salvage of a DCIA flap was possi-
ble due to early detection of venous failure. No flaps were
returned to theatre unnecessarily and microdialysis also pre-
dicted partial flap necrosis in 2 cases.
Conclusion: Our experience at Guys has shown micro-
dialysis is safe, provides real time, continual flap monitoring
giving early prediction of flap ischaemia.
References
1. Setala, et al. Journal of Reconstructive Surgery 2006;22(2):87–95.
2. Jyranki, et al. Annals of Plastic Surgery 2006;56(April (4)):387–93.
doi:10.1016/j.bjoms.2009.06.048
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The effective management of high ﬂow vascular malfor-
mations of the head and neck
Andrew Monaghan ∗, I. McCafferty, S. Lamin, H.
Nishikawa, R. Williams
University Hospital Birmingham NHS Trust, United
Kingdom
Introduction: High flow vascular malformations (arteriove-
nous malformations) of the head and neck are some of
the most challenging lesions to treat. Traditional man-
agement includes embolisation followed shortly afterwards
by surgical excision. Incomplete excision inevitably leads
to recurrence due to recruitment of collateral circulation.
Surgery is often associated with massive haemorrhage; the
literature has numerous reports of intraoperative deaths.
Method: This presentation will report the results of
embolisation of high flow malformations of the head and neck
using Onyx. Onyx comprises of an ethylene-vinyl alcohol
copolymer with a lava-like flow pattern. Micronized tantalum
powder is added to the mixture for radiopacity.
Results/conclusion: Onyx differs from conventional
embolisation methods in that it fills the lesion and obliterates
the nidus; the recruitment of collateral circulation does not
183
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shown little beneﬁt. The principal aim of this study is to determine
whether manual reduction or IMF provides a better result in terms
of occlusion and radiographic reduction of mandibular fractures.
Methods: All patients presenting to the Gold Coast hospital with
fractures of the mandible not including the condylar head or neck
and without midface injuries were offered participation in the study.
Randomisation into either manual reduction or intraoperative IMF
was undertaken. Data was collected on operative duration, occlusal
results, radiographic results, and complications. The patient and
assessor were blinded as to the technique used intraoperatively.
Results: 36 patients were randomised during the study period.
Patients treated with manual reduction had a signiﬁcantly shorter
operative duration. There was no difference between either the
radiograpic interpretation of reduction or the objective occlusal
result. Difﬁculties in maintaining patient followup made assessment
of complications difﬁcult.
Discussion: Manual reduction of fractures of the mandible
produces equivalent results to the use of intraoperative
intermaxillary ﬁxation. In addition this can be undertaken in a
shoter duration of time. This translates into less costly procedures
as not only is operative time diminished but additional hardware
(eg IMF screws, arch bars, wire) are not required.
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Assessment of the effects of pressors on graft blood ﬂow after
free tissue transfer surgery: phase I results
K.A. Eley, D. Young, S.R. Watt-Smith. Oxford Radcliffe Hospitals
NHS Trust, UK
Introduction: Patients with intra-oral carcinoma frequently require
support to mitigate the hypotensive effects of sedation in the
early recovery period. Sympathomimetic agents may increase the
systemic blood pressure but the resulting vasoconstriction may
paradoxically reduce ﬂap perfusion and result in ﬂap failure.
Difﬁculty remains in the appropriate management of patients
undergoing free ﬂap surgery post-operatively on the Intensive Care
Unit.
Aims: To identify the optimal agent to improve systemic blood
pressure whilst maintaining ﬂap perfusion.
Method: The effects of four vasopressors (Noradrenaline,
Adrenaline, Dobutamine and Dopexamine) upon microsurgically
transplanted tissue were investigated in 25 patients. Utilising laser
Doppler probes a continuous waveform of tissue perfusion was
obtained for the transplanted tissue and compared to a control site.
All patients were, in addition to standard ITU care, monitored
using LiDCO Plus Rapid, to optimise ﬂuid balance.
Results: The preliminary (mid-point) ﬁndings of this research
were presented at the Annual Conference 2009. Following recent
completion of data collection deﬁnitive data analysis is currently
being completed.
The effects of the four trialled drugs are dose dependent with
Dobutamine frequently improving tissue perfusion of the ﬂap, but
with the adverse effect of a tachycardic response.
Conclusions: Dobutamine and Adrenaline rarely have adverse
effects upon transplanted tissue, but frequently result in an
unacceptably tachycardic patient. Approval (pending funding) has
recently been granted for extension of this research project to
investigate the optimal concentration of the most efﬁcacious agent
determined in this phase, with comparison to metaraminol – which
does not appear to result in tachycardia.
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Mandible fracture patterns seen in British servicemen
subjected to blast injury
J. Breeze, A.G. Gibbons, N. Hunt, A.M. Monaghan, A. Hepper,
M. Midwinter. Academic Department of Military Surgery and
Trauma, Royal Centre for Defence Medicine, UK
Introduction: Blast injuries are the primary cause of injury to
coalition soldiers in Iraq and Afghanistan. There have been isolated
case reports and experimental data describing mandible fracture
patterns secondary to blast injury but to date no signiﬁcant case
series has been published.
Method: All mandible fractures sustained by British servicemen
secondary to blast injury between 01 January 2004 and
30 September 2009 were identiﬁed.
Results: During this period 60 mandible fractures were identiﬁed
in total. 22 servicemen survived to obtain treatment back in the
UK while the remaining 38 died from wounds, predominantly from
primary brain injury. No British servicemen in this case series died
speciﬁcally from facial wounds.
Careful analysis of the mandible fractures using radiographs,
clinical notes and situational operational reports ascertained that
35 of these fractures were most likely secondary to the blast
wave itself and not from associated shrapnel. Unlike previous case
reports and experimental data we found no evidence of unusual
fracture patterns such as horizontal splits.
Clinical relevance: A number of fractures were found to have
been secondary to blunt impacts from a serviceman’s weapon
or equipment and further research is ongoing to see how this
information can change current battleﬁeld protocols.
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Utility of a generic risk prediction score in predicting
outcomes after orofacial surgery for cancer.
D. Tighe. Queen Victoria Hospital, East Grinstead, UK
Introduction: Head and Neck surgery for cancer is fraught with
patient risk. Systematically measuring and auditing risk in Head
and Neck Surgery is impossible without a consensus comparator
or ‘gold standard’. Understanding how individual patient variation
and peri-operative events alter risk is fundamental to auditing
outcome in a meaningful way.
Methods: Post operative outcomes (n = 305) over a three year
period (2005–2008) are reported from one centre of excellence
(Queen Victoria Hospital, East Grinstead) treating major Head
and Neck surgical cases. The predictive accuracy of a popular
generic risk prediction tool, the POSSUM equation for morbidity
and P-Possum, is reported for the ﬁrst time in the discipline of
Maxillofacial Surgery.
Results: Morbidity rates are broadly in line with other international
published data but lower than expected mortality outcomes. The
POSSUM morbidity equation showed reasonable discrimination
(C Statistic 0.74) as did the P POSSUM mortality equation
(C Statistic 0.75) but both were shown to have poor ﬁt overall [Hos-
mer and Lemeshow goodness of ﬁt tests for morbidity c2 = 31.64
at 8 d.f (P = 0.00011) and for mortality was c2 = 5.51 at 1 d.f
(P = 0.0189) respectively]. Of note, no improvement was demon-
strated after excluding procedures requiring emergency return to
theatre nor extremely minor procedures during the audit period.
Conclusions: A ‘Standard of Care’ index for major Head and
Neck surgery, for the purposes of mortality and morbidity audit is
an unmet need. Collaboration within the speciality could produce
such a score within 2 years.
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FUNCTIONAL FIBRINOGEN TO PLATELET RATIO USING
THROMBOELASTOGRAPHY AS A PREDICTIVE PARAMETER FOR
THROMBOTIC COMPLICATIONS FOLLOWING FREE TISSUE
TRANSFER SURGERY: A PRELIMINARY STUDY
RACHEL J. PARKER, S.O.P.D., M.I.C.R.,1 KAREN A. ELEY, M.B.Ch.B.(Hons.), M.R.C.S.(Ed), P.G.C.T.L.C.P., F.H.E.A., M.Sc.,2*
STEPHEN VON KIER, M.I.C.R.,1 OLIVER PEARSON,1 and STEPHEN R. WATT-SMITH, M.B.B.S., B.D.S., F.D.S.R.C.S., M.D.3
Background: Microvascular free tissue transfer in head and neck surgery has become an indispensable tool. Anastomotic thrombosis is
one of the leading causes of flap failure; however, there are no validated methods to accurately identify and quantify those patients most
at risk of thrombotic complications. The aim of this study was to determine if functional fibrinogen to platelet ratio using thrombelastogra-
phy could preoperatively identify patients at risk of thrombotic complications. Materials and Methods: Twenty nine patients undergoing free
tissue transfer surgery for head and neck pathology underwent routine TEG1 analysis, with calculation of functional fibrinogen to platelet
ratio at induction of anesthesia. All perioperative thrombotic complications were recorded and crossreferenced with preoperative ratios.
Data was further compared to results obtained from 42 healthy volunteers. Results: The mean functional fibrinogen to platelet ratio was
significantly higher in the surgery group compared to healthy volunteers. Of the 29 patients studied, 31% (n 5 9) had some form of throm-
botic event, with all but one patient having a ratio 42% (mean 47% 6 7%). For those patients without thrombotic events, the mean ratio
was 37% 6 5%. Conclusion: A functional fibrinogen to platelet ratio above 42% as measured by TEG1 may be useful in identifying those
patients likely to develop thrombotic complication. VC 2012 Wiley Periodicals, Inc. Microsurgery 32:512–519, 2012.
Microvascular free tissue transfer following ablative
oncological surgery has become an indispensable tool in
head and neck reconstruction, with reported success rates
of 90–99%.1–3 The cohort of patients with perioral malig-
nancy are typically of advanced age, chronically abused
alcohol and/or tobacco with associated comorbidity, plac-
ing them at increased risk of both flap and general post-
operative complications. Additionally, it is well docu-
mented that patients with malignant disease are at
increased risk of venous thromboembolism (VTE), with
malignancy being the etiological factor in 20% of VTE
events in the community, and a 100-fold increase in inci-
dence in hospitalized patients.4,5 In patients undergoing
free tissue transfer, this risk is further compounded by
immobility and prolonged surgical procedures.
Flap failure may occur due to vascular complications
despite meticulous microvascular technique, with venous
thrombosis being more common than arterial occlusion.2
This thrombogenic effect may be the result of several
factors. Expression of the proteolytic enzyme CP (cancer
procoagulant, a cysteine proteinase) by malignant tumor
cells is known to directly activate factor X without inter-
action with the intrinsic or extrinsic coagulation path-
ways.6–8 Increased levels of TF (tissue factor), PAI-1
(plasminogen activator inhibitor), the inflammatory cyto-
kines TNF (tumor necrosis factor), IL1, IL8 (interleukins),
and VEGF (vascular endothelial growth factor) are all
associated with tumor thrombosis.8,9 Additionally, reduced
expression of regulators of coagulation such as tPA (tissue
plasminogen activator) and TM (thrombomodulin) on the
endothelial surface and concomitant increased production
and deposition of fibrin are also observed in tumor-related
thrombosis. Therefore, it would be expected to see higher
flap failure rates in malignancy cases; however, reported
rates do not appear to support this.10–13
Early identification of the failing flap is paramount
for successful salvage. A method to reliably predict those
patients most at risk would permit additional measures to
be instigated in an attempt to minimize flap failure.
Thrombelastography (TEG1) has been used for many
years to detect coagulopathy and hypercoagulable states,
and is now widely used as a near-site hemostasis moni-
tor.14–16 TEG 1 technology analyses the functional activ-
ities of the cellular elements, such as platelet cytoplasmic
granules and platelet surfaces, in conjunction with plasma
components. Because the TEG1 analyzer monitors the
shear elasticity of clotting blood, it is sensitive to all of
the interacting cellular and plasmatic components. These
include coagulation and fibrinolytic factors, activators,
and inhibitors which may affect the rate or structure of a
clotting sample and its breakdown. The TEG1 analyzer
can be used to calculate the ratio of functional fibrinogen
to platelets (the ‘‘functional’’ component being only the
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fibrinogen which is biologically active) by utilizing an
additional reagent.
The aim of this study was to determine if the ratio of
functional fibrinogen to platelets, as measured by TEG1
could be reliably utilized as a predictor of intraoperative
and postoperative thrombotic complications following
free tissue transfer surgery.
MATERIALS AND METHODS
A retrospective review of patients undergoing surgery
for head and neck pathology with free-flap reconstruction,
performed by the senior author, between April 2006 and
June 2007 was conducted.
Functional fibrinogen to platelet ratio was determined
at the induction of anesthesia and this baseline result
used for subsequent analysis. All patients, as per local
routine practice, had regular TEG1 analyses (without the
additional functional fibrinogen to platelet ratio) per-
formed throughout the perioperative period in addition to
routine hematology and biochemistry investigations
(including a coagulation screen).
Calculation of Functional Fibrinogen to Platelet
Ratio
TEG1 analysis was completed using the TEG1 5000
hemostasis analyzer (Hemoscope Corp, Niles, IL). This
measures the viscoelastic properties of blood, and the result-
ing hemostasis profile is a measure of the time it takes for
the first fibrin strand to be formed, the kinetics of clot for-
mation and the strength and dissolution of the clot (Fig. 1).
Approximately 80–90% of the strength of the maximum
amplitude (MA) is related to platelet numbers and function.
A ‘‘Clauss correlated’’ functional fibrinogen level
(TEG-Fib) achieved through the addition of the monoclo-
nal antibody c7E3 [abciximab (ReoPro1, Eli Lilly, IN)],
which binds the glycoprotein IIb/IIIa receptor on the pla-
telet surface, was used to remove the platelet component
of the clot to measure the fibrinogen contribution to clot
strength, expressed as MAR.
With the concurrent use of an unmodified TEG1
sample, the independent contribution of fibrinogen and
platelets to the overall clot strength could be determined.
For standard TEG1 analysis, a 1 ml sample of whole
blood was added to a kaolin activator vial. After invert-
ing the vial to ensure adequate mixing, 360 lg of kaolin
activated whole blood was transferred to the analyzer. To
test the functional fibrinogen level, 355 lg of the remain-
ing kaolin activated whole blood was added to a second
cup which contained 5 lg abciximab (Fig. 2). Analytical
software within the TEG1 software (version 4.2.3) was
used to calculate the functional fibrinogen level (FLEV)
through the transformation of the MA value.
As the maximal amplitude (MA) of thromboelastogra-
phy using whole blood (MAW) measures clot strength
and represents the collective contribution of both fibrino-
gen and platelets we were first able to inhibit the platelet
function, and subsequently calculate the functional fibri-
nogen to platelet ratio using the equation:
Functional fibrinogen to platelet ratio ¼ MAR
MAW
3100
In total, 29 patients (male: n 5 17; female: n 5 12),
with a mean age of 58 years (32–83 years) had functional
fibrinogen to platelet ratios available (Table 1). Preopera-
tive anticoagulation in line with local protocol at the time
of the study was not used.
The functional fibrinogen to platelet results were com-
pared to data previously obtained from a healthy adult
control group (n 5 42). Participants in this group were
freely consenting laboratory staff, who each donated 1 ml
of blood for baseline modified functional fibrinogen and
standard TEG1 testing. Data were collected to permit fa-
miliarity with the methodology and as such no demo-
graphic data were stored.
Figure 1. Schematic diagram of TEG1 trace. TEG1 parameters illustrate the functional activity of clot initiation, kinetics, maximal strength,
and clot stability. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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Because blood analysis utilizing TEG1 constitutes
routine patient care (with no additional blood samples
required), and the control group were laboratory staff,
ethical approval was not required in the United Kingdom.
Statistical analysis was performed with an Independ-
ent samples Mann Whitney U test and Fishers Exact Test
on SPSS version 17 (Statistical Package for the Social
Sciences, IBM Corp, Somers, NY), with results displayed
as mean 6 SD.
RESULTS
The functional fibrinogen to platelet ratio results were
significantly higher in the surgery group (40.8 6 7.4)
compared to healthy controls (32.4 6 6.1), (P < 0.05; In-
dependent samples Mann-Whitney U test). Within the
surgery group, patients with malignancy (n 5 26) had
higher ratios compared to those with benign pathologies
(n 5 3), with mean functional fibrinogen to platelet ratios
of 41% 6 7% and 38% 6 2%, respectively (Table 1).
Of the 29 patients studied, 31% (n 5 9) had some
form of thrombotic event (Table 1). One patient had an
early venous anastomotic thrombotic event, which was
detected prior to wound closure, with no postoperative
flap complications following thrombus removal and
repeat anastomosis. Five patients experienced flap compli-
cations, necessitating return to the operating theatre
where anastomotic thrombosis was identified as the cause.
Of these, three were arterial thromoboses, with successful
salvage in one case; two were venous thrombosis, with
both flaps ultimately lost. In the remaining three cases
thrombosis within the internal jugular vein (IJV) was
noted and removed at the time of primary surgery, with
no further complication. There were no incidents of deep
vein thrombosis or pulmonary emboli.
The functional fibrinogen to platelet ratio results were
stratified into two groups, based upon the apparent clus-
tering of thrombotic complications in those with ratios
above 42% (Table 2). In group A (ratio < 42%), one
patient experienced flap complications (ratio 34%), with
ultimate loss of both fibula and radial flaps on postopera-
tive day 11 (Fig. 3).
In group B (ratio 42%), eight patients experienced
thrombotic complications; with three flap failures on days
1, 5, and 9, respectively. In the first case (ratio 45%),
repeat surgery was complicated with further anastomotic
thrombosis, but salvage successful. In the second patient
(ratio 55%), both free flaps (fibula and latissimus dorsi)
were lost, with subsequent failure of a repeat free flap. In
the final patient (ratio 42%), repeat surgery was unevent-
ful. The incidence of all thrombotic complications was
statistically higher in group B (P 5 0.003; Fishers Exact
Test), (Fig. 4).
The groups were similar for both age and BMI
(Table 2). Only one patient had a previous history of VTE
Figure 2. Schematic diagram to show: Large trace (red) 5 the MA as a function of fibrinogen and platelet activity on whole blood (MAW);
small trace (pink) 5 the MA as a function of fibrinogen contribution alone, after exposure to Reopro (MAR). Allowing for the determination
of the independent contributions of fibrinogen and platelets to overall clot strength. MAR/MAW 3 100. [Color figure can be viewed in the
online issue, which is available at wileyonlinelibrary.com.]
Table 2. Comparison of Thrombotic and Flap Complications, With
Age and Body Mass Index (BMI) for the Two Subgroups of Func-
tional Fibrinogen to Platelet Ratios [Mean (Range)]
Group A B
Functional fibrinogen to platelet ratio <42% 42.0
n 5 16 n 5 13
Age (years) 55 6 15 62 6 14
BMI (kg m22) 27 6 6 23 6 5
Thrombotic events n 5 1 n 5 8
Flap loss n 5 1 n 5 3
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(deep vein thrombosis), and there were no prior incidences
of anastomotic complications for any of the patients stud-
ied. The patient with a past history of DVT had a func-
tional fibrinogen to platelet ratio of 46% at induction of
anesthesia for flap surgery, but did not experience any
thrombotic complications at or following surgery.
Figure 4. Graph showing the functional fibrinogen contributions of the patient group (green) compared to healthy controls (blue) as meas-
ured by TEG1 analysis. Patients who experienced thrombotic events are highlighted (~). [Color figure can be viewed in the online issue,
which is available at wileyonlinelibrary.com.]
Figure 3. Flow diagram correlating flap outcomes with functional fibrinogen to platelet ratio.
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A functional fibrinogen to platelet ratio of 42%
results in a sensitivity of 89% and specificity of 75% for
predicting thrombotic events.
DISCUSSION
This preliminary study has demonstrated that func-
tional fibrinogen to platelet ratio performed at induction
of anesthesia may be a useful preoperative predictor of
patients likely to experience thrombotic complications.
Patients undergoing surgery had significantly higher
ratios compared to normal controls consistent with the
increased risk of VTE in malignant disease states.
During the study period, a further 19 free flaps were
completed, resulting in 48 flap procedures by the senior
author. In this group one patient underwent successful
flap salvage for anastomotic venous occlusion. The over-
all free-flap success rate for the study period was 92%.
However, a free-flap survival rate of 86% was achieved
in the 29 patients studied, lower than would be expected.
This discrepancy is likely to represent a combination of
chance, and an increased request rate for a functional
fibrinogen to platelet ratio in patients who may have been
clinically perceived to be at increased risk of flap throm-
bosis.
The number of patients included in this study was
small, making further validation with a prospective study
necessary. However, in the majority of cases thrombotic
complications may have been predicted preoperatively
with high functional fibrinogen to platelet ratios. One of
the 16 patients (6%) in group A (ratio <42%), and 8 of
the 13 patients (62%) patients in group B (ratio 42%)
experienced thrombotic flap complications.
There are numerous scoring methods to identify
patients at high risk for VTE; however none specifically
identify those patients likely to have free-flap thrombotic
events leading to flap failure. The use of the Caprini
score in our patient cohort would result in the majority
of our patients being deemed high risk—since they are
mostly over the age of 60 years (two points), have malig-
nancy (two points), are having major surgery (two
points), and depending upon the donor site, will have an
immobilizing plaster (two points).17 In view of smoking
and alcohol use, many will also score additional points
for comorbidity. However, not all experienced thrombotic
complications. In the NHS, in view of financial con-
straints, it is necessary to target therapy to those most in
need. Using unfractionated heparin needs to be fully jus-
tified, and the use of devices such as implantable dop-
plers are expensive, and are a luxury which cannot be
afforded to every patient. By identifying those in a cohort
of patients all deemed ‘‘high risk’’ that are more likely to
develop thrombotic flap complications additional meas-
ures to prevent or identify early flap failure can be insti-
tuted. These additional measures may include additional
chemical thromboprophylaxis such as unfractionated hep-
arin (particularly intraoperatively), or monitoring devices
such as Doppler probes or microdialysis.18
Patients included in this study had the functional fibri-
nogen to platelet ratio measured at the time of induction
of anesthesia (when the first routine TEG1 is ordinarily
performed) to avoid the need for an additional blood
sample. As a result, high risk patients were not identified
at a sufficiently early time to institute preoperative addi-
tional anticoagulation. It would be interesting to see the
effect of performing the test on the day prior to surgery,
so that preventative measures could be implemented. In a
recent amendment of the hospital protocol on the preop-
erative management of surgical patients it has been
decided that all patients should now receive a dose of
2,500 U of dalteparin the night prior to surgery. The ben-
efit of this small additional dose is questionable.
No demographic data were available for the healthy
control group. Age, sex, and ethnicity have been demon-
strated to impact upon TEG1 results,19,20 and it is likely
that the age distribution of the control group was lower
than the study group. However, it is the correlation of a
high ratio with thrombotic complications, rather than
comparison to healthy controls which is of most impor-
tance. Although all patients undergoing free tissue trans-
fer under the care of the senior author, have standard
TEG1 analysis, functional fibrinogen to platelet ratios
(which is an additional test) were not routinely obtained.
Full preoperative screening for hereditary thrombophilia
is not routinely undertaken, and often the first indication
of problems is a failing flap. The short time to obtain a
functional fibrinogen to platelet ratio at the induction of
anesthesia is one of the key benefits of the test.
Whilst included as a thrombotic complication, the sig-
nificance of thrombosis within the internal jugular vein
seen at primary surgery is unclear. This was found in
three patients, at the time of surgery, without subsequent
flap complication. Where IJV thrombus was removed,
additional anticoagulation measures, including intraopera-
tive unfractionated heparin, were instigated with close
clinical surveillance. This is likely to have reduced poten-
tial adverse sequelae in these patients. We have noted an
increased incidence of IJV thrombosis detected at primary
surgery than is alluded to in the literature.21,22
A number of factors for flap failure have been
discussed in the literature, including extrinsic compression
of the pedicle, the use of interpositional vein grafts, and
technical error.2 Despite sound surgical technique, a
hypercoaguable state may still predispose a patient to
thrombotic events that may ultimately jeopardize the micro-
vascular anastomosis.23 It has been reported that 96% of
microsurgeons routinely use anticoagulants in an attempt
to minimize postoperative thrombotic complications.24
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Without a mechanism to detect high risk patients,
targeted therapy is not possible, subjecting all patients to
the potential adverse effects of these measures.
The recognized risk factors for thrombosis are related
to one or more elements of Virchow’s triad—stasis, ves-
sel injury, and hypercoagulability; factors frequently
encountered in oncology patients undergoing free tissue
transfer. High plasma fibrinogen levels have been corre-
lated with increased thromboembolic risk in patients with
cancer or cardiovascular disease.23 Kuo et al.23 investi-
gated the impact of hyperfibrinogenemia on patency of
microvascular anastomoses. Using a rodent model, they
performed femoral artery and vein anastomosis with and
without intraveneous administration of fibrinogen. Laser
Doppler flowmetry was used to assess the patency of the
anastomosis preoperatively and 2 h postoperatively. Vas-
cular patency was assessed 7 days postoperatively. They
found that there was no statistical difference in patency
of the femoral vessels after vessel division and reanasto-
mosis. This experimental data did not support their clini-
cal findings of 20% of patients with hyperfibrinogenemia
suffering postoperative thrombotic events resulting in flap
failure. The increased functional fibrinogen to platelet ra-
tio seen in those patients experiencing thrombotic compli-
cations in this study is consistent with the finding of
microvasular complications associated with hyperfibrino-
genemia; elevated fibrinogen being a recognized finding
in patients with malignancy.25
Wang et al.26 reviewed the outcome of 58 flaps in
patients with recognized hypercoaguability. They reported
an increased flap thrombosis rate of 20.7% compared to
the average for all flap cases of 4.2%. In their patient
cohort, none of the failing flaps were salvageable. The
authors discussed the potential of flap complications
being amenable to mechanical thrombolytics, systemic
anticoagulation, and change of the target donor vessels,
making preoperative identification of at-risk patients of
key importance. In our cohort, the only successful post-
operative successful salvage was in the case of an arterial
thrombus on postoperative day 2, in whom the baseline
functional fibrinogen to platelet ratio was 49%.
Whilst TEG1 is increasingly being utilized in postop-
erative surgical management, the current study is the first
to highlight the potential predictive benefit of the tech-
nique in free-flap surgery.
CONCLUSION
Functional fibrinogen to platelet ratio levels may be a
useful tool to identify patients likely to experience post-
operative thrombotic events. Further prospective valida-
tion is required, however, the results of this preliminary
study suggest that this method may aid clinicians in
targeting additional anticoagulation methods and close
surveillance to those patients most at risk, reducing
patient morbidity.
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bstract
ost microsurgeons report the use of anticoagulants in their routine practice. Anti-Xa concentrations are preferentially used to monitor
reatment with low molecular weight heparin (LMWH). The aim of this retrospective study was to measure the therapeutic response to
tandard dosing with LMWH (using anti-Xa) in patients after ablative and reconstructive surgery for head and neck cancer, and to review the
ssociated risk of bleeding. We retrospectively reviewed 153 patients who had undergone resection of primary or recurrent tumours of the
ead and neck with free flap reconstruction. In total, 173 free flap procedures were completed. Medical records were reviewed to find the
nticoagulation regimen used, anti-Xa result, patients’ weight, and any associated complications. Fourteen patients returned to theatre because
f bleeding; of these no cause was identified in 6 and a haematoma was evacuated. The distribution of unexplained haematoma was similar
or all dose regimens of dalteparin. Anti-Xa results were available in 47 cases, and of these, 22 (47%) were within the prophylactic range
0.2 IU/ml or more). Our results highlight the high incidence of inadequate response to standard prophylactic doses of LMWH in patients with
ead and neck cancer. Increasing the dose of dalteparin does not seem to increase the risk of bleeding or formation of a haematoma. These
ndings may be transferable to other surgical specialties.
 2013 The British Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.
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ntroduction
icrovascular free tissue transfer is a reliable technique for
econstruction of the head and neck, with a reported success
f 90–99%.1 However, despite improvements in technical
xpertise there remains an appreciable risk of anastomotic
hrombosis, most notable within the first 48 hours, with
esultant disastrous consequences.2 The use of anticoagu-
ants after free tissue transfer is controversial and practices
ary,3,4 but in an international survey of the management
f free flaps in 1989, Salemark5 reported that prophylactic
∗ Corresponding author.
E-mail  addresses: Karen.a.eley@gmail.com (K.A. Eley),
achel.parker@ouh.nhs.uk (R.J. Parker),
teve.watt-smith@ndm.ox.ac.uk (S.R. Watt-Smith).
L
b
i
o
o
t
a
f
266-4356/$ – see front matter © 2013 The British Association of Oral and Maxillofacia
http://dx.doi.org/10.1016/j.bjoms.2013.01.017
193H; Heparin; Dalteparin; Head and neck malignancy
ntithrombotic agents were used in 91% of centres. Today,
he most commonly used agents seem to be aspirin and low
olecular weight heparin (LMWH). These are used to min-
mise the risk of anastomotic thrombosis and as prophylaxis
gainst venous thromboembolism (VTE) in patients who
re typically immobile after prolonged operations. However,
hese agents are not without risk, which include bleed-
ng, haematoma, thrombocytopenia, and gastric irritation.
MWH has broadly replaced unfractionated heparin (UFH)
ecause it has better pharmacokinetic properties and an
mproved safety profile.6 With only a moderate prolonging
f the activated partial thromboplastic time, measurement
f anti-Xa concentrations are preferentially used to moni-
or LMWH therapy.7 For dalteparin the recommended peak
nti-Xa concentration is 0.5–1.0 IU/ml or 1.0–2.0 IU/ml for
ull anticoagulation with twice daily and once daily dosing,
l Surgeons. Published by Elsevier Ltd. All rights reserved.
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espectively; and 0.2–0.4 IU/ml for prophylactic anticoag-
lation for VTE.7,8 The same regimen for prophylaxis is
outinely used for all patients post-operatively, irrespective
f their body mass index. The aim of this retrospective study
as to measure the therapeutic response to standard doses of
MWH in patients (using anti-Xa concentrations) after abla-
ive and reconstructive surgery for head and neck cancer, and
o review the associated risk of haematoma for the varying
ose regimens.
atients  and  methods
etween 2006 and 2009 we retrospectively reviewed all
atients at our unit who had ablative surgery for head
nd neck cancer with free tissue transfer. Patients’ med-
cal records and the departmental database were used to
btain information relating to prescription of anticoagu-
ants, pre-operative weight, comorbidity, and post-operative
orbidity. Comorbidity was assessed using the Adult Comor-
idity Evaluation-27 (ACE-27) scoring system, which has
our grades of decompensation: none, mild, moderate, and
evere.9 The presenting tumour was not included in this
coring process. At the time of the study routine prophy-
axis included dalteparin 5000 IU once daily with or without
spirin 75 mg once daily post-operatively. We recorded the
nti-Xa results and incidence of bleeding that required a
eturn to the operating theatre. Since the end of 2008 we
ave requested anti-Xa concentrations 4 hours after the ini-
ial dose of dalteparin with subsequent adjustment of dose, to
nsure optimal treatment with LMWH. Only those results of
nti-Xa tests which could be confidently confirmed as being
one at the correct time interval were included for data analy-
is. The prophylactic range (at 4 hours) was considered to be
F
(
(
able 1
atients’ details, comorbidities, and free-flap reconstruction by bleeding complicati
Return to theatre for bleeding (n = 14) 
Cause identified (n = 8) Caus
ex
Male 5 3 
Female 3 3 
ean (SD) age (years) 54 (16) 66 (16
ean (SD) weight (kg) 82 (14) 60 (7)
CE-27
0 3 2 
1 4 4 
2 1 0 
ree flap
Radial 4 4 
ALT 1 1 
Fibula 2 
Latissimus dorsi – 1 
Fibula and radial 1 – 
Fibula and ALT – – 
Fibula and latissimus dorsi – – 
Other – – 
LT: anterolateral thigh flap.
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.2–0.4 IU/ml. For the purpose of this study, we considered
hat post-operative haematoma and bleeding for which no
ause was found were related to the anticoagulant given. Sta-
istical analysis was done using the Statistical Package for the
ocial Sciences (SPSS version 18.0, IBM, USA). Descriptive
nalysis was first completed using histograms, box plots, and
catter plots. Statistical comparison was done using paired
tudent’s t-tests and Chi square tests. Probabilities of 0.05
ere considered significant.
esults
f the 153 patients, 18 underwent more than one free flap pro-
edure (16 had 2 procedures; 2 had 3 procedures) as a result
f recurrence (n  = 3), a second primary tumour (n  = 3), to aid
unction (n  = 7), or due to flap failure (n  = 7) (Table 1). Three
urther flaps failed, and patients subsequently had delayed
r pedicled reconstruction. In 5 cases the flap was success-
ully salvaged (including treatment with leeches, n = 1), and
 further 2 patients lost an area of skin paddle.
Fourteen patients required a return to theatre because of
leeding. In 8 of these an active bleed was identified sec-
ndary to loose Ligaclips (Ethicon) (n  = 1), bleeding from
he anastomosis (n  = 1), erosion of a vessel by a drain (n  = 1),
r another identified bleed from a vessel (n  = 5). However, in
 no active bleeding was identified and a haematoma was
vacuated. Table 1 shows the ACE-27 score, age, and
eight for the three groups. The distribution of unexplained
aematoma, was similar for all dalteparin regimens (Table 2,
ig. 1), and the difference between groups was not significant
p = 0.71).
Most patients had dalteparin with or without aspirin
Table 3). Nine patients were managed post-operatively with
ons.
No bleeding complications (n = 159)
e not identified (n = 6)
93
66
) 61 (14)
 71 (18)
55
89
15
93
18
21
9
8
5
1
4
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Table 2
Dalteparin prescription in patients with no bleeding or haematoma and in those with unexplained post-operative haematoma. Data are number (%).
Dalteparin dose (IU) No bleeding
complications (n = 159)
Active bleeding identified
at return to theatre (n = 8)
Unexplained haematoma
(n  = 6)
2500 once a day 7 (5) 0 0
5000 once a day 100 (63) 5 4
5000 twice a day 34 (21) 1 2
7500 or more once a day 18 (11) 2 0
Table 3
Anticoagulation regimen and number of associated bleeding complications.
Dalteparin dose (IU)
2500 once a day 5000 once a day 5000 twice a day 7500 or more once a day Total
Aspirin No aspirin Aspirin No aspirin Aspirin No aspirin Aspirin No aspirin
No complications 5 2 71 29 19 15 13 5 159
Identified bleed 0 0 4 1 1 0 2 0 8
H
T
U
t
fl
i
t
b
t
m
o
F
h
h
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w
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w
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a
saematoma 0 0 3 1 
otal 5 2 78 31 
FH, and 5 were ultimately started on warfarin because of
hrombosis within the internal jugular vein or problematic
ap salvage, or both. There were no complications identified
n those managed with UFH.
Anti-Xa results were available in 47 cases, and a further
est done in three patients after the dose of dalteparin had
een adjusted (Fig. 2). Of these, 22 (44%) were within
he prophylactic range (0.2 IU/ml or more) (Table 4). The
ean (SD) weight of patients with anti-Xa concentrations
f less than 0.2 IU/ml was 84 (24) kg (range 48.5–157),
ig. 1. Distribution of dalteparin prescription in patients with no bleeding/
aematoma complications (a) and those experiencing unexplained
aematoma (b).
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5
5
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1952 0 0 0 6
22 15 15 5 173
nd for those with a concentration of 0.2 IU/ml or more it
as 65 (12) kg (range 45–86). There was a strong negative
orrelation (p  = 0.01) with the anti-Xa result with increasing
eight. The anti-Xa concentration improved in 2 of the 3
atients who had the dose adjusted. Of the 47 cases with
nti-Xa results there were six flap complications. One was
uccessfully salvaged, but 5 were ultimately lost. All but
wo anti-Xa results were below 0.2 IU/ml, with patients
eceiving a dalteparin dose of 5000 IU every day.
Anti-Xa results were available in 8 of 14 patients
ho required a return to theatre because of bleeding or
aematoma. Of these 5 had identified vessel bleeding in
hom only 2 had anti-Xa concentrations within the prophy-
actic range (mean 0.13; range 0.01–0.24). Of the remaining
hree patients with a haematoma, two had anti-Xa concen-
rations within the prophylactic range (mean 0.26; range
.1–0.47).
One patient, an 82-year-old man, was treated for sus-
ected post-operative pulmonary embolism, although there
as some doubt associated with the diagnosis. He weighed
0 kg and had a mandibulectomy and reconstruction with a
bula free flap. He had been prescribed dalteparin 5000 IUwice daily with no adjuvant aspirin. Anti-Xa concentration
as not measured.
able 4
esult of anti-Xa tests in 47 cases with varying doses of dalteparin (three
atients had repeat tests).
alteparin dose (IU) Anti-Xa concentration (U/ml)
Less than 0.2 0.2 or more
500 once a day 6 0
000 once a day 18 14
000 twice a day 2 5
500 or more once a day 2 3
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iscussion
t has been shown that anti-Xa results strongly correlate with
ean patient weight, which is consistent with studies on the
nti-Xa response to dalteparin in those who are obese.10 It
mplies that standard dose regimens are not suitable for all
atients. However, despite a variable anti-Xa response to pro-
hylactic regimens in routine clinical practice, prescription
s rarely adjusted according to a patient’s weight. The results
vailable from the manufacturer state that mean (SD) peak
4 hour) concentrations of anti-Xa in trials after single doses
f 2500, 5000, and 10,000 IU of dalteparin were 0.19 (0.04),
.41 (0.07), and 0.82 (0.10) IU/ml, respectively.11 However,
n our study, a dose of 2500 IU was rarely enough to bring
he anti-Xa concentration into the prophylactic range.
Measuring anti-Xa concentrations in patients and adjus-
ing the dose of dalteparin seems to be a safe and reliable way
o ensure efficacy. In our group 56% had an anti-Xa concen-
ration below 0.2 IU/ml, which is not deemed sufficient for
rophylaxis. Although the dose was adjusted, few had a repeat
est to find out the resultant effect. Of the three patients who
id, the result in one was still not in the prophylactic range.
Our results are limited by the retrospective nature of the
tudy. The accuracy of the anti-Xa results rely on clear
ocumentation of the time that dalteparin was given and
enepuncture done. While most patients were cared for in
he intensive care unit, which uses electronic administration
ecords, it is anticipated that some blood tests for anti-Xa
oncentrations were not perfectly timed. Patients with head
nd neck malignancy are typically advanced in age and have
f
t
196ith varying dalteparin dose.
ultiple comorbidities. This can prolong recovery, reduce
obility, and increase the risk of VTE, which is further
eightened by the procoagulant effects associated with malig-
ant disease. Despite a high proportion of patients having
nti-Xa concentrations below the prophylactic range, the inci-
ence of VTE in our group was low with only one case
dentified. However, since the anti-Xa concentration was not
easured in this patient, it is impossible to know whether
he dose of dalteparin was appropriate. It is possible that the
ncidence of VTE was under-reported as a result of patients
eing treated at peripheral hospitals after discharge, although
t would be expected that such treatment would be reported
o the operating surgeon and documented in the medical
ecords. Further contributing factors that reduced the inci-
ence of VTE in this group include the intraoperative and
arly post-operative use of pneumatic compression devices,
ntithrombotic stockings, and where possible, early mobili-
ation.
The adverse outcomes in patients with acute coronary
yndrome and anti-Xa concentrations below the therapeutic
ange have been reported,12 but we know of no such relation
eported after flap surgery. A number of factors may inter-
ere with the effectiveness of LMWH given subcutaneously
n patients with head and neck cancer including low car-
iac output, reduced peripheral blood flow, or subcutaneous
edema during the early post-operative period.13 This further
ighlights the benefit of routine monitoring of anti-Xa.While LMWH reduces the risk of VTE, the benefits
or free flaps remain uncertain. Animal studies have shown
hat dalteparin prevents arterial thrombosis as effectively as
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FH.14,15 Reported success rates for free tissue transfer in
ead and neck malignancy are 90%–96%,16–19 which are
onsistent with our findings. Of the 10 flaps lost, anti-Xa
esults were available in 5, and only 2 of these were in the ther-
peutic prophylactic range. In most cases flaps failed after the
ritical 48-hour post-operative period. Potential contributing
actors leading to failure include pregnancy, diabetes melli-
us, and cardiorespiratory diseases. Olsson et al.20 noted that
f two patients with anastomotic thromboses, both had anti-
a concentrations below 0.3 IU/ml, and that pre-operative
nticoagulation with 2500–5000 IU was not reliable.
The ideal anticoagulant for free flap surgery would
ot only effectively reduce thrombosis in the pedicle, but
ould do so with minimal adverse side effects. Statins,
n view of their vasoprotective action, anticoagulation,
nd anti-inflammatory properties, are potential alternatives
o traditional anticoagulants, but currently no intravenous
reparations are available. In our group, 35 patients (20%)
ere on statins at the time of surgery, and of these, 5 had
ap or haematological complications, or both (lost flap n  = 2;
dentified bleed n  = 2; haematoma n = 1). In view of the small
umbers the data fail to yield any significant correlations, but
here is certainly scope for future research. The risk, in terms
f bleeding or formation of a haematoma, did not seem to be
nfluenced by the dose of dalteparin, or prescription of aspirin.
ince all patients were given heparin in some form, and only
 very small number were managed with UFH, it is not pos-
ible to compare these findings with those encountered with
FH or in the absence of anticoagulation. Previous studies
ave reported that LMWH has a substantially reduced risk
f adverse side effects, including formation of a haematoma
hen compared with UFH.21 However small, the use of
MWH carries risk, but this seems to be outweighed by the
rophylactic benefits. Our results highlight the high incidence
f inadequate response to standard prophylactic doses of
MWH in patients with head and neck cancer. These findings
ay be transferable to other oncological surgical specialties.
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Letters to the Editor
Coagulopathies and the use of LiDCO Plus Rapid mon-
itoring in patients following head and neck cancer
resection and reconstruction
Sir,
We read with interest the short communication by Abdel-
Galil et al.1 regarding the intraoperative use of the LiDCOTM
PlusRapid monitoring device (LiDCO Ltd, Cambridge, UK).
As described in our letter of 2009,2 and at the BAOMS Annual
Conference in 2009, we can attest to its benefits.
We have been using LiDCOTM Plus Rapid for patients
undergoing major head and neck surgery for the past 3 years
- introduced as part of an ongoing research study on the effects
of pressors on free tissue transfer.
We reported the ease of use of this system in our patients
in whom invasive arterial pressure monitoring is frequently
employed. Optimising fluid balance is paramount to min-
imise post-operative morbidity and flap survival. The results
of our 3 year retrospective review of patients undergoing
head and neck cancer resection and reconstruction prior to
and following introduction of LiDCOTM Plus Rapid moni-
toring (146 free flap procedures), demonstrated that the key
benefits were a reduction in intra-operative fluid adminis-
tration, (when taking urine output and operative procedure
length into account the LiDCOTM group received less fluid
per hour (p < 0.04)) and decreased post-operative hospital
stay (p < 0.02).
Unlike Abdel-Galil et al.1 we do not routinely use a strict
protocol for fluid bolusing, but we have noted that during
operation colloids are used more than crystalloids when using
LiDCOTM Plus Rapid. In view of this, attention needs to be
paid to the potential adverse effects of induced coagulation
abnormalities associated with artificial colloids.
Patients with cancers of the head and neck are commonly
susceptible to coagulopathies, and we encounter prothrom-
botic complications in roughly 5% of our patients. We
therefore disagree with the statement of Felstead and Perkins3
that thrombosis within the internal jugular vein is rare. The
key to successful management of these patients is the appro-
priate selection of anticoagulation treatment, and we reported
in Shanghai that standard prescription, low molecular weight
heparin is frequently insufficient. We use thromboelastogra-
phy (TEG)4 to monitor our patients perioperatively, and we
monitor the dalteparin response by measuring anti-Xa. This
is another aspect to our ongoing research.
We continue to investigate the use of the LiDCOTM Plus
Rapid system in monitoring our patients, and welcome the
results of a prospective randomised controlled trial by Abdel-
Galil et al.
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Wire loop technique for retrieval and reduction of the
displaced condylar fragment
Sir,
I have read the paper by Jones SD, et al.1 with interest, and
would like to mention several technical matters that I think
are important.
The screw technique described necessitates the use of
a rotary instrument deep in the infratemporal fossa, which
0266-4356/$ – see front matter © 2010 The British Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.
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production will be presented. The implants
were produced for a particular patient indi-
vidually with high accuracy in order to
achieve not only fully functional, but also
aesthetic defect replacements.
Conclusion: Individual implants compen-
sate the loosed function and repair patient’s
aesthetic visage, reduce time necessary for
surgery and are comfortable for surgeons
during the surgery.
doi:10.1016/j.ijom.2009.03.652
P180
Suction drainage of odontogenic
keratocysts of the mandible
B. Liu ∗, Y.F. Zhao, W.F. Zhang
Department of Oral and Maxillofacial
Surgery, School of Stomatology, Wuhan
University, Wuhan, Hubei Province, China
Background and Objectives: The aim of
this study was to evaluate the effects of
suction drainage on odontogenic kerato-
cysts (OKCs) of the mandible and its role
in conjunction with curettage. To analyse
the effect of suction drainage on Ki-67
and IPO-38 labelling indices of odonto-
genic keratocysts before and after suction
drainage.
Methods: Biopsy and suction drainage
were performed simultaneously in 39 cases
of OKC of the mandible. Clinical and
radiological examinations of these patients
were carried out regularly. The curettage
via intraoral incision was completed until
the extent of disease significantly shrunk.
The volume of the cavity and area of
the cyst on a panoramic radiograph were
measured preoperatively and postopera-
tively. The labelling index (LI), employing
two cell proliferation markers IPO-38 and
Ki-67, was studied by the immunohis-
tochemical technique. From preoperative
and postoperative specimens of each case
were stained with monoclonal antibod-
ies for IPO-38 and Ki-67 respectively.
The labelling indices for Ki-67 and IPO-
38 were recorded and compared between
fields. Comparison was made between
preoperative and postoperative labelling
indices.
Results: After a mean duration of suction
drainage of 5.5 months, the size of OKCs
had shrunk by a mean of 62.4% based
on the panoramic radiographs findings.
A parakeratinised epithelium was trans-
formed into a hyperplastic, stratified, non-
keratinising squamous epithelium after
suction drainage in 37 cases (94.9%), and
higher inflammatory density was found
postoperatively than preoperatively. Post-
operatively, there was higher inflammatory
density in metaplastic epithelium than in
classic OKC epithelium. The radiolucent
area of cyst on a panoramic radiograph was
linearly related to the volume in the cavity.
The average LIs for Ki-67 and IPO-38 were
lower postoperatively than preoperatively,
and with LI for Ki-67 significantly lower
(P = 0.021). When postoperative LI for
Ki-67 in metaplastic epithelium was com-
pared with that in classic parakeratinised
epithelium, there was a decreased LI in
the former (P = 0.033). No complication
occurred after curettage and no recurrence
appeared with an average follow-up of 4
years.
Conclusions: It appears that suction
drainage resulted in the classic paraker-
atinised epithelium of OKC transformed
histologically to metaplastic squamous
epithelium and induced new bone for-
mation surrounding the cyst. It preserved
anatomical structures and reduced
recurrence after secondary curettage.
doi:10.1016/j.ijom.2009.03.653
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Clinical and patient subjective
evaluation of different
reconstruction methods in
mandibular defects
Q. Wan
Department of Oral and Maxillofacial
Surgery, School of Stomatology, Wuhan
University, Wuhan, Hubei Province, China
Background and Objectives: To evalu-
ate retrospectively the clinical and patient
subjective outcomes of different recon-
struction methods in mandibular defects.
Methods: A retrospective analysis of
254 patients undergoing reconstruction
of mandibular defects over the past 15
years was performed. The patients were
divided into four groups according to
the reconstruction methods: free bone
grafts (FBG group; n = 122); particulate
bone cancellous marrow grafts (PBCM
group; n = 91); reconstruction plates (RP
group; n = 22); microvascular free flaps
(MFF group; n = 19). The clinical history
review, clinical and radiological examina-
tion, and questionnaires were performed
to compare the survival rates, complica-
tion rates, functional and aesthetic results
among four groups. Sample characteristics
were described with descriptive statistics
and comparisons of results among the
groups were made with Fisher exact tests
(alpha = 0.05).
Results: The mean follow-up was 58.7
months (range, 3–176 months), lost 31
patients. 9 patients died, survival rate was
lowest in RP group (P = 0.02). 14 patients
had complications, complication rates
were no significant different among four
groups (P = 0.45). The functional and aes-
thetic comparison showed that mastication,
diet, satisfaction of facial appearance, oral
continence, social activities, and speech
were no significant different among four
groups (P > 0.05 respectively). The bite
force was lowest in RP group (P = 0.012).
Conclusions: This study demonstrates that
clinically and patient subjectively eval-
uated results of the four reconstruction
methods were no significant different.
According patient’s etiopathogenesis, dis-
eased region, treatment planning, age,
sexuality, and occupation, etc., to choose
the optimal method for each patient is the
key factor to get the best prognosis.
doi:10.1016/j.ijom.2009.03.654
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Are routine prophylactic
dalteparin doses appropriate in
patients undergoing head and
neck cancer resection and
reconstruction?
S.E. Bond
Department of Maxillofacial Surgery, The
John Radcliffe Hospital, Headington,
Oxford, United Kingdom
The use of free flap surgery for recon-
struction following head and neck cancer
has become routine practise. Intra- or
postoperative anastomotic thrombosis is
the leading cause of flap failure occurring
most frequently during the first two post-
operative days. In an attempt to address
this, approximately 96% of microsurgeons
report to routinely use anticoagulants.
Additionally, this group of patients are
at increased risk of postoperative venous
thromboembolism (VTE), and the need
for adequate prophylaxis critical. Low
molecular weight heparins (LMWH) have
broadly replaced unfractionated heparin
due to more preferable pharmacokinetics
and a better safety profile. With only
a moderate prolonging effect on the
activated partial thromboplastic time,
anti-Xa levels are preferentially used to
monitor LMWH therapy. For dalteparin
the manufacturer recommends the peak
anti-Xa level to be 0.5–1.0 U/mL and the
trough > 0.1 U/mL. The adverse outcomes
in patients with acute coronary syndrome
with subtherapeutic anti-Xa levels have
been reported. The aim of this study was
to review the anti-Xa response to standard
dalteparin prophylaxis in patients follow-
ing free flap surgery for head and neck
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cancer. We retrospectively reviewed 50
patients undergoing head and neck cancer
surgery at our unit between January and
December 2008. Following complications
secondary to anastomotic thrombosis, we
recently introduced close anticoagulant
monitoring in our patients to include
routine thromboelastogram, and anti-Xa
levels following dalteparin administration
in patients deemed to be at increased risk.
Current postoperative prophylaxis in use
includes aspirin 75 mg (following a 300 mg
loading dose on day 1 postoperative), and
dalteparin 5000 units once daily. Anti-Xa
results were available in 17 patients.
Review of these results revealed that all
but one patient had levels identifying
subtherapeutic levels of anticoagulation,
necessitating increased dosages of dal-
teparin. With close attention to adequate
anticoagulation, none of these 17 patients
experienced flap failure or VTE. Certainly
the potential non-response to standard
dalteparin dosing may have been predicted
in those patients with high body mass
index, although data evaluating the safety
of using weight-based doses of LMWH
in obese patients are limited. A number
of factors might interfere with the effec-
tiveness of subcutaneous administrated
LMWHs in head and neck cancer patients,
including low cardiac output, decreased
peripheral blood flow, or subcutaneous
oedema during the early postoperative
period. These preliminary results highlight
the high frequency of inadequate response
to standard prophylactic LMWH dosing
in patients with head and neck cancer,
warranting further investigation.
doi:10.1016/j.ijom.2009.03.655
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Is the ratio of functional
ﬁbrinogen to platelets as
measured by
thromboelastography a
predictive parameter for
thrombotic complications in free
tissue transfer surgery?
R. Parker, K.A. Eley, S.E. Bond ∗,
S.R. Watt-Smith
Department of Maxillofacial Surgery, The
John Radcliffe Hospital, Headington,
Oxford, United Kingdom
The risk of total flap loss after free
microvascular tissue transfer is estimated
to be between 2 and 6%. Flap failure is
most frequently due to anastomotic throm-
bosis, occurring in the early postoperative
period. The exact causes of events lead-
ing to thrombotic occlusion still are not
clearly elucidated, although authors have
observed detrimental effects of increased
platelet counts, platelets aggregation, and
elevation of fibrinogen levels on flap
survival. In patients with hyperfibinogen-
emia related to oral cancer, the safety
of performing a successful microsurgical
procedure for complex tissue defects has
been debated, and the correlation between
hyperfibrinogenemia and vascular throm-
bosis in microsurgery remains unclear.
Rodent research suggests no significant
difference in the platelet counts associated
with hyperfibrinogenemia, yet increased
plasma fibrinogen levels are associated
with increases in platelet aggregability.
Observation of our patients undergoing
free tissue transfer in the head and neck
subjectively revealed increased flap fail-
ure associated with both elevations in
fibrinogen and platelet levels. We retro-
spectively reviewed 42 patients undergoing
free tissue transfer following head and neck
cancer resection. The ratio of preopera-
tive fibrinogen to platelet was calculated
for each patient preoperatively. A con-
trol group of normal fibrinogen to platelet
ratio results were obtained from 49 healthy
volunteers. Fibrinogen to platelet ratios
in patients with head and neck cancer
preoperatively were significantly higher
(P < 0.001) than this control group. In
total, seven patients (17%) experienced
major graft failure secondary to thrombotic
events. Two of these patients had intraoper-
ative thrombotic events. The preoperative
fibrinogen to platelet ratio was above 50%
in six patients, correctly identifying their
increased thrombotic tendency. In the one
patient with a preoperative ratio of 34%,
postoperative results demonstrated con-
tinuing elevating ratios, which may have
highlighted forthcoming flap failure. These
preliminary results suggest that the use of
preoperative fibrinogen to platelet ratios
may aid in identifying patients at increased
risk of anastomotic thrombosis.
doi:10.1016/j.ijom.2009.03.656
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Structural characteristics of the
asymmetric mandible revealed
by three-dimensional computed
tomography
W. Park ∗, J.Y. Kim, J.W. Choi,
B.C. Kim, S.H. Lee
Department Advanced General Dentistry
and Department of Oral and Maxillofacial
Surgery, Dental Hospital, Yonsei
University, Seodaemungu, Seoul, Korea
Background and Objectives: Facial asym-
metry is one of the most complex
dentofacial deformity. To achieve good
postoperative results, accurate diagnosis
and proper treatment planning is manda-
tory. To analyse three-dimensional bony
architecture and structure, 3D computed
tomography (CT) is very effective method.
Although 3D CT image can show exact
3D image in virtual space, there is no
definite protocol for analysing complex
craniofacial structures. In this study, we
tried to compare the 3D characteristics of
mandible between symmetric and asym-
metric patients in 3D CT.
Methods: 40 dataset of deformity patients
were used in this study. 20 patients were
facial asymmetry and 20 patients were
mandibular prognathism without facial
asymmetry. After setting proper mid-
sagittal plane, reference points which can
represent facial growth and development.
With these highly reproducible reference
points, 3D structural analysis was per-
formed and compared with both groups.
Results: Condylar length showed remark-
able difference in asymmetric group than
symmetric group. However, not only the
condylar length but also angular compo-
nents showed difference in asymmetric
group. This result means that facial asym-
metry is complex linear, angular difference
in affected and non-affected site.
Conclusions: 3D evaluation of asymmet-
ric mandible gives much information to
understand asymmetric dentofacial defor-
mity. This information will be very useful
knowledge in treatment planning facial
asymmetry.
Acknowledgement. This work was sup-
ported by the Korea Healthcare technology
R&D Project (A080006) for LSH.
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Instant reconstruction of defect
of oral cancer with composite
ﬂaps
H. Zhu ∗, J. He
Department of Oral and Maxillofacial
Surgery, Shanghai Ninth People’s Hospital,
Shanghai, China
Background and Objectives: Large area
defect will be remained for radical resec-
tion of cranial-maxillofacial region in some
of the advanced oral cancer. It seriously
affects the masticatory and linguistic func-
tion and the appearance of the patients.
Composite flaps were designed to accom-
plish one-stage repair large defect after oral
cancer operation.
Methods: From June 1998 to June 2006,
8 composite flaps were designed to repair
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Are routine prophylactic Dalteparin doses appropriate 
in patients undergoing head and neck cancer resection 
and reconstruction? 
Miss Karen A Eley1, Ms Rachel Parker2, 
Mr Stephen E Bond3, Mr Stephen R Watt-Smith3
Department of Oral & Maxillofacial Surgery, Oxford Radcliffe Hospitals NHS Trust, 
Headley Way, Oxford OX3 9DU, UK
INTRODUCTION:
The use of free flap surgery for reconstruction following head and neck cancer has
become routine practise. Intra-or post-operative anastomotic thrombosis is the
leading cause of flap failure1,2 occurring most frequently during the first two
postoperative days1. Additionally, this group of patients are at increased risk of post-
operative venous thromboembolism3, and the need for adequate prophylaxis critical.
In an attempt to address this, approximately 96% of microsurgeons report to routinely
use anticoagulants1.
Low molecular weight heparins (LMWH) have broadly replaced unfractionated
heparin due to more preferable pharmacokinetics and improved safety profile4. With
only a moderate prolonging effect on the activated partial thromboplastic time, anti-Xa
levels are preferentially used to monitor LMWH therapy5. For Dalteparin the
manufacturer recommends the peak anti-Xa level to be 0.5-1.0U/ml and the trough
>0.1 U/ml5,6. The adverse outcomes in patients with acute coronary syndrome with
subtherapeutic anti-Xa levels have been reported7.
AIMS:
To determine the anti-Xa response to standard Dalteparin doses in
patients following free flap surgery for head and neck cancer.
METHODS:
We retrospectively reviewed all patients undergoing free tissue transfer
for head and neck cancer at our unit with respect to low molecular
weight heparin dose and anti-Xa results. Standard Venous
Thromboembolism (VTE) prophylaxis in our unit includes Aspirin 75mg,
and Dalteparin 5000 IU/od. Between 2006 and 2009, the authors (SWS
& SB) completed 150 free tissue transfer procedures spanning 133
surgical sessions and 114 patients for head and neck cancer or
associated complications. The patient notes were unavailable for 7
patients. In total, Anti Xa results were available following 41 surgical
procedures (35 patients).
DISCUSSION:
In total, only five patients had anti Xa results within the therapeutic range, only one of whom was
on the standard dosage of 5000 units/od. There was significant flap morbidity associated with this
dose regimen, with a flap loss rate of 16%. (n=4); with increased anticoagulation, two of these
patients underwent successful free tissue transfer, and two had successful pedicled flaps. Of the
102 free flap procedures in which an anti Xa was not performed, 60 patients were given 5000
IU/od, with one flap requiring salvage, and two flaps lost; 32 patients were given 5000 IU/bd, with
three flaps salvaged and four flaps lost; and five patients were given 7500 IU/od, with one flap
salvaged, and one flap lost. The flap failure rate for this group was 7%.
Overall, one patient developed post-operative pulmonary embolism, whilst on 5000 units/bd (anti-
Xa not performed), and the flap failure rate 9%.
Anti-Xa is more likely to be conducted on patients with concern regarding clotting, contributing to
the higher incidence of flap failure in this group.
Studies suggest that standard prophylactic Dalteparin doses of 5000 units od are appropriate in
hospitalised patients in preventing VTE.9 Whilst prophylactic doses prevented VTE in all but one
of our patients, the number of patients with anti-Xa results in the therapeutic range is small,
potentially reflecting the prothrombotic potential of patients with head and neck malignancy.
CONCLUSIONS:
Standard prophylactic doses of Dalteparin, may not be suitable doses for use in patients with
head and neck cancer undergoing free flap surgery, and anti-Xa monitoring is advocated.
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RESULTS:
Dalteparin 
Dose
Non-
Therapeutic
Age
(Years)
Weight
(Kg)
Flap 
Failure
2500 OD 5 63 12 82 16 0
5000 OD 25 59 12 77 24 4
5000 BD 8 54 12 88 35 0
>7500 OD 3 55 12 88 21 1
Dalteparin 
Dose
Therapeutic
Age
(Years)
Weight
(Kg)
Flap 
Failure
2500 OD 0 - - 0
5000 OD 1 74 57 0
5000 BD 3 53 7 56.4 4 1
>7500 OD 1 88 84 0
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
2500 OD 5000 OD 5000 BD >7500 OD
Dalteparin Dose
Therapeutic
Non-Therapeutic
Day of Flap Failure in 
Non-Therapeutic 
Dalteparin Patients
Day Flap
5000 OD
1 23 Fibula
2 8 Radial
3 35 Fibula
4 2 Fibula
>7500 OD
1 22
Radial 
(partial loss)
Post-operative Day of Flap 
Failure in Therapeutic 
Dalteparin Patients
Day Flap
5000 od 13 Radial
Therapeutic Dalteparin Dose 
Non-Therapeutic Dalteparin Dose 
6 Patients were managed 
with IV Heparin, 4 of these 
were ultimately 
warfarinised
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Is the ratio of functional fibrinogen to platelets as measured by 
thromboelastography a predictive parameter for thrombotic 
complications in free tissue transfer surgery?
Miss Karen A Eley, Miss Rachel Parker,
Mr Oliver Pearson, Mr Stephen E Bond, Mr Stephen R Watt-Smith
INTRODUCTION:
The risk of total flap loss after free microvascular tissue transfer is estimated
to be between 2 and 6%1, most frequently as a result of anastomotic
thrombosis in the early postoperative period. The exact cause of thrombotic
occlusion are unknown,2 although authors have observed detrimental effects
of increased platelet counts, platelet aggregation, and elevation of fibrinogen
levels on flap survival.3-5
Rodent research suggests no significant difference in the platelet counts
associated with hyperfibrinogenemia,2 yet increased plasma fibrinogen levels
are associated with increases in platelet aggregability. 6
Thromboelastography (TEG®) is a method of measuring the viscoelastic
properties of a blood clot, developed in Germany in 1948.
AIMS:
To determine if the ratio of functional fibrinogen to platelets
is a predictor for thrombotic failure of free tissue transfer
following head and neck cancer resection.
METHODS:
The ratio of functional fibrinogen to platelets was determined pre-operatively in 42 patients undergoing free tissue transfer for head and neck
malignancy. The results were compared to those obtained from 49 healthy volunteers. Modified thromboelastography was performed on the
TEG® 5000 Haemoscope, which utilises the addition of monoclonal antibody fragment c7E3, binding to the platelet surface fibrinogen receptor
glycoprotein GP11a/IIIb7. The independent contribution of fibrinogen and platelets to clot strength could thus be determined, and a ratio of
fibrinogen to platelets calculated.
RESULTS:
Fibrinogen to platelet ratios in patients with head and neck cancer
preoperatively were significantly higher (p<0.001) than the control
group.
Overall there was a 16.6% (n=7) thrombotic complication rate. This
resulted in an overall graft failure rate of 11.9% (n=5). Two patients
had intra-operative thrombotic events. The pre-operative fibrinogen to
platelet ratio was above 50% in six patients (graph), correctly
identifying their increased thrombotic tendency. In the one patient
with a pre-operative ratio of 34%, post-operative results demonstrated
continuing elevating ratios, that may have highlighted forthcoming
flap failure.
CONCLUSIONS:
These preliminary results suggest that the use of pre-operative
fibrinogen to platelet ratios may aid in identifying patients at
increased risk of anastomotic thrombosis.
REFERENCES:
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DISCUSSION:
The ratio of functional fibrinogen to platelet contribution is
significantly higher in patients with head and neck cancer compared
to the normal population. The hypercoaguable state of cancer patients
is well recognised. This increased clotting tendency is of high
significance in this group in view of the necessity for microvascular
free tissue transfer.
In most patients the ratio of functional fibrinogen to platelets
accurately predicted thrombotic events.
This study identifies a potential pre-operative predictor of patients in
whom thrombotic events may be anticipated and suitable
anticoagulation could therefore be instituted.
This study included only a small number of patients, and further study
is required to further examine these findings.
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Abstract
Percutaneous endoscopic gastrostomy (PEG) and nasogastric tubes (NGT) are routine after resection and reconstruction of oral cancer. The
selection of the most appropriate method of feeding can be challenging, as both methods carry morbidity. This makes correct selection
paramount. The objectives of this retrospective review were to identify the benefits and complications of feeding with PEG and NGT in
patients with oral malignancy. We retrospectively reviewed 144 patients who had undergone oral cancer resection and reconstruction, to
compare PEG and NGT feeding and to identify the key factors that aid selection of the most appropriate feeding method. We used these factors
to develop the Key to Appropriate Replacement Enteral Nutrition (KAREN) scoring system. One hundred and twenty of the 144 patients
were managed with PEG, and of these, 9 used it for less than 28 days. The mean (range) duration of use was 13 (5–63) days, and 1.9 (1–5)
tubes/patient were used. The KAREN scoring system assigned the correct method of feeding in 92% of cases. The scoring system requires
prospective validation but could provide clinicians with a tool to assist in a sometimes difficult decision.
© 2011 The British Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.
Keywords: PEG; Gastrostomy; Nasogastric feeding; NGT; Head and neck cancer; Oral cancer; Free flap
Introduction
The incidence of head and neck cancer continues to rise, with
oral cancer increasingly affecting younger patient groups.
Typically, patients have a history of smoking tobacco,
or alcohol misuse, or both, with concurrent illnesses and
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occasionally concurrent malignancies.1 Between 35% and
60% of patients with head and neck malignancy are mal-
nourished, and optimised nutritional support is vital for their
postoperative recovery.1,2 Patients frequently require enteral
feeding to bypass the oral cavity and pharyx to permit healing
of the surgical site, and recovery of a safe swallow mech-
anism. In certain cases patients will become reliant upon
long-term enteral nutritional support. In the early 1990s per-
cutaneous endoscopic gastrostomy (PEG) tubes became the
preferred method of feeding such patients.3 Despite their
popularity, PEG tubes are associated with both morbidity
and mortality, and they should be restricted to those patients
who require longer term nutritional support. However, tube
0266-4356/$ – see front matter © 2011 The British Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.bjoms.2011.11.012
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selection can be difficult. Available guidance4–7 suggests that
PEG tubes should be considered if it is anticipated that nutri-
tional intake is likely to be inadequate for a period of longer
than 2–4 weeks.
The potential benefits of insertion of a PEG tube at the
time of resection have previously been reported.8 The aim
of this study was to review the benefits and complications of
PEG and nasogastric (NG) feeding in patients managed in
our unit, and develop a scoring system that has the potential
to aid selection of the most appropriate tube.
Materials and  methods
We retrospectively reviewed all patients who had primary
or secondary head and neck cancers resected with imme-
diate free flap reconstruction between January 2006 and
2010. A total of 144 patients were identified, and their med-
ical records, and the electronic reporting systems (Centricity
PACS and CaseNotes©) were reviewed to obtain details of
type of tumour, operation, method of postoperative feeding,
duration of feeding, and associated complications.
We routinely obtain consent from patients for the use of
medical records for audit and research purposes as part of
the consent process for operations. Ethical approval for a
retrospective review of casenotes as part of an audit of clinical
practice was not required.
Routine practice at the time of the study included (where
required) the insertion of a PEG by the upper gastrointesti-
nal surgeons using the pull technique (which provides direct
endoscopic visualisation of the upper gastrointestinal tract)
immediately preoperatively. PEG tubes were placed once the
anaesthetist had secured the airway. For patients to be man-
aged with NGT, these were placed at the end of the operation
with the aid of a flexible endoscope, with post-operative radi-
ological confirmation of the position. Patients were ventilated
for the first post-operative night on the Critical Care Unit,
with typically fewer elective tracheostomies performed.9 All
patients were given standard postoperative antibiotic prophy-
laxis, and gastric protection. Typically, a PEG was selected
when nutritional support was likely for 4 weeks or more, with
consideration given to the volume of the tumour, its site,
and whether the patient was to have postoperative adjuvant
treatment.
Statistical analysis was aided by the Statistical Package
for the Social Sciences (version 18, SPSS Inc, Chicago, IL,
USA) and comprised binary logistic regression. After the data
had been analysed and the decision-making processes had
been reviewed, the Key to Appropriate Replacement Enteral
Nutrition (KAREN) scoring system was developed to assist
in identifying those patients most likely to require prolonged
nutritional support and therefore should receive a PEG tube.
Though it was created retrospectively, this scoring system
provides a basis for future prospective analysis. Data are
expressed as mean (range) or number of patients.
Results
The 144 patients (male n  = 88, and female n = 56) had a mean
age of 62 (29–88) years. The diagnosis in all but 4 patients
was squamous cell carcinoma (SCC); 3 had sarcomas, and
1 had a malignant ossifying fibromyxoid tumour. A primary
tumour was resected in 126 cases, a second primary tumour
in 9, and recurrent tumours in 9. The site of excision and
method of reconstruction are shown in Table 1.
Nasogastric tube  feeding
Twenty-four patients were managed postoperatively with
NGT, and of these, 3 ultimately required a PEG tube; 2
because of postoperative complications unrelated to the NGT
that prolonged their need for nutritional support (hypoxic
brain injury after a respiratory arrest, and postoperative pneu-
monia, n  = 1 each). These were inserted at 21 and 30 days,
respectively. The final patient had a PEG tube placed as a sep-
arate outpatient procedure after discharge and before starting
a course of radiotherapy to the pharynx.
The duration of use of the NGT was 13 (5–63) days. In
addition to the two patients ultimately progressing to PEG,
2 further patients were reliant upon NGT for longer than 28
days (33 and 63 days respectively). In the first case this was
the result of a perforated colonic diverticulum unrelated to
the primary resection. The second patient had an NGT for
63 days after resection of a commisure and tumour of the
cheek with reconstruction using a radial forearm free flap and
local rotation flap. Early return to oral nutrition was antici-
pated, but post-operative recovery was eventful with return to
the critical care unit due to respiratory failure. The use of NG
feeding was discontinuous with times of full oral nutrition
before succumbing to further complication.
Patients required the insertion of a mean of 1.9 NGT (1–5
tubes/patient), as a result of accidental removal or dislodge-
ment. Two patients developed complications directly related
to their NGT, which resulted in prolonged stay in hospital
(aspiration pneumonia in both cases).
Percutaneous endoscopic  gastrostomy  (PEG)
The remaining 120 patients were given PEG tubes. Five were
inserted preoperatively in the endoscopy suite a mean of 14
(2–26) days preoperatively, and the remainder (n  = 115) at
the time of operation. This group included one patient who
required open jejunostomy because of coexisting pancreatic
disease.
There were no serious PEG-related complications in the 5
who had had the PEG preoperatively. One patient developed
complex feeding problems (diabetic gastroparesis as a result
of autonomic neuropathy), and ultimately required supple-
mental Total Parental Nutrition (for one month) in addition
to jejunal gastrostomy extension.
Postoperative imaging of the abdomen was required in 10
patients (computed tomography (CT), n = 7, and fluoroscopy,
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Table 1
Site of excision and type of free flap used.
Site ALT
(n = 14)
Radial
(n  = 96)
Fibula
(n  = 12)
LD (n = 7) Scapular
(n = 1)
ALT + fibula
(n = 4)
Radial + fibula
(n = 10)
Total
(n  = 144)
Alveolus, mandible,
retromolar trigone
2 11 12 2 1 3 10 41
Maxilla 0 1 0 1 0 1 0 3
Floor of mouth,
ventral tongue
1 18 0 0 0 0 0 19
Lateral/posterior
tongue
6 48 0 3 0 0 0 57
Buccal
mucosa/cheek/lip
5 13 0 1 0 0 0 19
Tonsillar fossa,
pharynx, soft palate
0 5 0 0 0 0 0 5
ALT = anterolateral thigh; LD = latissimus dorsi.
n = 3) who had PEG or jejunostomy tubes inserted at the time
of operation. The indications for imaging included signif-
icant abdominal pain, early sepsis, and confusion, raising
concern of a PEG leak. This occurred on an average of 6.3
days post insertion (3–12 days). In one case CT showed a
colonic injury secondary to insertion of the PEG tube, which
required laparotomy and removal of the PEG. A leak from
the PEG was found on imaging in one patient, who also had a
laparotomy. In both cases subsequent recovery was unevent-
ful. In a further 3 patients imaging identified an abdominal
cause for their symptoms that was unrelated to the gastros-
tomy (ischaemic bowel, acute pancreatitis, and perforated
colonic diverticulum). In the remaining 5 patients imaging
was within normal limits.
Of the 120 patients managed with PEG, 19 developed
minor complications (16%). These included abdominal pain
that did not warrant investigation (n  = 4), problems associated
with the feed (n  = 3), leakage of feed around the stoma (n  = 2),
overgranulation of the stoma (n  = 7), infection of the skin at
the site (n  = 2), and accidental removal of the tube (which did
not require replacement or further intervention) (n  = 1).
To date, 13 patients continue to use the PEG tube and their
mean duration of use is 795 (310–1344) days at the time of
writing. Thirty patients died with their PEG tubes still in use,
resulting in a mean duration of use at the time of death of 186
(2–654) days. The remaining 77 patients had their PEG tubes
removed as a separate outpatient endoscopic procedure or at
the time of further operation. The mean duration of use from
insertion to request for removal was 141 (13–636) days, and
to the date of actual removal 212 (27–733) days.
Selection of  postoperative  feeding  route
In those patients managed with a PEG tube, 9 patients used
it for less than 28 days, and in these patients NGT may have
been more appropriate. All nine patients had minimal coex-
isting medical problems with ASA grade I or II, and were
treated by partial glossectomy with a radial forearm free flap
up to 6 cm × 4 cm in size.
In the NGT group, the four patients who required pro-
longed nutritional support had unpredictable postoperative
complications. The combination of comorbidity and excision
site was not sufficient to predict these events preoperatively.
Development of  a  preoperative  scoring  system
The scoring system (Table 2) was devised from a combina-
tion of statistical analysis of the retrospective review, and
additional information from the medical records. Not every
patient required feeding for the whole period before radio-
therapy was started. Binary logistic regression between the
NG and PEG groups, using only those patients who were
deemed appropriately managed, showed no significant differ-
ence between the groups for age or sex. ASA grade (grouped
for I–II, and III–IV), alcohol intake, and type of free flap all
met or approached 95% significance (p  = 0.06, p  = 0.012, and
p = 0.09, respectively).
Table 2
Key to appropriate replacement enteral nutrition (KAREN) score.
Definition Score
K Known  clinical tumour stage T3 or T4 3
A ASA Grade: III–V 3
Alcohol consumption: >40 units/week 3
R Reconstruction:
Fibula/ALT/Latissimus dorsi 2
≥ 2 simultaneous free flaps 3
Radiotherapy: More than one field
following surgery planned
2
E Excision of tumour:
Anterior 2/3 of tongue+/− Floor of mouth 1
Posterior 1/3 tongue 2
Total glossectomy 4
Mandibulectomy 2
Tonsillar fossa/ pharyngeal/ soft palate 2
N Number of regular medications: >3 2
Method of nutritional support Total score
Nasogastric Tube 0–3
PEG Tube 4 or more
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Table 3
Scoring system used retrospectively in 142 patients.
Type of feeding Correctly
predicted
(n = 131)
Incorrectly
predicted
(n = 11)
Total
(n = 142)
Nasogastric tube 21 1 22
Percutaneous
endoscopic
gastrostomy
110 10 120
ASA grade, alcohol intake, and type of free flap were
insufficient in isolation to select the method of feeding accu-
rately. Further factors typically used in decision-making,
including clinical stage of tumour, site of tumour, and planned
radiotherapy (together with number of sites) were therefore
included to improve the scoring system. Patients who were
prescribed many drugs orally often remain reliant on their
PEG tube for these despite almost full return to oral nutri-
tion. The number of drugs was therefore considered to be a
further contributing factor in selection.
Using this method, all 9 patients who had the PEG tube
in place for less than 28 days would have been identified as
more suitable for an NGT than a PEG. For the NGT group, the
KAREN score would have identified only 1 of the 4 patients
who required prolonged nutrition. However, two patients
developed unpredictable postoperative complications (perfo-
rated colonic diverticulum, and hypoxic brain injury). Taking
these two patients into consideration, and applying the scor-
ing system to the remaining 142 patients (Table 3), resulted
in a prediction rate of 92%.
Discussion
The risks associated with placement of a PEG include bleed-
ing, injury to the bowel, compromise of the airway, and
possible seeding of malignant cells. Tumours of the oral
cavity may result in obstruction of the upper airway, and
in these cases a secure endotracheal tube is advocated dur-
ing placement of a PEG. Failure to do so has resulted in
deaths.10 Placement of a PEG at the time of operation min-
imises demands of time on endoscopy lists and eliminates the
risks of local anaesthesia or sedation. The upper gastrointesti-
nal tract can be examined for any coexisting conditions, and
appropriate management of gastrooesophageal reflux disease
may be instigated to minimise postoperative morbidity. The
seeding of malignant cells as a result of upper gastrointestinal
endoscopy before resection of oral cancer is a potential risk,
but was not seen in any of the patients studied.
The main problem associated with NGT is displacement.
Patients required a mean of 1.9 tubes each postoperatively, a
finding similar to those of previous studies.3 Reinsertion of
an NGT in patients after resection of head and neck cancer
and reconstruction can be challenging. The swallow mech-
anism is often inhibited, the tissues may be insensate, and
postoperative swelling may obstruct the passage of the tube.
Other reported problems include nasal irritation and mucosal
ulceration.2 Two of the patients in this study developed aspi-
ration pneumonia, probably secondary to dislodgement of
the NGT during feeding, despite confirmation of its position
before feeding was started. The diameter of the NGT is rela-
tively small, which makes giving drugs through it difficult.11
This is particularly problematic in patients with cancer of the
head and neck who have several coexisting conditions that
require multiple drugs.
The complication rate was higher in the PEG tube group,
with two major complications directly related to the PEG
tube (2%). Iatrogenic injury to the colon at the time of PEG
insertion is particularly rare, and in reported cases may not
present for many weeks after insertion of the PEG.12 Imaging
was requested in 10 patients (8%), but was within normal
limits in 5.
Major complications contributed to this high investigation
rate. The minor complication rate was 16%, which resulted
in an overall complication rate of 18%. This is lower than
previously reported.3,13 It is likely that there are a number
of contributory factors to this. Insertion of a PEG is com-
pleted only by a senior member of the surgical team, and
only after the airway has been secured. The nursing staff fol-
low a protocol of flushing out a tube before use, and patients
are taught how to manage the PEG as soon as they are able.
Patients are closely followed up in the outpatient department
after discharge, with support from the dieticians and clinical
nurse specialists. This ensures that the site of the stoma is
inspected often, and preventive mechanisms put in place to
avoid complications.
The mean duration of use of a PEG until request for
removal was 141 days, and to actual removal 212 days. This
indicates a mean of 71 days from the point of referral to
removal – an appreciable delay. Subsequent changes have
been instigated, with a resultant reduction in waiting times
for endoscopic removal of a PEG. In addition, the require-
ment for endoscopic removal may be reduced with the use
of “cut and push” tubes, which are currently being evaluated.
All patients are assessed and followed up by the dietician
and speech and language teams. The decision to remove the
PEG is multifactorial, and while discussion of removal may
have taken place earlier during the follow-up, the date of
referral for removal was considered to be more accurately
documented.
Further concern about the use of PEG is a delay in return
to normal feeding, which may result from protracted disuse
of the muscles of deglutition.2,14 Rogers et al.15 reported
decreased quality of life scores in patients who continued to
use their PEG compared with those who had had it removed
or had not used a PEG tube at all. However, those who
continued to use the PEG tube were also more likely to
have had adjuvant treatment and to have more advanced
disease, both of which are important contributors to qual-
ity of life scores. The impact on quality of life of a delay in
re-establishing oral nutrition is difficult to quantify. It is dif-
ficult to compare patients’ satisfaction accurately between
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NGT and PEG tubes, as this would entail randomisation
of feeding tubes, which would be inappropriate in many
cases.
In the group of patients studied, the KAREN scoring
method seemed reliable, with selection of the correct tube
in 92% of patients. The system uses the key factors that are
likely to result in prolonged nutritional support including the
size and site of the tumour, the method of reconstruction, and
the extent of planned postoperative radiotherapy. However,
the results should be interpreted within the limits of a retro-
spective review. By the nature of the study only those patients
who had free tissue transfers were included, and so the vol-
ume of the tumour was much greater than in patients treated
by local resection and local flaps/mucosal grafts. As we work
in a tertiary referral centre, we often see larger tumours, which
contributes to our greater use of PEG. The scoring system
was developed and assessed only on retrospective data at
one centre in a group of patients with perioral malignancies.
However, these data should be available prospectively, and
the study provides the basis for prospective review to permit
refinement and the creation of a highly accurate and reliable
tool.
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Cervico-facial infections following dental extraction
D.W. Anchassi, M.K. George, K. Fan. Kings College Hospital
NHS Foundation Trust, UK
Introduction: Tooth extraction is the deﬁnitive treatment for
resolution of dental infections and pathology. Some patients require
hospital admission for management of subsequent post extraction
sepsis with its associated morbidity. The objective of the study was
to evaluate the incidence, risk factors and impact associated with
cervico-facial infection post routine dental extractions.
Method: A retrospective study was carried out of all patients
admitted with cervico-facial infection following dental extraction
over 17 months. Clinical records were analysed for demographic
data, type, number and nature of tooth extraction along with
circumstances prior to admissions.
Results: Of 201 patients admitted with loco-regional infection 43
met the criteria. 44% of these patients had no medical history of
note. Extractions were most commonly of wisdom teeth (47%),
with 35% multiple and 53% surgical extractions. 67% of patients
had oral antibiotics before admission. Sixty percent of patients
presented via A&E although 51% of patients had prior dental
review. Seventy-nine percent of patients required incision and
drainage under GA. Six patients (14%) spent between them 34 days
in Intensive Care Unit. 54% of patients had resultant scarring and
one suffered antibiotic anaphylaxis.
Conclusion: Post extraction sepsis can be associated with
morbidity and mortality. This may be reduced by identiﬁcation
of those at risk along with more aggressive initial management at
post extraction reviews. Medical history was not as strongly linked
as expected. Multiple and/or more complex extractions of wisdom
teeth are associated with a high risk.
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Routine use of percutaneous endoscopic gastrostomy (PEG)
in head and neck oncology: beneﬁts and pitfalls
K.A. Eley, S.R. Watt-Smith. Oxford Radcliffe Hospitals NHS
Trust, UK
Introduction: The risks of PEG feeding have been recently debated
within the literature. Whilst the majority of authors report the
insertion of a PEG tube prior to the commencement of radiotherapy,
it has become our routine practice for insertion to take place at the
time of primary cancer resection.
Aims: The aim of this retrospective review was to determine the
complication rate with routine use of PEG tube in comparison to
those patients where a nasogastric feeding tube is utilised in the
post-operative period.
Methods:We retrospectively reviewed all patients undergoing head
and neck cancer resection and reconstruction performed in the
Department of Oral & Maxillofacial Surgery over a 4 year period,
during which time over 170 surgical procedures were performed.
Results: In total, 70% of patients undergoing free ﬂap surgery for
head and neck malignancy received a PEG tube at the time of their
surgery. In those where a nasogastric tube was used in preference
to a PEG tube the majority of patients required re-insertion of
their NG tube at least once, and in some cases up to six times
during the recovery period. The risks and beneﬁts of the PEG will
be discussed, including one mortality directly associated with a
PEG leak.
Conclusions: Insertion of PEG tubes at the time of primary
surgery is not risk free, but should be considered in patients
where it is anticipated that oral re-feeding will be delayed or
where radiotherapy is likely to be required.
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Mucous plugs as a cause of benign salivary gland obstruction:
are they underdiagnosed? A restrospective study
M. Warner, M. Brennand Roper, S. Gowrishanker, J. Makdissi,
S. Whitley. St Bartholomews’s and the Royal London Hospitals
NHS Trust, UK
Introduction and Aims: Mucous plugs may cause identical
symptoms to those of stones and strictures. We highlight their
incidence and the importance of Digital Subtraction Sialography
(DSS) to identify and treat a pathology that is seldom considered
and under-diagnosed via other imaging techniques.
Material and Methods: We present a 4-year retrospective study
of 328 patients referred for parotid and submandibular DSS.
Results and Statistics: DSS identiﬁed mucous plugs in 113
(34.5%) of our 328 cases. Of the mucous plugs identiﬁed,
74 (65.5%) occurred as a single entity. 20 (17.7%) were associated
with a stricture, 16 (14.2%) associated with a stone, whilst 2 (1.8%)
occurred with both a stone and stricture.
Mucous plugs were more common in the submandibular salivary
gland (59.3%, n = 67) than the parotid (40.1%, n = 46).
41 (36%) of our patients diagnosed with mucous plugs via DSS,
underwent primary investigation with an ultrasound scan. None of
these ultrasounds identiﬁed mucous plugs.
Conclusions and Clinical relevance: This study demonstrates that
DSS is the essential tool for the diagnosis of mucous plugs when
a ductal obstruction is clinically suspected. Ultrasonography is
inadequate.
The beneﬁts of DSS in this situation are two fold. By excluding
stones and strictures as a differential diagnosis, more invasive
treatment is avoided. Secondly, in the case of mucous plugs, DSS
can be therapeutic. Further analysis is currently being undertaken.
This study identiﬁes mucous plugs as a cause of symptomatic
salivary gland pathology in their own right, and their incidence is
higher than reported in the literature.
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Predictive biomarkers for malignant transformation to
carcinoma ex-pleomorphic adenoma
A. Schache, R. Shaw, J. Risk, T. Liloglou, A. Triantafyllou,
D. Lowe, G. Hall. University of Liverpool, UK
Introduction and Aims: The diagnostic criteria for Carcinoma
Ex-Pleomorphic Adenoma (CXPA) are varied and histopathology
interpretation is subjective. A diagnostic biomarker for malignancy
would aid histological diagnosis and may be a predictive tool in
the benign precursor for CXPA, Pleomorphic Adenoma (PA).
Material and Methods: We analysed a series of 59 salivary
neoplasms, 28 PA (47%) and 31 CXPE (53%), for quantitative
promoter methylation using two methylation analysis techniques.
DNA was extracted by micro-dissection from FFPE samples
and bisulphite treated. Quantitative methylation data for 7 gene
promoters was obtained. p16, TIMP3 and MLH1 promoter
methylation was determined using pyrosequencing whilst RASSF1,
RARb, TMF and CYGB promoter methylation was assessed using
quantitative real-time polymerase chain reaction (RT-PCR).
Results and Statistics: The MLH1 gene promoter was essentially
unmethylated in all cases. TIMP3 and p16 showed correlation
between methylation and malignancy. In particular, signiﬁcant
methylation of p16 was shown in 8/28 (29%) CXPA samples
compared with 0/27 (0%) in Pleomorphic adenoma samples
(sensitivity 0.29, speciﬁcity 1.00).
qMSP results showed correlation between promoter methylation
and tumour type for both RARb and RASSF1 (sensitivity and
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Free microvascular transfer of segmental corticocancel-
lous femur for reconstruction of the alveolar ridge
Sir,
We read the article “Free microvascular transfer of seg-
mental corticocancellous femur for reconstruction of the
alveolar ridge” by Gaggl et al with great interest and we
congratulate them on obtaining good results with this new
method of bony reconstruction.1 The femur has been the
source of bone for management of non-union of the lower
limbs but the bone is normally taken from the medial condyle
and not the femoral shaft. The vascular pedicle for these
is also based on the genicular artery and associated venae
comitantes.2,3
As mentioned in the paper, the reconstruction of the bony
facial defect can be achieved by using free flaps such as
scapula, fibula, and iliac crest. Another source of bone is the
distal radius, which has given promising results for smaller
bony defects involving the alveolus and atrophic mandibles.
Harvesting a composite radial free flap carries the risk of
postoperative fracture of the radius, which can be minimised
by taking less than 40% of the radial circumference and pro-
phylactic plating of the radius. This paper does not deal with
these key issues with the femoral flap. The consequences of
femoral fracture would be devastating. A study by Chowaniec
et al (Presented at Bioengineering Conference, Proceedings
of the IEEE 31st North Eastern Annual Conference, 2005)
on human cadavers showed that if you take more than 35%
of the circumference of the femur, the mean (SD) maximal
load tolerated by the femur drops from 840 (297) pounds to
810 (235) pounds. As this flap weakens the femur slightly
and also it changes structural integrity, fixation of the femur
may well be prudent.
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Myocardial infarction diagnosed by troponin concentra-
tion in postoperative patients with head and neck cancer
admitted on the day of operation
Sir,
Theatre direct admission (TDA), whereby patients for
elective operations attend a holding bay on the day of opera-
tion, and are admitted to a ward postoperatively, has been
introduced in hospitals throughout the UK, including our
own. This way of increasing throughput was introduced to
them maxillofacial department in 2007.
Initial reports about same day surgical admissions in vas-
cular and colorectal surgery have been favourable.1,2
Though TDA has been a success for most of our patients,
we noted appreciable morbidity in those admitted by this
route for resection and reconstruction of cancers of the head
and neck.
Patients are assessed preoperatively to exclude those with
coexisting conditions for which preoperative admission to a
ward is required. As a consequence, preselected “low risk”
patients for TDA should have little postoperative morbidity.
We reviewed all patients who underwent major operations
for head and neck cancer in our department from 2003 to
2007, to find out the incidence of troponin-positive myocar-
dial infarction.
Of the 131 patients admitted to the ward preoperatively,
troponin concentrations were requested for 33 patients, and
were significant in nine (7% of the total patients). In the
15 patients admitted by TDA, troponin concentrations were
requested in seven patients, and were positive in three (20%
of the total patients).
The high incidence of myocardial infarction may reflect
a cluster that would have occurred at this time irrespec-
tive of the route of admission. Despite this, these results
raised sufficient concern for us to instigate a return to pre-
operative admission to a ward for all our patients who
were having major operations for cancer of the head and
neck. Subsequent repeat audit of 49 patients admitted pre-
operatively to the ward, showed significant improvement
in postoperative cardiac morbidity, with troponins being
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requested in 12 patients, and positive in only one (2% of
total patients).
The surgical stress response is a systemic reaction to injury
that includes endocrine, immunological, and haematologi-
cal effects, with a magnitude and duration proportional to
the injury.3,4 The combination of a patient’s anxiety asso-
ciated with admission to hospital, and the serious stress
response from an extensive operation, are probable con-
tributory factors to postoperative complications such as
myocardial infarction.5 TDA may therefore not be appro-
priate for all patients having major operations.
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Use of uterine dilators to create a safe tunnel for a
microvascular pedicle in the radiated neck
Sir,
Microvascular free tissue transfer is a standard method
for the reconstruction of complex surgical defects in the head
and neck region, and its use has resulted in advanced and
technically difficult cases being accepted for operation. Adju-
vant chemoradiation has improved disease-free survival, but
recurrence and second primary tumours still cause problems.
Repeated operations with neck dissection and radiation can
make the neck difficult to operate on when further recon-
struction is needed.1,2 Microvascular anastomosis must be
perfectly constructed if a free flap is to be successful; exter-
nal compression, twisting or kinking of the pedicle, or tension
on the site of anastomosis must be avoided.3 These can be dif-
ficult to achieve in the previously operated or radiated neck.
The creation of a tunnel from the neck to the oral cavity can
Fig. 1. The tunnel for the pedicle is made with uterine dilatators.
cause undesirable bleeding or damage to vital structures in
the neck such as the hypoglossal and lingual nerves.
We present a new and safe technique that creates a tunnel
from the neck to the intraoral space. We used standard uterine
dilators (Aesculap®, Tuttlingen, Germany) to create a tunnel
for a vascular pedicle in 12 patients who had had previous
head and neck operations and radiotherapy. Care must be
taken to ensure that immediately surrounding tissues are not
at risk during the first insertion of the chosen size of dilator.
Dilatation is done using increasing sizes of calibre. At the
end of dilatation the largest dilator (26 mm) is left in place
for 20 minutes to allow the vascular pedicle to be tunnelled.
There were no complications, and use of these dilators is
simple and fast (Fig. 1).
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Re: Postoperative ﬂuid balance in patients having opera-
tions on the head and neck
Sir,
Bryniarska et al.1 highlighted important concerns in the
management of patients after head and neck surgery. We
identified similar problems with postoperative fluid over-
load in our patients after reconstruction with free flaps.
After resection of head and neck cancers and reconstruc-
tion our patients remain intubated and ventilated for the
first postoperative night. Hypotensive episodes are common
as a consequence of anaesthesia maintained with propofol
and morphine. Potential consequences of this are inade-
quate flap perfusion and fluid overload secondary to boluses
of fluid given in an attempt to normalise blood pres-
sure.
Complications resulting from inappropriate fluid man-
agement are thought to develop in as many as 50% of
perioperative patients, and their adverse outcomes are well
documented.2,3
The unresolved dilemma is the relation between flap per-
fusion, systemic blood pressure, cardiac output, and which
drugs have the most influence on flap perfusion. We are
currently evaluating various alpha-agonists and inotropes to
identify the optimal treatment for flap perfusion.
As part of this ongoing research we introduced continuous
monitoring of cardiac output perioperatively. Measurement
of cardiac output or stroke volume is a necessary facet of car-
ing for critically ill patients.4 Previously only possible using
invasive pulmonary artery catheters, the LiDCOTM Plus sys-
tem is one method of minimally invasive monitoring that is
now available to us.5 This system calculates the variations
in pulse pressure, systolic pressure, and stroke volume that
occur through the respiratory cycle, providing reliable infor-
mation regarding the patient’s response to fluids.5 As it is
routine practise to obtain central venous access and moni-
tor arterial pressure in patients with head and neck cancer,
LiDCOTM plus could be used, with the potential to optimise
perioperative fluid balance.
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Re: Allergy to metal caused by materials used for inter-
maxillary ﬁxation: Case report
Sir,
The patient’s eczema disappeared after 2 days1 but the
other symptoms persisted for 11 days. The recovery struck
us as fast, but we do not understand why the symptoms dis-
appeared so quickly.
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Re: Letter to the Editor: Will any wire do?
Sir,
I share the problem faced by Walker and McCann.1 I work
in a busy trauma referral centre and we usually keep one
wiring set for temporary wiring on patients with avulsed teeth,
or fractures.
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tion from artefacts caused by the internal or external fixation.
Transcutaneous ultrasound can detect early evidence of heal-
ing of long bones [Joseph et al., 1999]. The effectiveness
of ultrasound evaluation of mandibular osteotomy sites with
non-union has been assessed.
Materials and methods: Two patients developed non-
union of composite DCIA free flap reconstructions of
the mandible following post-operative radiotherapy and
chemotherapy. Infective episodes were complicated by neu-
tropenia in one case. Treatment included hyperbaric oxygen
therapy, surgical debridement, removal of failed internal fix-
ation,and external fixation.
The progress of bony healing was monitored with serial
orthopantomographs and ultrasound scans of the osteotomy
gaps with the external fixation in-situ. The detection of
echogenic foci was the criterion for initial calcification as
this has been histologically shown to correlate with callus
maturation [Moed et al., 1998].
Results: Transcutaneous ultrasound scanning detected
early callus formation that preceded the radiographic changes
by several weeks.Clinical relevance: Trancutaneous ultra-
sound provides early objective evidence of progressive bony
healing and is reassuring for both the patient and surgeon.
doi:10.1016/j.bjoms.2009.06.168
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A comparison of skin graft success in the head and neck
with and without the use of a pressure dressing
Christopher Carter ∗, J. Morrison, G. Markose, W.S. Hislop,
W.J.R. Currie
Crosshouse Hospital, Kilmarnock, United Kingdom
Introduction/aims: There was a perception within the Max-
illofacial Unit that there was a higher infection rate of skin
grafts in the head and neck where a pressure dressing was
applied. The infection usually led to a variable loss of the
skin graft and subsequent morbidity.
The aim of this study was to compare the healing of skin
grafts in the head and neck with and without the use of pres-
sure dressings. This would then be compared to published
data.
Materials/methods: A retrospective analysis was under-
taken of patients who had undergone excision of a skin lesion
on the head or neck and reconstruction with a skin graft
between 2005 and 2008. Success was determined by the per-
centage take of the graft and the absence of infection. The
demographics, site of skin graft harvest and recipient site of
each group were also analysed for significant differences.
Results/conclusions: The results of the study are dis-
cussed and the use of pressure dressings debated. Given the
significant morbidity associated with skin graft loss, recom-
mendations for future practice will be discussed.
doi:10.1016/j.bjoms.2009.06.169
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Intra-operative use of LiDCO—is there an effect on the
volume of intravenous ﬂuids used by anaesthetists during
free ﬂap surgery for head and neck cancer?
Karen Ann Eley ∗, S.R. Watt-Smith
Oxford Radcliffe Hospitals NHS Trust, United Kingdom
The deleterious effects of inappropriate fluid prescription
have been well documented, and include prolonged hospital
stay. Patients with head and neck cancer have multiple co-
morbidities and optimal fluid administration is paramount.
Previously only possible using pulmonary artery catheters,
the LiDCOTM plus system calculates the variations in pulse
pressure, systolic pressure, and stroke volume that occur
through the respiratory cycle, providing reliable information
regarding the patient’s response to fluids.
LiDCO Plus monitoring was introduced as part of a clin-
ical research trial, and has become routinely used during all
free flap procedures in our department.
The aim of this study was to determine if LiDCO Plus
had an impact upon intra-operative fluids in this cohort of
patients.
We retrospectively reviewed the clinical notes of all
patients in whom the LiDCO Plus system had been used intra-
operatively. These were case matched to patients prior to the
introduction of LiDCO Plus, to determine the volume and
type of fluids prescribed, and post-operative patient course.
Statistical analysis is currently been undertaken, but sub-
jectively it appears that the use of LiDCO Plus has reduced
the volume of intra-operative fluid administration, and
decreased post-operative morbidity and in-patient hospital
stay.
The LiDCO Plus system is suitable for use in patients
undergoing head and neck cancer surgery since it is rou-
tine practice to obtain arterial and central venous access.
This system provides the anaesthetist with another indicator
of patient filling status, which is more reliable than central
venous pressure, since it is unaffected by change in patient
positioning.
doi:10.1016/j.bjoms.2009.06.170
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Use of desﬂurane to maximise teaching in busy day case
oral and maxillofacial surgical operating theatre
Leo Cheng ∗, Alastair Mulcahy, John Meads, Helen
Drewery
Barts and the London NHS Trust, United Kingdom
Introduction: Training time is pressurised because of the
imposition of the European Working Time Directives. In
order to maximise the training time in day case theatres with-
out prolonging the patients’ recovery time, less turn round
time between patients is crucial. We investigated the feasi-
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RESULTS:
• Both groups were similar for:
• Flap Type
• Age
• Sex
• Weight
• Intra-operative fluid administration
• Colloids were more frequently used in the LiDCO™ group (p<0.03)
• When urine output and procedure length were taken into account, the LiDCO™
group received less fluid per hour than the routine group (p<0.04)
• Post-operative morbidity and mortality was decreased in the LiDCO™ group
• 7 post-operative deaths occurred in the routine group
• Post-operative hospital stay was significantly less in the LiDCO™ group (p<0.02)
Intra-operative use of LiDCO™ Plus –
Is there an effect on the volume of intravenous 
fluids used by anaesthetists during free flap 
surgery for head and neck cancer?
Miss Karen A Eley, Mr Stephen R Watt-Smith
Department of Oral & Maxillofacial Surgery, Oxford Radcliffe Hospitals NHS Trust, 
Headley Way, Oxford OX3 9DU
AIM:
To determine if the intra-operative use of
LiDCO™ has an impact upon the volume of
fluid used intra-operatively by
anaesthetists, and subsequent post-
operative morbidity and hospital stay.
METHODS:
A retrospective review of all patients undergoing free flap procedures for head
and neck cancer to determine intra-operative fluid prescrbing, and post-operative
recovery in those patients in which LiDCO™ Plus monitoring was used
compared to those prior to its induction.
INTRODUCTION
Complications resulting from inappropriate fluid management are thought to
occur in as many as 50% of perioperative patients, and their adverse outcome
well documented.1,2
We have recently introduced continuous cardiac output monitoring for our
patients perioperatively as part of an ongoing research project. Measurement of
cardiac output or stroke volume has been regarded as a necessary facet of
caring for critically ill patients [3]. Previously only possible using invasive
pulmonary artery catheters, the LiDCOTM plus system is one method of
minimally invasive monitoring that is now available to us [4]. The Stroke Volume
Variance (SVV) is derived directly from the arterial pressure waveform. This
system is appropriate in head and neck cancer patients since it is routine
practise to obtain central venous access and arterial monitoring. This method
provides reliable information regarding the filling status of the patient avoiding
inappropriate fluid administration.
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DISCUSSION:
Peri-operative monitoring of cardiac output allows early recognition of occult hemodynamic
abnormalities and can guide resuscitation [5]. Studies have clearly identified a reduction in
post-operative morbidity associated with targetted fluid administration [6]. The results of
our study on a small patient population suggest that the intra-operative use of LiDCO™
Plus monitoring results in an increased tendency for colloid filling, and a decreased fluid
balance per hour. Post-operative in hospital stay was significantly reduced in the LiDCO™
group, with an associated fall in post-operative complications. Further investigations are
currently being conducted to determine and optimise peri-operative filling status.
CONCLUSION:
LiDCO™ Plus is an additional source of patient monitoring suitable for patients undergoing
free flap surgery, permitting goal directed therapy, and resulting in decreased post-
operative morbidity.
LiDCO™ Routine
Male 52% 52%
Female 48% 48%
Age (years) 58 ± 9 62 ± 15
Weight (Kg) 76 ± 24 69 ± 14
Operation Length (Hours) 8 ± 1.3 7 ± 1.8
Fluid Input/Output LiDCO™ Routine
Crystalloid (Litres) 6.0 ± 1.5 6.4 ± 1.9
Colloid (Litres) 0.7 ± 0.7 0.4 ± 0.8
Blood (Units) 0.7 ± 1 0.8 ± 1
Total Fluid In (Litres) 7.0 ±1.7 7.0 ± 2.1
Urine Output (Litres) 1.1 ± 0.7 1.2 ± 1.0
Balance (Litres) 5.9 ± 1.7 5.9 ± 1.8
Balance/procedure length (ml/hr) 728 ± 169 814 ± 250
Average Hospital Stay 
(Days)
LiDCO™ 13.6 ± 5
Routine 21.7 ± 18
0
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Frequency of Flap Type Per Group
LiDCO
Routine
Between January 2006 and April 2009, 157 free flap procedures were completed during 140 surgical sessions in our department. The notes for 7 patients were
unavailable for review, the anaesthetic chart missing in the notes of a further patient, and the LiDCO™ data corrupt in a further two patients. These patients were
therefore excluded from the study. In total, 146 free flaps were completed during 130 surgical sessions on 111 patients for primary head and neck cancer resection or
reconstruction of associated problems. LiDCO ™ monitoring was used for 27 free flap sessions (24 patients; 3 patients undergoing two separate surgical procedures).
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in terms of survival benefit, partly because of the more
unpredictable nature of clinical presentation of lymphatic
metastases in melanoma. We examine the reasoning behind
advice for different patterns of lymph node resection follow-
ing different cutaneous malignancies.
doi:10.1016/j.bjoms.2009.06.035
9
The value of PET/CT in head and neck oncology diagnos-
tic dilemmas
Liviu Marius Hanu-Cernat ∗, P. Nankivell, G. James
Worcestershire Royal Hospital, Worcester, United Kingdom
PET/CT is currently restricted to specific clinical circum-
stances such as an unknown primary with neck nodal disease
and suspicion of recurrence in previously treated areas when
CT and MRI failed to provide a diagnosis.
An audit of 24 head and neck oncology patients who
benefited from PET/CT was carried out analysing clinical
situations and organisational settings leading to a request
for PET/CT, the timeframe from request to scan, reasons
for requesting the scan, significant diagnostic findings and
evaluation of treatment related implications.
The waiting time ranged from 2 to 30 days with a median
of 13 days.
There were 10 cases of carcimoma of unknown primary
and 12 patients who received treatment previously, 9 with
surgery and chemoradiotherapy and 3 with chemoradiother-
apy alone.
In the previously treated group presentation was with sus-
pected recurrent/residual local disease in 8 cases, regional in
11 cases, loco-regional in 2 cases, metastases in 2 cases and
widespread disease in 1 case.
Reasons for requesting PET/CT were an unknown
primary, suspected recurrent/residual disease, suspected
metastases and suspected malignancy, with one or more rea-
sons per request.
PET/CT identified 8 primary tumours, recurrent/residual
disease or absence of disease in 10 cases, confirmed metas-
tases in 6 cases and clarified the extent of tumour in 12
cases.
The reasons for requesting PET/CT were matched by cor-
responding significant diagnostic findings in 23 cases and
extra significant diagnostic findings in 3 cases with treatment
related implications in 15 cases.
The results are analysed statistically and discussed in the
context of available literature.
doi:10.1016/j.bjoms.2009.06.036
10
Changes in inferior alveolar nerve following mandibular
distraction in dogs
Mohamed Bahaa Khidr ∗, Aly Abdul Haleem, Mohamed
Foda
Oral and Maxillofacial Surgery Department, Al-Minia Uni-
versity, Egypt
Introduction: DO represents a last time point in the histor-
ical evolution of reconstructive surgery through inductive
surgery. It is well known fact that the mechanical or physical
potentialities can influence the biological tissue behavior.
Aims: The evaluation of the biological tissue response of
inferior alveolar nerve through mandibular bone distraction.
Materials/methods: This study was performed on 20 dogs
divided to two groups. The first group included 10 animals
subjected to corticotomy at the mandibular angle then dis-
tracted on either side of the corticotomy line by external
distractor for 10 mm length using two different rates of dis-
traction. Half of this group (5 dogs) underwent distraction
rate of 1.0 mm/day for 10 days, while for the rest of the group
the distraction rate was 2.0 mm/day for 5 days. The second
group included 10 animals subjected to the same procedures
but the distraction was performed for 20 mm distance. In each
subgroup of the two main groups one animal was subjected
to bilateral corticotomy but distracted only at one side. The
non-distracted side was taken as a control. The consolidation
period was 6 weeks.
Results: Results indicated inferior alveolar nerve changes;
comprising signs of severe degeneration, marked separation
of the perineural sheath, decrease in number of axons and
intervening areas of edema were seen in animals subjected
for increased length with higher rate of distraction.
Conclusions: DO must be done at lower rate to avoid the
deleterious effect on the inferior alveolar nerve.
doi:10.1016/j.bjoms.2009.06.037
Post-operative troponinpositive cardiac events inpatients
undergoing head and neck cancer resection admitted on
the day of surgery
Karen Ann Eley ∗, S.R. Watt-Smith
Oxford Radcliffe Hospitals NHS Trust, United Kingdom
Theatre direct admission (TDA), whereby patients for elec-
tive operations attend a holding bay on the day of operation,
and are admitted to a ward postoperatively, has been intro-
duced in hospitals throughout the UK, including our own.
Initial reports about same day surgical admissions in vascular
and colorectal surgery have been favourable.
Patients are assessed preoperatively to exclude those with
coexisting conditions for which preoperative admission to a
ward is required. As a consequence, pre-selected “low risk”
patients for TDA should have little postoperative morbidity.
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We reviewed all patients who underwent major surgery for
head and neck cancer in our department from 2003 to 2008,
to determine the incidence of troponin positive myocardial
infarction.
Prior to the introduction of TDA admissions, 7% of 131
patients had troponin positive cardiac events during the post-
operative recovery phase. This increased to 20% during the
seven month period of TDA admissions, and subsequently
returned to 2% following re-introduction of pre-operative
ward admission.
The surgical stress response is a systemic reaction to injury
that includes endocrine, immunological, and haematological
effects, with a magnitude and duration proportional to the
injury. The combination of a patient’s anxiety associated with
admission to hospital, and the serious stress response from
an extensive operation, are probable contributory factors to
postoperative complications such as myocardial infarction.
TDA may therefore not be appropriate for all patients having
major operations.
doi:10.1016/j.bjoms.2009.06.038
Three-dimensional imaging and characterisation of bone
using a novel omnidirectional ultrasound array: proof of
concept
Duncan F. Campbell a,∗, David K. Smythe a,b
a Monklands District General Hospital, Airdrie, Scotland,
United Kingdom
b University of Glasgow, United Kingdom
Introduction/aims:Fundamental to bone surgery is our inabil-
ity to assess the progression of bone healing. Currently we
have to wait for rigid union. Ideally, when is the best time
to remove fixation? How successful are bone morphogenic
proteins and other advanced techniques? In short, we need
better ways to see healing bone.
Materials/methods:We have built and tested a novel proto-
type 2D ultrasound array in association with the Universities
of Strathclyde and Bristol, employing principles derived from
seismic reflection imaging. The 550 elements in our pla-
nar array are omnidirectional. Each is activated in turn as
a point source illuminating the whole volume beneath the
array, while all 550 simultaneously receive the backscattered
echoes. The conversion of the resulting dataset into a true 3D
volumetric image is done using standard geophysical indus-
try software. The full image is obtained within an inverted
pyramid about 60 mm below the 48 mm × 42 mm array. Res-
olution is 1 mm horizontally and about 0.3 mm vertically,
but in contrast to conventional ultrasound methods does not
degrade with depth.
Results: Imaged inorganic phantoms and cut samples of
bovine bone show that the technology transfer of 3D imaging
from the seismological to the medical ultrasound domain is
successful, even though the elements at present have limited
omnidirectionality and a frequency of only 2 MHz.
Conclusions/clinical relevance: The image makes
allowance for the widely different sound velocities of
bone/tissue: the elastic properties (and hence strength) of
bone can be estimated directly from the data.
doi:10.1016/j.bjoms.2009.06.039
13
Ultrasound guided interstitial photodynamic therapy of
deep seated lesions
Sorcha MacKay ∗, Waseem Jerjes, Tahwinder Upile, Zaid
Hamdoon, Syedda Abbas, Farai Nhembe, Shinali Patel,
Simon Morley, Colin Hopper
UCLH Head & Neck Centre, London, United Kingdom
Introduction: Photodynamic therapy is a minimally invasive
therapy that results from the interaction between a photosen-
sitiser, oxygen and light. The delivery of light can by either
by surface illumination or interstitial application.
We describe the intraoperative application of ultrasound
in guiding light delivery in photodynamic therapy.
Method and materials: A total of 60 patients with vari-
ous deep seated pathologies in the head and neck, upper and
lower limbs were treated with mTHPC-photodynamic ther-
apy. 2D Ultrasound was used to guide the needle insertion in
the diseased area.
Results: It was possible to clearly identify the needles
during insertion in all treatments and it was possible to
guide parallel needle insertions using ultrasound. Although
the resolution of ultrasound is not as good as other imaging
modalities (i.e. CT, MRI) it was satisfactory in identifying
the centre and the peripheries of the pathological lesions.
Ultrasound is very easy to perform, non-invasive, rela-
tively inexpensive, quick and convenient, suited to imaging
soft tissues and does not cause any discomfort.
Conclusion: Ultrasound can be used to guide ‘real-time’
photodynamic therapy of deep seated tumours and other
malformations and can augment the information from other
imaging modalities without affecting the patient’s treatment
outcome.
doi:10.1016/j.bjoms.2009.06.040
14
Binge drinking amongst 8845 13–14-year-old English
pupils and the harms they suffered
Sharon Cheung ∗, Fran Ridout, Allan Hackshaw, Stephen
Sutton, Ken Gannon, Iain Hutchison
Barts and The London NHS Trust, United Kingdom
Introduction: The aim of the research was to find out about
attitudes to drinking and the drinking habits of young people
in order to inform intervention programmes to discourage
binge drinking.
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Post-operative troponin positive cardiac events in 
patients undergoing head and neck cancer 
resection admitted on the day of surgery
Miss Karen A Eley, Mr Stephen R Watt-Smith
Department of Oral & Maxillofacial Surgery, Oxford Radcliffe Hospitals NHS Trust, 
Headley Way, Oxford OX3 9DU, UK
INTRODUCTION:
Theatre Direct Admissions (TDA) is a method of increasing throughput of patients introduced in hospitals across the UK. Patients attend a holding bay pre-
operatively, in close proximity to theatres, and are transferred to the ward post-operatively. Initial reports about same day surgical admissions in vascular and
colorectal surgery have been favourable.1,2 Patients are assessed preoperatively to exclude those with coexisting conditions for which preoperative admission to a
ward is required. As a consequence, pre-selected “low risk” patients for TDA should have little postoperative morbidity.
AIMS:
To determine the incidence of post-operative troponin positive Myocardial
Infarction (MI) rate in patients following head and neck cancer resection and
reconstruction patients admitted pre-operatively to the ward compared to those
via TDA.
METHODS:
Retrospective review of all patients undergoing resection and reconstruction for
head and neck cancer between 2003-2008 (n=195), in the department of Oral
& Maxillofacial Surgery, Oxford, to determine incidence of troponin positive MI
rate.
DISCUSSION:
The surgical stress response is a systemic reaction to injury that includes
endocrine, immunological, and haematological effects, with a magnitude and
duration proportional to the injury.3,4 The combination of a patient’s anxiety
associated with admission to hospital, and the serious stress response from an
extensive operation, are probable contributory factors to postoperative
complications such as myocardial infarction.5
Chiang et al 6 reported an incidence of 3.6% among patients undergoing
microvascular head and neck reconstruction. Our patient cohort was of more
advanced age in comparison, with increased co-morbidity.
The increased incidence of MI in patients admitted via TDA may reflect a cluster
that occurred at this time, irrespective of admission method.
In response to these findings, our unit continues to use pre-operative ward
admission for all patients undergoing resection and reconstruction for head and
neck cancer.
The pre-operative night spent on the ward provides an opportunity to become
accustomed to hospital stay, and the opportunity to further discuss the surgical plan
thereby allaying any residual concern.
Further research is warranted on the optimised therapy for patients undergoing this
type of surgery, and we are currently investigating the benefit of perioperative
monitoring of stoke volume variance to optimise fluid balance.
CONCLUSIONS:
TDA may not be appropriate for all patients having major operations, in view of
the compounding stress associated with this method of hospital admission.
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RESULTS:
Oral & Maxillofacial Department, Oxford Radcliffe Hospitals NHS Trust
Cohort Admission Type
Troponin
Total
Positive Negative 
Total 
Requests
Total Not 
Requested
1 Ward Admission 9  (7%) 24 33 (25%) 98 131
2
Theatre Direct 
Admission 
3 (20%) 4 7 (47%) 8 15
3
Reinstitution of 
Ward Admission
1 (2%) 11 12 (24%) 37 49
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